EOS Med Chem, Medicinal Chemical is Big: EOS Med Chem Building block stock list 2354

EOS Med Chem is TOP 100 of China CRO & CMO company, mainly in custom synthesis.
2019 CHINA CPHI E2A62
2019 WORLD CPHI 101C45
FDA New, GMP Do
Clinical Phase II, III Intermediates
GMP Custom synthesis, Full Document

R&D Center: 8000 sq, More than 100 hoods
Pilot Plant: 20000sq, 40 reactors from 5-200L
Manufacturing Site: 800000sq, 40 reactors from 100-5000L
Web:

www.eosmedchem.com
Email: info@eosmedchem.com ; eosmedchem@gmail.com

Name: APX-115 (free base) Ewha-18278 (free base), CAS: 1270084-92-8, stock 19.3g, assay 98.3%, MWt: 279.34, Formula: C17H17N3O, Solubility: DMSO : 250 mg/mL (894.97 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Metabolic Enzyme/Protease, Target: NADPH Oxidase, Biological_Activity: APX-115 free base (Ewha-18278 free base) is a potent, orally active pan NADPH oxidase (Nox) inhibitor with Ki values of 1.08 μM, 0.57 μM, and 0.63 μM for Nox1, Nox2 and Nox4, respectively. APX-115 free base effectively prevents kidney injury[1].
IC50 & Target: Ki: 1.08 μM (Nox1), 0.57 μM (Nox2) and 0.63 μM (Nox4)[1]
In Vitro: APX-115 free base (5 μM; 60 min) almost completely suppresses high glucose-induced proinflammatory and profibrotic molecule expression in the mouse podocyte cell line[2]. 
In the kidney, APX-115 free base attenuates Nox gene upregulation and protein expression while improving inflammatory and fibrotic processes[2]. 
In Vivo: APX-115 free base (oral gavage; 60 mg/kg/day; for 12 weeks) significantly improves insulin resistance in diabetic mice[2]. 
APX-115 free base treatment decreases the urinary excretion of albumin and plasma creatinine levels[2].

Name: RTC-30, CAS: 1423077-95-5, stock 14.1g, assay 98.9%, MWt: 492.51, Formula: C24H23F3N2O4S, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: RTC-30 is an optimized phenothiazine with anti-cancer potency. RTC-30 contains a hydroxylated linker (N) that confers increased oral bioavailability[1].
In Vitro: RTC-30 (0-40 μM; 48 hours) inhibits H1650 lung adenocarcinoma cell growth with an GI50 of 15 μM[1].

Name: AF40431, CAS: 181125-92-8, stock 12.7g, assay 98.9%, MWt: 319.35, Formula: C17H21NO5, Solubility: DMSO : 25 mg/mL (78.28 mM; ultrasonic and adjust pH to 1 with TFA), Clinical_Informat: No Development Reported, Pathway: GPCR/G Protein;Neuronal Signaling, Target: Neurotensin Receptor;Neurotensin Receptor, Biological_Activity: AF40431, the first reported small-molecule ligand of sortilin, has an IC50 of 4.4 µM and a Kd of 0.7 µM . AF40431 is bound in the neurotensin-binding site of sortilin[1].
IC50 & Target: IC50: 4.4 µM (sortilin)
Kd: 0.7 µM (sortilin)[1]

Name: DBCO-NHS ester 2, CAS: 1384870-47-6, stock 38.3g, assay 99%, MWt: 430.45, Formula: C25H22N2O5, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Antibody-drug Conjugate/ADC Related, Target: ADC Linker, Biological_Activity: DBCO-NHS ester 2 is a cleavable linker that is used for making antibody-drug conjugate (ADC). DBCO-NHS ester 2 is a derivative of Dibenzylcyclooctyne (DBCO) used in copper-free click chemistry[1].

Name: TBOPP, CAS: 1996629-79-8, stock 34.4g, assay 98.9%, MWt: 490.49, Formula: C24H21F3N2O4S, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: TBOPP is a selective inhibitor of DOCK1 with an IC50 of 8.4 μM. TBOPP binds to the DOCK1 DHR-2 domain with high affinity (Kd of 7.1 μM), has anti-tumor activity for broader types of tumors[1].
IC50 & Target: IC50: 8.4 μM (DOCK1); Kd: 7.1 μM (DOCK1 DHR-2 domain)[1]
In Vitro: TBOPP (12.5 µM; 3 days; 3LL cells) treatment inhibits DOCK1-mediated invasion, macropinocytosis, and survival under the condition of glutamine deprivation without impairing the biological functions of the closely related DOCK2 and DOCK5 proteins[1].
In Vivo: TBOPP (0.67 mg per mouse; administrated on days 0, 1, 3, and 5; for 2 weeks; C57BL/6 mice) treatment effectively suppresses metastasis of cancer cells in vivo and the number of lymphocytes in the spleen is not changed, the body weight is also unchanged between TBOPP-treated and non-treated mice[1].

Name: p32 Inhibitor M36 M36, CAS: 802555-85-7, stock 11g, assay 98.9%, MWt: 448.52, Formula: C23H28N8O2, Solubility: DMSO : 5 mg/mL (11.15 mM; ultrasonic and warming and heat to 80°C), Clinical_Informat: No Development Reported, Pathway: TGF-beta/Smad;Epigenetics, Target: PKC;PKC, Biological_Activity: p32 inhibitor M36 (M36) is a p32 mitochondrial protein inhibitor, which binds directly to p32 and inhibits p32 association with LyP-1[1].
IC50 & Target: p32[1]
In Vitro: p32 Inhibitor M36 inhibits SF188 glioma cells proliferation (IC50 of 77.9 μM in complete media) and is much more potent under low glucose conditions with an IC50 of 7.3 μM[1]. 
p32 Inhibitor M36 is selective for p32 overexpressing cells[1]. 
p32 Inhibitor M36 is also a potent inhibitor of patient-derived neurospheres with an IC50 of 2.8 μM[1].

Name: DPA-714, CAS: 958233-07-3, stock 10g, assay 98.4%, MWt: 398.47, Formula: C22H27FN4O2, Solubility: DMSO : 41.67 mg/mL (104.57 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: DPA-714 is a high affinity translocator protein (TSPO) ligand (Ki=7 nM), which is designed with a fluorine atom in its structure, allowing labelling with fluorine -18 and in vivo imaging using positron emission tomography. [18F]DPA-714 successfully evaluates for the specific imaging of inflammation in various models of neuroinflammation and in a brain tumor model[1][2].
IC50 & Target: Ki: 7 nM (TSPO)[1]

Name: JMS-17-2, CAS: 1380392-05-1, stock 39.3g, assay 98.3%, MWt: 419.95, Formula: C25H26ClN3O, Solubility: DMSO : 25 mg/mL (59.53 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: GPCR/G Protein;Immunology/Inflammation, Target: CXCR;CXCR, Biological_Activity: JMS-17-2 is a potent and selective CX3CR1 antagonist with an IC50 of 0.32 nM[1].
IC50 & Target: IC50: 0.32 nM (CX3CR1)[1]
In Vivo: JMS-17-2 (10 mg/kg; aministered i.p.; twice a day for three weeks) causes a dramatic reduction of tumors in both skeleton and visceral organs in SCID mice[1].

Name: Gefitinib-based PROTAC 3, CAS: 2230821-27-7, stock 39.6g, assay 98.1%, MWt: 934.51, Formula: C47H57ClFN7O8S, Solubility: DMSO : ≥ 60 mg/mL (64.20 mM), Clinical_Informat: No Development Reported, Pathway: JAK/STAT Signaling;Protein Tyrosine Kinase/RTK;PROTAC, Target: EGFR;EGFR;PROTAC, Biological_Activity: Gefitinib-based PROTAC 3, conjugating an EGFR binding element to a VHL ligand via a linker, induces EGFR degradation with DC50s of 11.7 nM and 22.3 nM in HCC827(exon 19 del) and H3255 (L858R mutantion) cells, respectively[1].
In Vitro: H3255 cells expressing L858R EGFR treated with Gefitinib-based PROTAC 3 (25 nM-10 μM; 24 hours), HCC827 cells expressing exon 19 del EGFR treated with Gefitinib-based PROTAC 3 (100 nM-10 μM; 24 hours), which enables the degradation of both exon-19 deletion EGFR as well as the mutant isoform containing the L858R activating point mutation, while sparing the WT EGFR[1].

Name: S29434 NMDPEF, CAS: 874484-20-5, stock 13.9g, assay 98.6%, MWt: 374.39, Formula: C21H18N4O3, Solubility: H2O : < 0.1 mg/mL (insoluble); DMSO : 12.5 mg/mL (33.39 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Autophagy, Target: Autophagy, Biological_Activity: S29434 (NMDPEF) is a potent, competitive, selective and cell-permeable inhibitor of quinone reductase 2 (QR2), with IC50s ranging from 5 to 16 nM for human QR2 at different organizational levels, and has good selectivity for QR2 over QR1. S29434 (NMDPEF) induces autophagy and inhibits QR2-mediated ROS production[1].
IC50 & Target: IC50: 5 nM (h QR2, expressed in E. coli, NRH as co-substrate), 16 nM (h QR2, expressed in E. coli, with BNAH as co-substrate)[1]

Name: LIT-001, CAS: 2245072-21-1, stock 30.9g, assay 98.7%, MWt: 645.70, Formula: C30H34F3N7O4S, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: GPCR/G Protein, Target: Oxytocin Receptor, Biological_Activity: LIT-001 is the first nonpeptide oxytocin receptor (OT-R) agonist (EC50=55 nM; Ki=226 nM). LIT-001 improves social interaction in a mouse model of autism[1].
IC50 & Target: EC50: 55 nM (OT-R)[1] 
Ki: 226 nM (OT-R)[1]
In Vitro: In vitro signaling experiments, LIT-001 is a nonbiased OT-R agonist on the two main signaling pathways of this receptor, with minor antagonist effect on V1a and agonist effect on V1b receptors, observed at high concentrations only[1].
In Vivo: LIT-001 (10-20 mg/kg; i.p.) alleviates core symptoms in the context of autism spectrum disorders (ASD )[1].

Name: BI 01383298, CAS: 2227549-00-8, stock 8.6g, assay 98.7%, MWt: 445.34, Formula: C19H19Cl2FN2O3S, Solubility: H2O : < 0.1 mg/mL (insoluble); DMSO : 37.5 mg/mL (84.21 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Membrane Transporter/Ion Channel, Target: Sodium Channel, Biological_Activity: BI 01383298 is a potent inhibitor of the sodium-citrate co-transporter (SLC13A5) that is highly expressed in the liver[1].
IC50 & Target: SLC13A5[1]

Name: THAL-SNS-032, CAS: 2139287-33-3, stock 9.2g, assay 98.4%, MWt: 869.02, Formula: C40H52N8O10S2, Solubility: DMSO : 100 mg/mL (115.07 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Cell Cycle/DNA Damage;PROTAC, Target: CDK;PROTAC, Biological_Activity: THAL-SNS-032 is a selective CDK9 degrader PROTAC consisting of a CDK-binding SNS-032 ligand linked to a thalidomide derivative that binds the E3 ubiquitin ligase Cereblon (CRBN)[1].
IC50 & Target: CDK9[1]
In Vitro: THAL-SNS-032 selectively induces degradation of CDK9[1]. 
THAL-SNS-032 diminishes elongating polymerase II[1]. 
THAL-SNS-032 inhibits proliferation of MOLT4 cells with an IC50 of 50 nM[1].

Name: Masupirdine (mesylate) SUVN-502 (mesylate), CAS: 1791396-46-7, stock 2.1g, assay 98.6%, MWt: 670.61, Formula: C23H32BrN3O9S3, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Neuronal Signaling;GPCR/G Protein, Target: 5-HT Receptor;5-HT Receptor, Biological_Activity: Masupirdine mesylate (SUVN-502 mesylate) is a potent, selective, orally bioavailable, and brain penetrant 5-HT6 receptor antagonist (Ki of 2.04 nM for human 5-HT6 receptor). Masupirdine mesylate (SUVN-502 mesylate) shows high selectivity over 5-HT2A receptor and other 100 target sites, and has potential for treatment of Alzheimer's disease[1].
IC50 & Target: Ki: 2.04 nM (human 5-HT6 receptor)[1]

Name: STING agonist-4, CAS: 2138300-40-8, stock 0.7g, assay 98.8%, MWt: 678.74, Formula: C34H38N12O4, Solubility: DMSO : < 1 mg/mL (insoluble or slightly soluble), Clinical_Informat: No Development Reported, Pathway: Immunology/Inflammation, Target: STING, Biological_Activity: STING agonist-4 is an stimulator of Interferon Genes (STING) receptor agonist with an apparent inhibitory constant (IC50) of 20 nM. STING agonist-4 is a two symmetry-related amidobenzimidazole (ABZI)-based compound to create linked ABZIs (diABZIs) with enhanced binding to STING and cellular function[1].
IC50 & Target: IC50: 20 nM (STING agonist-4)[1]
In Vitro: STING agonist-4 (Compound 2) (0.3-30 μM; 2 hours) causes phosphorylation of IRF3 and STING that is inhibited by the TBK1 inhibitor BX795 and induces dose-dependent secretion of IFN-β with an EC50 of 3.1 μM[1].
STING agonist-4 (Compound 2) (0.001 nM-1 μM) inhibits binding of full-length STING to the solid support with an apparent dissociation constant (Kd) of approximately 1.6 nM[1].
STING agonist-4 (Compound 2) (0-100 μM) is 18-fold more potent than cGAMP (an endogenous STING ligand), with an EC50 of 53.9 μM[1].
STING agonist-4 (Compound 2) (3 μM; 4 hours) promotes production of interferon γ-induced protein 10 (IP-10), IL-6 and TNF-α by a mechanism that is dependent on STING-mediated activation of TBK1[1].

Name: SBI-425, CAS: 1451272-71-1, stock 19g, assay 98.2%, MWt: 341.77, Formula: C13H12ClN3O4S, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Metabolic Enzyme/Protease, Target: Phosphatase, Biological_Activity: SBI-425 is a potent, selective and oral bioavailable tissue-nonspecific alkaline phosphatase (TNAP) inhibitor[1]. Long-term administration of SBI-425 effectively reaches and inhibits TNAP in the vasculature, improving cardiovascular parameters and survival at a dose that does not cause a detectable change in bone[2].

Name: C-021 (dihydrochloride), CAS: 1784252-84-1, stock 33.2g, assay 99%, MWt: 540.57, Formula: C27H43Cl2N5O2, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Immunology/Inflammation;GPCR/G Protein, Target: CCR;CCR, Biological_Activity: C-021 dihydrochloride is a potent CC chemokine receptor-4 (CCR4) antagonist. C-021 dihydrochloride potently inhibits functional chemotaxis in human and mouse with IC50s of 140 nM and 39 nM, respectively. C-021 effectively prevents human CCL22-derived [35S]GTPγS from binding to the receptor with an IC50 of 18 nM[1].
In Vitro: The in vitro oxidative metabolic stability of C-021 (Compound 1b) is evaluated by measuring the rate of drug consumption in human liver microsomes (HML), thus providing intrinsic clearance values (CLint). C-021 exhibits CLint value of 17,377 mL/h/kg[1].
In Vivo: The potency of C-021 (Compound 1b) is evident after subcutaneous administration in the murine oxazolone-induced contact hypersensitivity test, a known model of acute skin inflammation. When C-021 is administered orally, however, very little inhibition is observed[1].

Name: RTC-5, CAS: 1423077-49-9, stock 30.6g, assay 98.3%, MWt: 510.96, Formula: C24H22ClF3N2O3S, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: JAK/STAT Signaling;Protein Tyrosine Kinase/RTK, Target: EGFR;EGFR, Biological_Activity: RTC-5 is an optimized phenothiazine with anti-cancer potency. RTC-5 demonstrates efficacy against a xenograft model of an EGFR driven cancer, its effects is attributed to concomitant negative regulation of PI3K-AKT and RAS-ERK signaling[1].
IC50 & Target: IC50: EGFR[1]
In Vitro: RTC-5 (0-40 μM; 48 hours) inhibits H1650 lung adenocarcinoma cell growth with an GI50 of 12.6μM[1].
RTC-5 (20-40 μM; 24 hours) negatively regulates PI3K-AKT and RAS-ERK pathways by decreasing phospho-AKT and phospho-ERK levels expression[1].

Name: Mcl1-IN-8, CAS: 678158-55-9, stock 37g, assay 98.5%, MWt: 393.50, Formula: C22H23N3O2S, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Apoptosis, Target: Bcl-2 Family, Biological_Activity: Mcl1-IN-8 (Comp8) is a Mcl-1-PUMA interface inhibitor, with a Ki of 0.3 μM. Mcl1-IN-8 (Comp8) exhibits dual activity on reduce PUMA-dependent apoptosis while deactivating Mcl-1-mediated anti-apoptosis in cancer cells[1].
IC50 & Target: Ki: 0.3 μM (Mcl1)[1].

Name: HOOCCH2O-PEG4-CH2COOH, CAS: 77855-75-5, stock 14.9g, assay 98.4%, MWt: 310.30, Formula: C12H22O9, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: PROTAC, Target: PROTAC Linker, Biological_Activity: HOOCCH2O-PEG4-CH2COOH, compound 5, is a symmetric PEG linker, used for the synthesis of the first class of Homo-PROTAC[1].

Name: TH-257, CAS: 2244678-29-1, stock 24.5g, assay 98.5%, MWt: 422.54, Formula: C24H26N2O3S, Solubility: DMSO : 250 mg/mL (591.66 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Cell Cycle/DNA Damage, Target: LIM Kinase (LIMK), Biological_Activity: TH-257 is a potent inhibitor of LIMK1 and LIMK2 with IC50 values of 84 nM and 39 nM for LIMK1 and LIMK2, respectively, and it can be used as a chemical probe for LIMK1 and LIMK2. TH-257 is an allosteric inhibitor targeting a binding pocket induced by an αC and DFG-out conformation. TH257 is exquisitely selective and no significant activity against the wider kinome has been observed in the KINOMEscan assay at 1 μM[1].

Name: Raphin1, CAS: 2022961-17-5, stock 9.2g, assay 98.5%, MWt: 231.08, Formula: C8H8Cl2N4, Solubility: DMSO : 125 mg/mL (540.94 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Metabolic Enzyme/Protease, Target: Phosphatase, Biological_Activity: Raphin1 is an orally bioavailable, selective inhibitor of the regulatory phosphatase PPP1R15B (R15B). Raphin1 binds strongly to the R15B-PP1c holophosphatase (Kd=33 nM), and shows ~30-fold selective in binding R15B-PP1c over R15A-PP1c. Raphin1 crosses the blood-brain barrier, and reduces organismal and molecular deficits in a mouse model of a protein misfolding disease[1].
IC50 & Target: Kd：33 nM (R15B-PP1c holophosphatase)[1]
In Vitro: Raphin1 causes a rapid and transient accumulation of its phosphorylated substrate, resulting in a transient attenuation of protein synthesis[1]. 
Raphin1 inhibits the recombinant R15B-PP1c holoenzyme, but not the closely related R15A-PP1c, by interfering with substrate recruitment[1].
In Vivo: Raphin1 improves weight of HD82Q mice treated from 4 to ∼10 weeks of age with 2 mg/kg of Raphin1 once a day by oral gavage. Raphin1 also decreases SDS-insoluble huntingtin assemblies and nuclear inclusions in the cortex of HD82Q mice[1].

Name: T-448, CAS: 1597426-53-3, stock 5.2g, assay 98.4%, MWt: 386.50, Formula: C17H20N4OS.1/2C4H4O4, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Epigenetics, Target: Histone Demethylase, Biological_Activity: T-448 is a specific and irreversible inhibitor of lysine-specific demethylase 1 (LSD1, an H3K4 demethylase), with an IC50 of 22 nM. T-448 enhances H3K4 methylation in primary cultured rat neurons[1].
IC50 & Target: IC50: 22 nM (LSD1)[1].

Name: G6PD activator AG1, CAS: 421581-52-4, stock 0.8g, assay 98.3%, MWt: 438.65, Formula: C24H30N4S2, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: G6PD activator AG1 is a glucose-6-phosphate dehydrogenase (G6PD) activator with an EC50 of 3 µΜ, extracted from patent WO2019023264A1, compound AG1[1].
IC50 & Target: IC50: 3 µΜ (G6PD)[1]

Name: C-178, CAS: 329198-87-0, stock 22.8g, assay 98.2%, MWt: 322.27, Formula: C17H10N2O5, Solubility: DMSO : 41.67 mg/mL (129.30 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Immunology/Inflammation, Target: STING, Biological_Activity: C-178, a covalent inhibitor of STING, binds to Cys91, potently and selectively suppresses the STING responses elicited by distinct bona fide activators in mouse but not human. C-178 significantly reduces STING-, but not RIG-I- or TBK1-, mediated IFN-β reporter activity. C-178 blocks palmitoylation (PMA)-induced clustering of STING; inhibits the CMA-induced phosphorylation of TBK1 (downstream protein kinase of STING)[1].
IC50 & Target: STING[1]

Name: Gemcabene (calcium) PD-72953 (calcium), CAS: 209789-08-2, stock 24.7g, assay 98.6%, MWt: 340.47, Formula: C16H28CaO5, Solubility: H2O : 10 mg/mL (29.37 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: Gemcabene calcium (PD-72953 calcium), a first-in-class lipid-lowering agent, lowers low-density lipoprotein cholesterol (LDL-C), decreases triglycerides, and raises high-density lipoprotein cholesterol (HDL-C) and lowers pro-inflammatory acute-phase protein, C-reactive protein (CRP), exerting anti-inflammatory activity[1][2][3].
In Vitro: Gemcabene calcium (PD-72953 calcium) significantly downregulates hepatic mRNA markers of inflammation (TNF-α, MCP-1, MIP-1β, CCR5, CCR2, NF-κB), lipogenesis and lipid modulation (ApoC-III, ACC1, ADH-4, Sulf-2), and fibrosis (TIMP-1 and MMP-2)[3].

Name: Qstatin, CAS: 902688-24-8, stock 1.9g, assay 98.4%, MWt: 293.16, Formula: C7H5BrN2O2S2, Solubility: DMSO : 83.33 mg/mL (284.25 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Anti-infection, Target: Bacterial, Biological_Activity: QStatin is a potent and selective inhibitor of SmcR (V. harveyi LuxR homologue) with an EC50 of 208.9 nM, binding tightly to SmcR and changes the flexibility of the protein, thereby altering its transcription regulatory activity. QStatin shows pan-QS (Vibrio quorum sensing) inhibitor activity in diverse Vibrio species and attenuates their virulence in an aquatic host. QStatin may be a sustainable antivibriosis agent useful in aquacultures[1].
In Vitro: QStatin (0.001 μM-10 μM; 5 hours) inhibits SmcR activity measured by the RLU level for V. vulnificusWT (pBB1), reveals EC50 of 208.9 nM[1].
QStatin (5 μM-50 μM; 16 hours) reduces the activities of SmcR-activated virulence factors (protease and elastase) in V. vulnificus in a dose dependent manner[1].
QStatin (5 μM-50 μM; 16 hours) has no effect on the cellular levels of SmcR, indicating that QStatin does not affect the expression or stability of SmcR[1].

Name: Deltasonamide 2, CAS: 2088485-34-9, stock 6.7g, assay 99%, MWt: 647.25, Formula: C30H39ClN6O4S2, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Metabolic Enzyme/Protease, Target: Phosphodiesterase (PDE), Biological_Activity: Deltasonamide 2 is a competitive, high affinity PDEδ inhibitor with a Kd of ~385 pM[1].
IC50 & Target: Kd: ~385 pM (PDEδ)[1]

Name: Col003, CAS: 328565-16-8, stock 6.8g, assay 98.5%, MWt: 257.24, Formula: C14H11NO4, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Metabolic Enzyme/Protease;Cell Cycle/DNA Damage, Target: HSP;HSP, Biological_Activity: Col003 is a potent inhibitor of Hsp47, competitively binds to the collagen binding site on Hsp47 (IC50, 1.8 μM), and inhibits collagen secretion by destabilizing the collagen triple helix[1].

Name: Homo-PROTAC pVHL30 degrader 1, CAS: 2244684-49-7, stock 10.1g, assay 98.9%, MWt: 1179.45, Formula: C58H82N8O14S2, Solubility: DMSO : ≥ 150 mg/mL (127.18 mM), Clinical_Informat: No Development Reported, Pathway: PROTAC, Target: PROTAC, Biological_Activity: Homo-PROTAC pVHL30 degrader 1 is a potent pVHL30 degrader based on PROTAC[1].
IC50 & Target: pVHL30[1] 
PROTAC[1]
In Vitro: Homo-PROTAC pVHL30 degrader 1 dimerizes von Hippel-Lindau (VHL) with high avidity in vitro and induces potent, rapid and proteasome-dependent self-degradation of VHL in different cell lines, in a highly isoform-selective fashion and without triggering a hypoxic response[1].

Name: Homo-PROTAC cereblon degrader 1, CAS: 2244520-98-5, stock 5.4g, assay 98.1%, MWt: 660.63, Formula: C32H32N6O10, Solubility: DMSO : 200 mg/mL (302.74 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: PROTAC, Target: PROTAC, Biological_Activity: Homo-PROTAC cereblon degrader 1 (compound 15a) is a highly potent and efficient cereblon (CRBN) degrader with only minimal effects on IKZF1 and IKZF3[1].
IC50 & Target: Celeblon[1].

Name: BETd-246, CAS: 2140289-17-2, stock 20.5g, assay 98.8%, MWt: 946.02, Formula: C48H55N11O10, Solubility: DMSO : 200 mg/mL (211.41 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Epigenetics;PROTAC, Target: Epigenetic Reader Domain;PROTAC, Biological_Activity: BETd-246 is a second-generation BET bromodomain (BRD) inhibitor, exhibiting superior selectivity, potency and antitumor activity[1].
IC50 & Target: BET BRD[1].
In Vitro: BETd-246 treatment (0-100 nM, 1-3 h) causes a dose-dependent depletion of BRD2, BRD3 and BRD4 in representative TNBC cell lines with 30-100 nM for 1 h or with 10-30 nM for 3 h incubation. 
BETd-246 (100 nM, 24/48 hours) displays strong growth inhibition and apoptosis induction activity in MDA-MB-468 cell lines. BETd-246 induces a rapid and time-dependent downregulation of MCL1 protein in all the TNBC cell lines evaluated. BETd-246 induces much stronger apoptosis than BETi-211. 
BETd-246 (100 nM, 24 hours) induces pronounced cell cycle arrest and apoptosis in TNBC cell lines[1].
In Vivo: BETd-246 (5 mg/kg, IV, 3 times per week for 3 weeks) treatment effectively inhibits WHIM24 tumor growth, similar to the antitumor activity of BETi-211 with higher dosage and more frequently administration. The treatment of 10 mg/kg induces partial tumor regression during treatment without apparent toxicity. BETd-246 has very limited drug exposure in the xenograft tumor tissue in MDA-M-231and MDA-MB-468 models[1].

Name: SEC inhibitor KL-2 KL-2, CAS: 900308-51-2, stock 30g, assay 98.6%, MWt: 333.74, Formula: C17H13ClFNO3, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: SEC inhibitor KL-2 (KL-2), a peptidomimetic lead compound, is a potent, selective super elongation complex (SEC) inhibitor and disrupts the interaction between the SEC scaffolding protein AFF4 and P-TEFb, resulting in impaired release of Pol II from promoter-proximal pause sites and a reduced average rate of processive transcription elongation. SEC inhibitor KL-2 exhibits an dose-dependent inhibitory effect on AFF4-CCNT1 interaction with a Ki of 1.50 μM[1].
IC50 & Target: SEC[1]

Name: SAHA chloroalkane T1, CAS: 1613617-05-2, stock 24.1g, assay 98.4%, MWt: 719.26, Formula: C33H55ClN4O11, Solubility: DMSO : 125 mg/mL (173.79 mM; Need ultrasonic); H2O : < 0.1 mg/mL (insoluble), Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: SAHA chloroalkane T1 is a chloroalkane capture tag by tethering Vorinostat (SAHA) and a chloroalkane tag T1[1].
In Vitro: SAHA chloroalkane T1 minimally affects SAHA potency in K-562 cells, allowing binding interactions with the targets to occur under conditions relevant to the desired cellular phenotype[1].

Name: Pilaralisib analogue XL147 analogue, CAS: 956958-53-5, stock 11.9g, assay 98.9%, MWt: 448.52, Formula: C21H16N6O2S2, Solubility: DMSO : ≥ 50 mg/mL (111.48 mM), Clinical_Informat: No Development Reported, Pathway: PI3K/Akt/mTOR;Apoptosis, Target: PI3K;Apoptosis, Biological_Activity: Pilaralisib analogue (XL147 analogue) is a representative and selective PI3Kα inhibitor extracted from patent WO2012006552A1, Compound 147 in Table 1.
IC50 & Target: PI3Kα[1]

Name: CD38 inhibitor 1, CAS: 1700637-55-3, stock 9.5g, assay 98.1%, MWt: 413.53, Formula: C22H27N3O3S, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: CD38 inhibitor 1 (compound 78c) is a potent CD38 inhibitor with IC50s of 7.3 nM and 1.9 nM for hCD38 and mouse CD38[1].
IC50 & Target: IC50: 7.3 nM (hCD38), 1.9 nM (mouse CD38)[1] 
Ki: 0.3 nM (WT hCD38)[1]
In Vivo: CD38 inhibitor (30 mg/kg; oral administration; 2 and 6 hours) significantly elevates NAD levels in liver and muscle[1].

Name: Resorufin sodium salt NSC 12097 sodium salt, CAS: 34994-50-8, stock 25.6g, assay 98.4%, MWt: 235.17, Formula: C12H6NNaO3, Solubility: DMSO : < 1 mg/mL (insoluble or slightly soluble), Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: Resorufin sodium salt (NSC 12097 sodium salt) is a highly fluorescent pink dye.

Name: sAJM589, CAS: 2089-82-9, stock 35.1g, assay 99%, MWt: 246.26, Formula: C16H10N2O, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Apoptosis, Target: c-Myc, Biological_Activity: sAJM589 is a Myc inhibitor which potently disrupts the Myc-Max heterodimer with an IC50 of 1.8 μM[1].
IC50 & Target: IC50: 1.8 μM (Myc)[1]
In Vitro: sAJM589 potently disrupts the Myc-Max heterodimer to reduce Myc protein levels in a dose dependent manner, with an IC50 of 1.8 μM[1]. 
sAJM589 suppresses cellular proliferation in diverse Myc-dependent cancer cell lines and anchorage independent growth of Raji cells[1].

Name: TRi-1, CAS: 246020-68-8, stock 27.5g, assay 99%, MWt: 328.73, Formula: C12H9ClN2O5S, Solubility: H2O : < 0.1 mg/mL (insoluble); DMSO : 62.5 mg/mL (190.13 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: TRi-1 is a potent, specific and irreversible inhibitor of cytosolic thioredoxin reductase 1 (TXNRD1), with an IC50 of 12 nM. TRi-1 has little mitochondrial toxicity for anticancer therapy[1].
IC50 & Target: IC50: 12 nM (TXNRD1)[1].

Name: Calcium dobesilate, CAS: 20123-80-2, stock 0.2g, assay 98.3%, MWt: 418.41, Formula: C12H10CaO10S2, Solubility: DMSO : 150 mg/mL (358.50 mM; Need ultrasonic), Clinical_Informat: Launched, Pathway: Apoptosis, Target: Apoptosis, Biological_Activity: Calcium dobesilate, a vasoprotective, is widely used in chronic venous disease, diabetic retinopathy and the symptoms of haemorrhoidal attack in many countries.

Name: (R)-Nedisertib (R)-M3814, CAS: 1637542-32-5, stock 3.6g, assay 98.3%, MWt: 481.91, Formula: C24H21ClFN5O3, Solubility: DMSO : 100 mg/mL (207.51 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: PI3K/Akt/mTOR;Cell Cycle/DNA Damage, Target: DNA-PK;DNA-PK, Biological_Activity: (R)-Nedisertib ((R)-M3814) is a less active R-enantiomer of Nedisertib, with an IC50 in the range of 7-30 nM for DNA-PK[1].
IC50 & Target: IC50: 7-30 nM (DNA-PK)[1]
In Vitro: Rac-Nedisertib (Compound 135) less actively inhibits DNA-PK, with an IC50 in the range of 7-30 nM[1].

Name: PEG6-(CH2CO2H)2, CAS: 77855-76-6, stock 28.1g, assay 98.1%, MWt: 354.35, Formula: C14H26O10, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: PROTAC, Target: PROTAC Linker, Biological_Activity: PEG6-(CH2CO2H)2 is a symmetric PEG PROTAC linker, for the synthesis of Homo-PROTACs which is bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation[1].
IC50 & Target: PROTAC linker[1]

Name: DUPA, CAS: 302941-52-2, stock 2.9g, assay 98.6%, MWt: 320.25, Formula: C11H16N2O9, Solubility: H2O : ≥ 150 mg/mL (468.38 mM), Clinical_Informat: No Development Reported, Pathway: PROTAC, Target: Ligand for Target Protein for PROTAC, Biological_Activity: DUPA, belongs to a class of glutamate ureas, is used as the targeting moiety in drug conjugate to selectively deliver cytotoxic drugs to prostate cancer cells[1][2].
In Vitro: DUPA is used as the targeting moiety to actively deliver Docetaxel (DTX) for treatment of prostate-specific membrane antigen (PSMA) expressing prostate cancer[1]. The DUPA-indenoisoquinoline conjugate exhibits an IC50 in the low nanomolar range in 22RV1 cell cultures[2].
In Vivo: The DUPA-indenoisoquinoline conjugate induces a complete cessation of tumor growth with no toxicity, as determined by loss of body weight and death of treated mice[2].

Name: SEC inhibitor KL-1 KL-1, CAS: 900308-84-1, stock 34.1g, assay 98.9%, MWt: 345.78, Formula: C18H16ClNO4, Solubility: DMSO : 41.67 mg/mL (120.51 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: SEC inhibitor KL-1 (KL-1), a peptidomimetic lead compound, is a potent, selective super elongation complex (SEC) inhibitor and disrupts the interaction between the SEC scaffolding protein AFF4 and P-TEFb, resulting in impaired release of Pol II from promoter-proximal pause sites and a reduced average rate of processive transcription elongation. SEC inhibitor KL-1 exhibits an dose-dependent inhibitory effect on AFF4-CCNT1 interaction with a Ki of 3.48 μM[1].
IC50 & Target: SEC[1]

Name: Lenalidomide-C5-NH2 Cereblon Ligand-Linker Conjugates 19;E3 ligase Ligand-Linker Conjugates 31, CAS: 2093388-45-3, stock 5.1g, assay 98.8%, MWt: 329.39, Formula: C18H23N3O3, Solubility: H2O : 50 mg/mL (151.80 mM; Need ultrasonic); DMSO : 5 mg/mL (15.18 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: PROTAC, Target: E3 Ligase Ligand-Linker Conjugate, Biological_Activity: Lenalidomide-C5-NH2 is the Lenalidomide-based Cereblon ligand used in the recruitment of CRBN protein. Lenalidomide-C5-NH2 can be connected to the ligand for protein by a linker to form PROTACs[1].

Name: STL127705, CAS: 1326852-06-5, stock 13g, assay 98.7%, MWt: 437.42, Formula: C22H20FN5O4, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: PI3K/Akt/mTOR;Cell Cycle/DNA Damage, Target: DNA-PK;DNA-PK, Biological_Activity: STL127705 (Compound L) is a Ku 70/80 heterodimer protein inhibitor, inhibits Ku70/80-DNA interaction, with an IC50 of 3.5 μM. STL127705 also inhibits Ku-dependent activation of DNA-PKCS kinase (IC50, 2.5 μM)[1].
IC50 & Target: IC50: 3.5 μM (Ku 70/80), 2.5 μM (DNA-PKCS)[1]

Name: Enclomiphene (citrate) (E)-Clomiphene (citrate);trans-Clomiphene (citrate);Enclomifene (citrate), CAS: 7599-79-3, stock 28.3g, assay 98.3%, MWt: 598.08, Formula: C32H36ClNO8, Solubility: DMSO : ≥ 50 mg/mL (83.60 mM), Clinical_Informat: Phase 3, Pathway: Others, Target: Estrogen Receptor/ERR, Biological_Activity: Enclomiphene citrate is a potent and orally active oestrogen receptor antagonist, with antioestrogenic property[1].

Name: Pinaverium bromide, CAS: 53251-94-8, stock 35.2g, assay 99%, MWt: 591.42, Formula: C26H41Br2NO4, Solubility: DMSO : 62.5 mg/mL (105.68 mM; Need ultrasonic), Clinical_Informat: Launched, Pathway: Membrane Transporter/Ion Channel;Neuronal Signaling, Target: Calcium Channel;Calcium Channel, Biological_Activity: Pinaverium bromide is an L-type calcium channel blocker with selectivity for the gastrointestinal tract, effectively relieves pain, diarrhea and intestinal discomfort, provides good therapeutic efficacies without significant adverse effects on Irritable bowel syndrome (IBS) patients[1].
IC50 & Target: Calcium channel[1].

Name: Blasticidin S, CAS: 2079-00-7, stock 16.4g, assay 98.8%, MWt: 422.44, Formula: C17H26N8O5, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Anti-infection, Target: Bacterial, Biological_Activity: Blasticidin S is a nucleoside antibiotic isolated from Streptomyces griseochromogenes. Blasticidin S is a potent inhibitor of protein synthesis in both prokaryotic and eukaryotic cells[1].
IC50 & Target: Antibiotic[1]
In Vitro: Blasticidin S (BlaS) is a broad spectrum antibiotic and inhibits cell growth in prokaryotes, fungi, plants, and mammalian cells[1].

Name: Bozitinib PLB-1001;CBT-101, CAS: 1440964-89-5, stock 24.3g, assay 98.1%, MWt: 424.38, Formula: C20H15F3N8, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Protein Tyrosine Kinase/RTK, Target: c-Met/HGFR, Biological_Activity: Bozitinib (PLB-1001) is a highly selective c-MET kinase inhibitor with blood-brain barrier permeability. Bozitinib (PLB-1001) is a ATP-competitive small-molecule inhibitor, binds to the conventional ATP-binding pocket of the tyrosine kinase superfamily[1].
In Vitro: Bozitinib (PLB-1001) (30 μM; 6 hours) inhibits the phosphorylation of MET and STAT3, has a robust inhibitory effect of PLB-1001 on MET and its downstream signaling pathways.

Name: Malic enzyme inhibitor ME1 ME1, CAS: 522649-59-8, stock 1.2g, assay 98.3%, MWt: 351.40, Formula: C20H21N3O3, Solubility: DMSO : 125 mg/mL (355.72 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: Malic enzyme inhibitor ME1 (ME1; compound 1) is a potent inhibitor of Malic enzyme (ME1) with an IC50 of 0.15 μM[1][2].
IC50 & Target: IC50: 0.15 μM (Malic enzyme)[1]
In Vitro: Malic enzyme inhibitor ME1 (ME1; ME1*) (50 μM; 72 hours) shows a significant reduction in total cell numbers[2]. 
Malic enzyme inhibitor ME1 shows a significant reduction in cell viability/metabolic activity in MTS cell[2]. 
Malic enzyme inhibitor ME1 dose-dependently reduces the number of colonies formed by both HCT116 and HT29 cells[2].

Name: Beta-d-N4-hydroxycytidine NHC, CAS: 3258-02-4, stock 39.9g, assay 98.5%, MWt: 259.22, Formula: C9H13N3O6, Solubility: DMSO : 250 mg/mL (964.43 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: Beta-d-N4-hydroxycytidine is a very potent anti-VEEV (venezuelan equine encephalitis virus) agent with EC50, EC90, and EC99 are 0.426, 1.036, and 2.5 μM, respectively[1].

Name: BTR-1, CAS: 18331-34-5, stock 35.7g, assay 98.4%, MWt: 249.35, Formula: C12H11NOS2, Solubility: H2O : < 0.1 mg/mL (insoluble); DMSO : 25 mg/mL (100.26 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Apoptosis, Target: Apoptosis, Biological_Activity: BTR-1 is an active anti-cancer agent, causes S phase arrest, and affects DNA replication in leukemic cells. BTR-1 activates apoptosis and induces cell death[1].
IC50 & Target: Apoptosis[1]
In Vitro: BTR-1 (10, 50, 100, and 250 µM, 5 days) dose-dependently causes cytotoxicity in human leukemic cells, with IC50s of 8 and 6 µM at 48 and 72 h, respectively[1].

Name: P62-mediated mitophagy inducer PMI, CAS: 1809031-84-2, stock 24g, assay 98.2%, MWt: 392.15, Formula: C14H9IN4O2, Solubility: DMSO : 1 mg/mL (2.55 mM; ultrasonic and adjust pH to 3 with 0.1 M HCL), Clinical_Informat: No Development Reported, Pathway: Autophagy, Target: Mitophagy, Biological_Activity: P62-mediated mitophagy inducer is a mitophagy regulator which activates mitophagy without recruiting Parkin or collapsing ΔΨm and retains activity in cells devoid of a fully functional PINK1/Parkin pathway[1].
IC50 & Target: mitophagy[1]

Name: MALAT1-IN-1, CAS: 827327-28-6, stock 21.3g, assay 98.1%, MWt: 323.39, Formula: C19H21N3O2, Solubility: DMSO : 125 mg/mL (386.53 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: MALAT1-IN-1 (compounds 5) is a potent and specific Malat1 (Metastasis-associated lung adenocarcinoma transcript 1) inhibitor. MALAT1-IN-1 modulated Malat1 downstream genes in a dose-dependent manner without affecting expression of nuclear enriched abundant transcript 1 (Neat1) [1].
IC50 & Target: Malat1[1]

Name: D3-βArr, CAS: 662164-09-2, stock 5.6g, assay 98.7%, MWt: 333.43, Formula: C20H23N5, Solubility: DMSO : ≥ 125 mg/mL (374.89 mM), Clinical_Informat: No Development Reported, Pathway: GPCR/G Protein, Target: TSH Receptor, Biological_Activity: D3-βArr is a positive allosteric modulator for thyrotropin receptor (TSHR), which initiates translocation of β-Arr 1 by direct TSHR activation and potentiates TSH-mediated preosteoblast differentiation in vitro[1].
IC50 & Target: Thyrotropin receptor (TSHR)[1]

Name: DC661, CAS: 1872387-43-3, stock 17.7g, assay 98.3%, MWt: 552.58, Formula: C31H39Cl2N5, Solubility: H2O : < 0.1 mg/mL (insoluble); DMSO : 62.5 mg/mL (113.11 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Apoptosis;Autophagy;Autophagy, Target: Apoptosis;Autophagy;Autophagy, Biological_Activity: DC661 is a potent palmitoyl-protein thioesterase 1 (PPT1) inhibitor, inhibits autophagy, and acts as an anti-lysosomal agent. Anti-cancer activity[1].
IC50 & Target: PPT1, autophagy[1]
In Vitro: DC661 (0.1 and 10 µM) accumulates autophagic vesicles in melanoma cells[1].

Name: Taribavirin (hydrochloride), CAS: 40372-00-7, stock 5.7g, assay 98.4%, MWt: 279.68, Formula: C8H14ClN5O4, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Anti-infection;Anti-infection, Target: HBV;HCV, Biological_Activity: Taribavirin hydrochloride is an orally active inosine monophosphate dehydrogenase inhibitor, has activity against a wide range of viruses, especially the hepatitis C virus and influenza virus. Taribavirin hydrochloride is a Ribavirin prodrug, is designed to concentrate within the liver to target HCV-infected hepatocytes while minimizing distribution within red blood cells (RBCs) and the development of hemolytic anemia[2].
IC50 & Target: Inosine monophosphate dehydrogenase[1]
In Vitro: Taribavirin hydrochloride (0-2 μM; 24 hours) significantly induces MCF-7 cell death, recording half inhibitory effect (IC50) of 0.756 μM in MCF-7 cells[1].

Name: Buparlisib NVP-BKM120;BKM120, CAS: 944396-07-0, stock 12.9g, assay 98.9%, MWt: 410.39, Formula: C18H21F3N6O2, Solubility: DMSO : ≥ 100 mg/mL (243.67 mM), Clinical_Informat: Phase 3, Pathway: PI3K/Akt/mTOR;Apoptosis, Target: PI3K;Apoptosis, Biological_Activity: Buparlisib (NVP-BKM120) is a pan-class I PI3K inhibitor, with IC50s of 52, 166, 116 and 262 nM for p110α, p110β, p110δ and p110γ, respectively.
IC50 & Target: IC50: 52 nM (p110α), 166 nM (p110β), 116 nM (p110δ), 262 nM (p110γ)[1]
In Vitro: Buparlisib (NVP-BKM120) exhibits 50-300 nM activity for class I PI3K’s, including the most common p110α mutants. Additionally, NVP-BKM120 exhibits lower potency against class III and class IV PI3K's, where 2, 5, >5, and >25 μM biochemical activity is observed for inhibition of VPS34, mTOR, DNAPK, and PI4K, respectively[1]. Buparlisib (NVP-BKM120) induces multiple myeloma (MM) cell apoptosis in both dose- and time-dependent manners. Buparlisib (NVP-BKM120) at concentrations ≥10 μM induces significant apoptosis in all tested MM cell lines at 24 h (P<0.05, compares with control). Therefore, 10 μM Buparlisib (NVP-BKM120) and 24-h treatment are chose in in the following experiments if not stated otherwise. Buparlisib (NVP-BKM120) treatment results in a dose-dependent growth inhibition in all tested MM cell lines. Buparlisib (NVP-BKM120) IC50 varies among tested MM cells. At 24 h treatment, IC50 for ARP-1, ARK, and MM.1R is between 1 and 10 μM, while IC50 for MM.1S is <1 μM, and IC50 for U266 is between 10 and 100 μM. In summary, NVP-BKM120 treatment results in MM cell growth inhibition and apoptosis in dose- and time-dependent manners[2].
In Vivo: In A2780 xenograft tumors, oral dosing of Buparlisib (NVP-BKM120) at 3, 10, 30, 60, and 100 mg/kg results in a dose dependent modulation of pAKTSer473. Partial inhibition of pAKTSer473 is observed at 3 and 10 mg/kg, and near complete inhibition is observed at doses of 30, 60, or 100 mg/kg, respectively. Inhibition of pAKT (normalized to total AKT) tracked well with both plasma and tumor drug exposure[1]. Mice receiving Buparlisib (NVP-BKM120) (5 μM per kg per day for 15 days) treatment has significantly smaller tumor burdens as compare with control mice, which are measured as tumor volume (P<0.05) and level of circulating human kappa chain (P<0.05). In addition, NVP-BKM120 treatment significantly prolongs the survival of tumor-bearing mice (P<0.05)[2].

Name: PAR-4 Agonist Peptide, amide (TFA) PAR-4-AP (TFA);AY-NH2 (TFA), CAS: 1228078-65-6, stock 30g, assay 98.4%, MWt: 794.82, Formula: C36H49F3N8O9, Solubility: DMSO : ≥ 250 mg/mL (314.54 mM); H2O : 100 mg/mL (125.81 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: GPCR/G Protein, Target: Protease-Activated Receptor (PAR), Biological_Activity: PAR-4 Agonist Peptide, amide TFA (PAR-4-AP TFA; AY-NH2 TFA) is a proteinase-activated receptor-4 (PAR-4) agonist, which has no effect on either PAR-1 or PAR-2 and whose effects are blocked by a PAR-4 antagonist[1].
IC50 & Target: PAR-4[1]
In Vivo: Compared with their BALB/cBy controls, SCID mice have a significantly greater abdominal response to colorectal distension (CRD) at the distension levels of 0.04 to 0.1 mL increasing the intensity of EMG response by 384% to 132%, respectively (P<0.01; P<0.01; P<0.01; P<0.001). PAR-4 activation effectively reverses this hypersensitivity (P<0.01, P<0.05; P<0.05; P<0.05)[1].

Name: Epsilon-momfluorothrin, CAS: 1065124-65-3, stock 6.9g, assay 98.4%, MWt: 385.35, Formula: C19H19F4NO3, Solubility: DMSO : 5 mg/mL (12.98 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: Epsilon-momfluorothrin is a type I synthetic pyrethroid insecticide, activates constitutive androstane receptor (CAR), and induces hepatocellular tumors in rats[1].
IC50 & Target: Constitutive androstane receptor[1]

Name: 1-(2'-O-4-C-Methylene-beta-D-ribofuranosyl)thymine, CAS: 206055-67-6, stock 5.5g, assay 98%, MWt: 270.24, Formula: C11H14N2O6, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Cell Cycle/DNA Damage, Target: Nucleoside Antimetabolite/Analog, Biological_Activity: 1-(2'-O-4-C-Methylene-beta-D-ribofuranosyl)thymine is a bicyclic nucleoside.

Name: 2’-O,4’-C-Methyleneuridine, CAS: 200435-92-3, stock 9.7g, assay 98.2%, MWt: 256.21, Formula: C10H12N2O6, Solubility: DMSO : 125 mg/mL (487.88 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Cell Cycle/DNA Damage, Target: Nucleoside Antimetabolite/Analog, Biological_Activity: 2’-O,4’-C-Methyleneuridine (Compound 15a) is a bicyclic nucleoside.

Name: 3'-Azido-3'-deoxy-5-methylcytidine, CAS: 1282040-14-5, stock 26.9g, assay 99%, MWt: 282.26, Formula: C10H14N6O4, Solubility: DMSO : 83.33 mg/mL (295.22 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Anti-infection;Anti-infection, Target: Reverse Transcriptase;HIV, Biological_Activity: 3'-Azido-3'-deoxy-5-methylcytidine (CS-92) is a potent xenotropic murine leukemia-related retrovirus (XMRV) inhibitor with a CC50 of 43.5 μM in MCF-7 cells. 3'-Azido-3'-deoxy-5-methylcytidine also inhibits HIV-1 reverse transcriptase with an EC50 of 0.06 μM in peripheral blood mononuclear (PBM) cells[1].

Name: 3'-Azido-3'-deoxy-5-fluorocytidine, CAS: 2095417-18-6, stock 33g, assay 99%, MWt: 286.22, Formula: C9H11FN6O4, Solubility: DMSO : 140 mg/mL (489.13 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Cell Cycle/DNA Damage, Target: Nucleoside Antimetabolite/Analog, Biological_Activity: 3'-Azido-3'-deoxy-5-fluorocytidine (Compound 12) is a cytidine derivative.

Name: 3'-Azido-3'-deoxy-beta-L-uridine, CAS: 2095417-28-8, stock 37.3g, assay 98.5%, MWt: 269.21, Formula: C9H11N5O5, Solubility: DMSO : 125 mg/mL (464.32 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Cell Cycle/DNA Damage, Target: Nucleoside Antimetabolite/Analog, Biological_Activity: 3'-Azido-3'-deoxy-beta-L-uridine (Compound 25) is a nucleoside derivative.

Name: 6-Amino-5-azacytidine, CAS: 105331-00-8, stock 23.1g, assay 98.6%, MWt: 259.22, Formula: C8H13N5O5, Solubility: H2O : 14.71 mg/mL (56.75 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Anti-infection, Target: Bacterial, Biological_Activity: 6-Amino-5-azacytidine inhibits the growth of bacteria E. coli[1].
IC50 & Target: Anti-bacteria (E. coli)[1]
In Vitro: 6-Amino-5-azacytidine has an ID50 of 33.9 μM against CCRF-CEM cells and inhibits the growth of WI-L2 cells by 39% at 100 μM[1].

Name: 3-Methylcytidine, CAS: 2140-64-9, stock 2.1g, assay 98.9%, MWt: 257.24, Formula: C10H15N3O5, Solubility: DMSO : 83.33 mg/mL (323.94 mM; Need ultrasonic); H2O : 90 mg/mL (349.87 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Cell Cycle/DNA Damage, Target: Nucleoside Antimetabolite/Analog, Biological_Activity: 3-Methylcytidine, a urinary nucleoside, can be used as a biomarker of four different types of cancer: lung cancer, gastric cancer, colon cancer, and breast cancer[1].

Name: N2-Methylguanosine, CAS: 2140-77-4, stock 34.4g, assay 98.2%, MWt: 297.27, Formula: C11H15N5O5, Solubility: DMSO : < 1 mg/mL (insoluble or slightly soluble), Clinical_Informat: No Development Reported, Pathway: Cell Cycle/DNA Damage, Target: Nucleoside Antimetabolite/Analog, Biological_Activity: N2-methylguanosine is a modified nucleoside that occurs at several specific locations in many tRNA's.

Name: 6-O-Methyl Guanosine, CAS: 7803-88-5, stock 26.3g, assay 98.4%, MWt: 297.27, Formula: C11H15N5O5, Solubility: DMSO : 130 mg/mL (437.31 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Cell Cycle/DNA Damage, Target: Nucleoside Antimetabolite/Analog, Biological_Activity: 6-O-Methyl Guanosine is a modified nucleoside[1]. 6-O-Methyl Guanosine (6-methylguanosine) inhibit colony-forming ability in a malignant xeroderma pigmentosum cell line[2].

Name: 6-Methyl-5-azacytidine, CAS: 105330-94-7, stock 29.9g, assay 98.8%, MWt: 258.23, Formula: C9H14N4O5, Solubility: DMSO : 125 mg/mL (484.06 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Epigenetics, Target: DNA Methyltransferase, Biological_Activity: 6-Methyl-5-azacytidine is a potent DNMT inhibitor.

Name: Gboxin, CAS: 2101315-36-8, stock 30.2g, assay 98.3%, MWt: 392.96, Formula: C22H33ClN2O2, Solubility: DMSO : 32.5 mg/mL (82.71 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Membrane Transporter/Ion Channel, Target: ATP Synthase, Biological_Activity: Gboxin is an oxidative phosphorylation inhibitor that targets glioblastoma. Gboxin inhibits the activity of F0F1 ATP synthase[1]. Antitumour activity[1].
IC50 & Target: F0F1 ATP synthase[1]
In Vitro: Gboxin (0-15 μM; 96 hours) specifically inhibit the growth of primary ‘high-throughput GBM sphere’ (HTS) cells but not that of cycling primary low-passage mouse embryonic fibroblasts (MEFs) or astrocytes[1].

Name: S-Gboxin, CAS: 2101317-21-7, stock 7.2g, assay 98.3%, MWt: 600.45, Formula: C27H32F3IN2O2, Solubility: DMSO : 93.33 mg/mL (155.43 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: S-Gboxin, a functional analogue of Gboxin, inhibits growth of mouse and human glioblastoma (GBM) with an IC50 of 470 nM[1]. Antitumour activity[1].

Name: CycLuc1, CAS: 1247879-16-8, stock 6.1g, assay 98.6%, MWt: 305.38, Formula: C13H11N3O2S2, Solubility: DMSO : ≥ 83.33 mg/mL (272.87 mM), Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: CycLuc1 is a brain penetrant luciferase substrate.
IC50 & Target: Luciferase[1]

Name: DSP-2230, CAS: 1233231-30-5, stock 25.6g, assay 98.1%, MWt: 419.40, Formula: C20H20F3N5O2, Solubility: DMSO : 125 mg/mL (298.04 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Membrane Transporter/Ion Channel, Target: Sodium Channel, Biological_Activity: DSP-2230 is a selective Nav1.7/Nav1.8 blocker[1][2].
IC50 & Target: Nav1.7/Nav1.8[1]

Name: His-Pro, CAS: 20930-58-9, stock 27.6g, assay 99%, MWt: 252.27, Formula: C11H16N4O3, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: His-Pro is a dipeptide consisting of histidyl and proline.

Name: OVA Peptide (257-264) (TFA), CAS: 1262751-08-5, stock 3.9g, assay 98.7%, MWt: 1077.15, Formula: C47H75F3N10O15, Solubility: H2O : 20 mg/mL (18.57 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: OVA Peptide (257-264) TFA is a class I (Kb)-restricted peptide epitope of OVA, an octameric peptide from ovalbumin presented by the class I MHC molecule, H-2Kb.
In Vitro: TAP1-I- and C57BL/6 macrophages may process Crl-OVA and full-length OVA in different cellular compartments and that the protein context of the OVA Peptide (257-264) epitope influences the extent of TAP-independent processing for MHC class I presentation. OVA Peptide (257-264) epitope is presented with a differential dependence on the TAP transporter depending on the protein context of the OVA epitope: OVA Peptide (257-264) contained within the MBPCrl-OVA or Crl-OVA bacterial fusion proteins is presented with little dependence on the TAP transporter, while OVA Peptide (257-264) contained within full-length ovalbumin is largely dependent on the TAP transporter, regardless of whether recombinant OVA is expressed in bacteria or the native protein is coupled to polystyrene beads[1].

Name: Danshenxinkun B, CAS: 65907-76-8, stock 20.3g, assay 98.7%, MWt: 280.32, Formula: C18H16O3, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: Danshenxinkun B is an antioxidative component of tanshen (Salvia miltiorhiza Bung) [1].

Name: GLP-1(7-37) (acetate), CAS: 1450806-98-0, stock 20.5g, assay 98.4%, MWt: 3415.72, Formula: C153H232N40O49, Solubility: H2O, Clinical_Informat: No Development Reported, Pathway: GPCR/G Protein, Target: Glucagon Receptor, Biological_Activity: GLP-1(7-37) acetate is an intestinal insulinotropic hormone that augments glucose induced insulin secretion[1].
In Vivo: GLP-1(7-37) (0.5, 5 or 50 pmol/min/kg) infused during the second hour of a 2-hour 11-mM hyperglycemic clamp produces a dose-related enhancement of the glucose-stimulated increase in plasma insulin concentration and an increased rate of glucose infusion in rats[2]. 
Infusion of GLP-1(7-37) (5 pmol/min/kg) from 1 hour through 7 hours produces a sustained increase in plasma insulin concentration relative to levels in rats infused with vehicle in rats with maintained glucose concentration at 11 mM[2].

Name: VL285, CAS: 1448188-57-5, stock 34.6g, assay 98.4%, MWt: 532.65, Formula: C29H32N4O4S, Solubility: DMSO : 125 mg/mL (234.68 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: PROTAC, Target: Ligand for E3 Ligase, Biological_Activity: VL285 is a potent VHL ligand with an IC50 of 0.34 μM[1].
IC50 & Target: VHL[1]
In Vitro: Treatment with VL285 attenuates the ability of HaloPROTAC3 to induce the degradation of GFP-HaloTag7[1].

Name: Phytic acid (dodecasodium salt hydrate) myo-Inositol, hexakis(dihydrogen phosphate) (dodecasodium salt hydrate);Inositol hexaphosphate (dodecasodium salt hydrate), CAS: 123408-98-0, stock 27.8g, assay 98.8%, MWt: 1000, Formula: C6H18O24P6.XH2O.12Na, Solubility: H2O : ≥ 250 mg/mL, Clinical_Informat: Phase 3, Pathway: Metabolic Enzyme/Protease;Metabolic Enzyme/Protease, Target: Xanthine Oxidase;Endogenous Metabolite, Biological_Activity: Phytic acid dodecasodium salt hydrate is a phosphorus storage compound of seeds and cereal grains. Phytic acid dodecasodium salt hydrate is known as a food inhibitor, which has a strong ability to chelate multivalent metal ions, specially zinc, calcium, iron and as with protein residue. Phytic acid dodecasodium salt hydrate inhibits the enzymatic superoxide source xanthine oxidase (XO), and has antioxidative, neuroprotective, anti-inflammatory effects[1][2][3][4].
IC50 & Target: Xanthine oxidase[3]
In Vitro: Phytic acid dodecasodium salt hydrate (myo-Inositol) inhibits the formation of uric acid from xanthine with an IC50 of about 30 mM. The generation of the superoxide is greatly affected by Phytic acid dodecasodium salt hydrate; the IC50 is about 6 mM, indicating that the superoxide generating domain of XO is more sensitive to phytic acid[3].

Name: (R)-(+)-Citronellal (+)-Citronellal, CAS: 2385-77-5, stock 0.7g, assay 98.1%, MWt: 154.25, Formula: C10H18O, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Metabolic Enzyme/Protease, Target: Endogenous Metabolite, Biological_Activity: (R)-(+)-Citronellal, isolated from citrus, lavender and eucalyptus oils, is a monoterpenoid and main component of citronellal oil with a distinct lemon scent. A flavouring agent. Used for insect repellent and antifungal properties[1][2].

Name: Sigma-2 receptor antagonist 1, CAS: 1802632-22-9, stock 32.2g, assay 98.4%, MWt: 431.59, Formula: C24H33NO4S, Solubility: DMSO : 250 mg/mL (579.25 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Neuronal Signaling;GPCR/G Protein, Target: Sigma Receptor;Sigma Receptor, Biological_Activity: Sigma-2 receptor antagonist 1 is a sigma-2 (σ-2) receptor antagonist.
IC50 & Target: Sigma-2 receptor

Name: (R)-Ofloxacin Dextrofloxacin, CAS: 100986-86-5, stock 33.2g, assay 98.4%, MWt: 361.37, Formula: C18H20FN3O4, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Anti-infection, Target: Bacterial, Biological_Activity: (R)-Ofloxacin (Dextrofloxacin) is an antibiotic useful for the treatment of a number of bacterial infections[1]. Antibacterial activity[1].

Name: HLY78, CAS: 854847-61-3, stock 39.9g, assay 98.7%, MWt: 267.32, Formula: C17H17NO2, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Stem Cell/Wnt, Target: Wnt, Biological_Activity: HLY78 is an activator of the Wnt/β-catenin signaling pathway, which targets the DIX domain of Axin and potentiates the Axin-LRP6 association to promote Wnt signaling transduction[1].
IC50 & Target: Wnt/β-catenin[1]

Name: NSC 185058, CAS: 39122-38-8, stock 13.6g, assay 98.3%, MWt: 215.27, Formula: C11H9N3S, Solubility: DMSO : ≥ 125 mg/mL (580.67 mM), Clinical_Informat: No Development Reported, Pathway: Autophagy;Metabolic Enzyme/Protease, Target: Autophagy;Cathepsin, Biological_Activity: NSC 185058 is an inhibitor of ATG4B, a major cysteine protease. Inhibition of ATG4B using NSC185058 markedly attenuates autophagic activity[1].
IC50 & Target: ATG4B[1] 
Autophagy[1]
In Vivo: NSC185058 is an ATG4B antagonist. ATG4B stimulates autophagy by promoting autophagosome formation through reversible modification of ATG8. Inclusion of the ATG4B inhibitor NSC185058 enhances the anti-tumor activity of radiation therapy (RT). NSC185058 decreases glioblastoma (GBM) cell tumorigenicity, and enhances the anti-tumor activity of RT when applied to orthotopic GBM xenograft models[1].

Name: CTPB, CAS: 586976-24-1, stock 38.6g, assay 98.6%, MWt: 554.13, Formula: C31H43ClF3NO2, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Epigenetics, Target: Histone Acetyltransferase, Biological_Activity: CTPB is a good activator of p300 histone acetyl transferase (HAT) enzyme[1].
IC50 & Target: p300 histone acetyl transferase (HAT)[1]
In Vitro: CTPB is a synthetic HAT activator, which promotes the transcription by increasing the H3 and H4 acetylation in nucleosome[1].

Name: IAXO-102, CAS: 1115270-63-7, stock 9.3g, assay 98%, MWt: 585.94, Formula: C35H71NO5, Solubility: Ethanol : 50 mg/mL (85.33 mM; Need ultrasonic); DMSO : < 1 mg/mL (insoluble or slightly soluble), Clinical_Informat: No Development Reported, Pathway: Immunology/Inflammation, Target: Toll-like Receptor (TLR), Biological_Activity: IAXO-102 is a TLR4 antagonist which negatively regulates TLR4 signalling. It inhibits MAPK and p65 NF-κB phosphorylation and expression of TLR4 dependent proinflammatory protein. IAXO-102 also prevents experimental abdominal aortic aneurysm development[1].
IC50 & Target: TLR4[1]
In Vitro: IAXO-102 (1-10 µM, for 2 hours) inhibits MAPK and p65 NF-κB phosphorylation in human umbilical vein endothelial (HUVEC) cells[1]. 
IAXO-102 (10 µM, for 17 hours) suppresses LPS induced proinflammatory proteins MCP-1 and IL-8 production in HUVEC[1].
In Vivo: IAXO-102 (3 mg/kg/day, s.c. for 28 days) significantly retards Angiotensin II induced increase in aortic diameter in mice[1].

Name: ZXH-3-26, CAS: 2243076-67-5, stock 4.5g, assay 98.5%, MWt: 785.27, Formula: C38H37ClN8O7S, Solubility: DMSO : 200 mg/mL (254.69 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Epigenetics;PROTAC, Target: Epigenetic Reader Domain;PROTAC, Biological_Activity: ZXH-3-26 is a selective PROTAC BRD4 degrader with a DC50/5h (DC50/5h referring to half-maximal degradation after 5 hours of treatment) of ~ 5 nM[1].
In Vitro: ZXH-3-26 represents the first small molecule to allow pharmacologic targeting of BRD4 without significant inhibition or degradation of BRD2/3[1].

Name: Piperaquine tetraphosphate tetrahydrate, CAS: 915967-82-7, stock 12.9g, assay 98.3%, MWt: 999.60, Formula: C29H32Cl2N6.4H3O4P.4H2O, Solubility: DMSO : < 1 mg/mL (insoluble or slightly soluble); H2O : 6 mg/mL (6.00 mM; Need ultrasonic), Clinical_Informat: Launched, Pathway: Anti-infection, Target: Parasite, Biological_Activity: Piperaquine tetraphosphate tetrahydrate is a potent anti-parasites agent, widely used in combination with other antimalarial agents[1].

Name: (R)-BAY1238097, CAS: 1564269-85-7, stock 33.3g, assay 98.5%, MWt: 451.56, Formula: C25H33N5O3, Solubility: H2O : < 0.1 mg/mL (insoluble); DMSO : 150 mg/mL (332.18 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Epigenetics, Target: Epigenetic Reader Domain, Biological_Activity: (R)-BAY1238097 is the R-isomer with lower activity of BAY1238097. BAY1238097 is a potent and selective inhibitor of BET binding to histones and has strong anti-proliferative activity in different AML (acute myeloid leukemia) and MM (multiple myeloma) models through down-regulation of c-Myc levels and its downstream transcriptome[1][2].
IC50 & Target: BET[1].

Name: Sotrastaurin AEB071, CAS: 425637-18-9, stock 39.1g, assay 98.9%, MWt: 438.48, Formula: C25H22N6O2, Solubility: DMSO : ≥ 50 mg/mL (114.03 mM), Clinical_Informat: Phase 2, Pathway: TGF-beta/Smad;Epigenetics, Target: PKC;PKC, Biological_Activity: Sotrastaurin is a potent pan-PKC inhibitor, with Kis of 0.22 nM, 0.64nM, 0.95 nM, 1.8 nM, 2.1 nM and 3.2 nM for PKCθ, PKCβ, PKCα, PKCη, PKCδ and PKCε, respectively.
IC50 & Target: IC50: 0.22 nM (PKCθ), 0.64 nM (PKCβ), 0.95 nM (PKCα), 1.8 nM (PKCη), 2.1 nM (PKCδ), 3.2 nM (PKCε)[1]
In Vitro: In cell-free kinase assays Sotrastaurin (AEB071) inhibits PKC, with Ki values in the subnanomolar to low nanomolar range. When Sotrastaurin is tested on a selected panel of kinases, the only enzyme on which Sotrastaurin displays an IC50value below 1 μM is glycogen synthase kinase 3β[1]. Sotrastaurin (AEB071) inhibits p-MARCKS, a PKC substrate, and pS6 in all the cell lines, independently of the mutational status. There is a slight inhibition of pERK at lower doses also in the GNA11 mutant cells, but not in the WT cells at any concentrations. This is consistent with previous reports indicating that Sotrastaurin inhibits ERK1/2 phosphorylation in GNAQ mutant cell lines[2].
In Vivo: The combination therapy results in a significantly enhanced reduction in tumor volume when compared to either Sotrastaurin (AEB071) or BYL719 alone (p=0.049 vs. BYL719 and p=0.022 vs. Sotrastaurin at day 26). There is even a greater effect when compared to vehicle control (p=0.016)[2]. Sotrastaurin (STN) treatment of liver donors and orthotopic liver transplantation (OLT) recipients (Gr.I) or of OLT recipients alone (Gr.II) prolongs animal survival, as 9 out of 10 rats in Gr. I, and 6 out of 6 rats in Gr.II survive >14 days. In contrast, only 4 out of 10 control OLT recipients remain alive at day 14 (p<0.01)[3].

Name: MS645, CAS: 2250091-96-2, stock 34.4g, assay 98.4%, MWt: 938.04, Formula: C48H54Cl2N10O2S2, Solubility: DMSO : 200 mg/mL (213.21 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Epigenetics, Target: Epigenetic Reader Domain, Biological_Activity: MS645 is a bivalent BET bromodomains (BrD) inhibitor with a Ki of 18.4 nM for BRD4-BD1/BD2. MS645 spatially constrains bivalent inhibition of BRD4 BrDs resulting in a sustained repression of BRD4 transcriptional activity in solid-tumor cells[1].
In Vitro: MS645 has cell growth inhibitory effects on noncancer cell lines of mouse macrophage RAW cells and nontumorigenic breast epithelial MCF10A with IC50s of 4.1 nM, 6.8 nM, 7.9 nM for triple-negative breast cancer (TNBC) cell lines HS5878T, BT549, and MCF 10A[1]. 
MS645 (15, 30, 60 nM) results in a dramatic reduction of c-Myc expression and an increase of p21, a tumor suppressor and cell-cycle inhibitor in HCC1806 cells[1].

Name: ZT-12-037-01, CAS: 2328073-61-4, stock 32.4g, assay 98.5%, MWt: 385.50, Formula: C21H31N5O2, Solubility: DMSO : 8.33 mg/mL (21.61 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: GPCR/G Protein, Target: Ras, Biological_Activity: ZT-12-037-01 is a STK19-targeted inhibitor, has a high-affinity interaction with STK19 protein and inhibits oncogenic NRAS-driven melanocyte malignant transformation. ZT-12-037-01 is an ATP-competitive inhibitor, inhibiting phosphorylation of NRAS (major isoform of Ras family) with an IC50 of 24 nM[1].
In Vitro: ZT-12-037-01 (3 μM; 14 days) significantly inhibits mutant NRAS-STK19-driven melanocyte colony formation and proliferation[1].
ZT-12-037-01 (0-3 μM) has an inhibitory effects of ZT-12-037-01 on STK19WT and STK19D89N-activated NRAS phosphorylation in HPMs[1].
In Vivo: ZT-12-037-01 (injection subcutaneously; 25-50 mg/kg; once daily; 21 days) inhibits growth of SK-MEL-2 xenograft melanoma and the sections of tumors indicates induction of apoptosis by increasing cleaved caspase-3[1].

Name: TH5487, CAS: 2304947-71-3, stock 27.5g, assay 98.4%, MWt: 541.18, Formula: C19H18BrIN4O2, Solubility: DMSO : 25 mg/mL (46.20 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: TH5487 is a potent 8-oxoguanine DNA glycosylase 1 (OGG1) inhibitor with an IC50 of 342 nM. TH5487 stops OGG1 from recognizing its DNA substrate, inhibits DNA repair and modifies OGG1 chromatin dynamics, which results in the inhibition of proinflammatory pathway genes[1].
In Vitro: TH5487 (5 μM; 1 hour) decreases TNFα- and LPS-induced proinflammatory gene expression to near pretreatment levels[1].
TH5487 (0-10 μM; 1 hour) perturbs binding of NF-κB to 8-oxoG–containing synthetic DNA in nuclear extracts from MLE 12 or hSAEC cells[1].
In Vivo: TH5487 (prophylactic intraperitoneally injection; 8-30 mg/kg; 1-9 hours) decreases TNFα or LPS induced the robust recruitment of neutrophils to the airways, and reduces the pulmonary neutrophil count in a time-dependent manner[1].

Name: ML230 CID44640177;SID 88095709, CAS: 1776055-05-0, stock 10g, assay 98.1%, MWt: 439.47, Formula: C25H21N5O3, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: ML230 (CID44640177; SID 88095709) is a selective inhibitor of ATP-binding cassette (ABC) transporter ABCG2, and 36-fold selective for ABCG2 over ABCB1 with EC50s values of 0.13 μM and 4.65 μM, respectively[1].
IC50 & Target: EC50: ABCG2 (0.13 μM)[1]

Name: Dooku1, CAS: 2253744-54-4, stock 36.8g, assay 98.7%, MWt: 326.20, Formula: C13H9Cl2N3OS, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: Dooku1, an analog of Yoda1, is a selective antagonist of the endogenous Piezo1 channel. Dooku1 inhibited 2 μM Yoda1-induced Ca2+-entry with IC50 values of 1.3 μM (in HEK 293 cells) and 1.5 μM (in HUVECs). Dooku1 inhibits Yoda1-induced relaxation of aorta[1].

Name: AB-680, CAS: 2105904-82-1, stock 7.9g, assay 98.7%, MWt: 580.82, Formula: C20H24ClFN4O9P2, Solubility: DMSO : 300 mg/mL (516.51 mM; Need ultrasonic), Clinical_Informat: Phase 1, Pathway: Immunology/Inflammation, Target: CD73, Biological_Activity: AB-680 is highly potent, reversible and selective small molecule inhibitor of CD73 (an ecto-nucleotidase), with a Ki of 4.9 pM for hCD73, displays >10,000-fold selectivity over related ecto-nucleotidases CD39. Anti-tumor activity[1].
IC50 & Target: Ki: 4.9 pM (hCD73)[1] 
IC50: 43 pM (Soluble hCD73)[1]
In Vitro: AB-680 (AB680) inhibits soluble hCD73 with an IC50 of 0.043 nM, also inhibits hCD73 in CHO cells, suppresses CD73 in human, mouse CD8+ T Cells and hPBMC, with IC50s of 0.070, 0.008, 0.66 and 0.011 nM, respectively[1].

Name: TK216, CAS: 1903783-48-1, stock 25.1g, assay 98.6%, MWt: 376.23, Formula: C19H15Cl2NO3, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Apoptosis, Target: Apoptosis, Biological_Activity: TK216 is a potent E26 transformation specific (ETS) inhibitor[1]. TK216 directly binds EWS-FLI1 and inhibits EWS-FLI1 protein interactions. TK216 blocks the binding between EWS-FLI1 and RNA helicase A. TK216 has anticancer activity[2].
IC50 & Target: ETS[1]
In Vitro: TK216 (500 nM; for 24-72 hours) induces apoptosis in DLBCL cell lines[1]. 
TK216 (0.03, 0.06, 0.125, 0.25, 0.5 μM) results in a dose-dependent inhibition of proliferation in Ewing Sarcoma A4573 cell line[1]. 
TK216 (0.1, 0.3, 1 μM) induces apoptosis in DLBCL cell lines, with the amount of cleaved-Caspase 3 normalized to b-actin and presented as fold over control[1]. 
TK216 has IC50s of 0.363 μM and 0.152 μM for HL-60 AML cell line and TMD-8 DLBCL cell line[1]. 
TK216 inhibits EWS-FLI1 (Ewing sarcoma breakpoint region 1/Friend leukemia virus integration 1 fusion protein) protein interactions, leading to a decrease in transcription and proliferation[1].
In Vivo: TK216 (po; 100 mg/kg; twice daily for 13 days) results in tumor growth inhibition of the TMD-8 xenograft model[1].

Name: (Rac)-Nedisertib (Rac)-M3814, CAS: 1637542-34-7, stock 29.5g, assay 98.4%, MWt: 481.91, Formula: C24H21ClFN5O3, Solubility: DMSO : ≥ 100 mg/mL (207.51 mM), Clinical_Informat: No Development Reported, Pathway: PI3K/Akt/mTOR;Cell Cycle/DNA Damage, Target: DNA-PK;DNA-PK, Biological_Activity: (Rac)-Nedisertib ((Rac)-M3814) is a racemate of Nedisertib, a potent DNA-PK inhibitor, with an IC50 of <3 nM[1].
IC50 & Target: IC50: <3 nM (DNA-PK)[1]
In Vitro: (Rac)-Nedisertib (Compound 137) potently inhibits DNA-PK, with an IC50 of <3 nM for DNA-PK, 0.5-5 μM for cellular pDNA-PK and 15-25 μM for KV11.1 (hERG, human ether a-go-go related gene)[1].

Name: PTI-428, CAS: 1953130-87-4, stock 8.8g, assay 98.4%, MWt: 354.36, Formula: C18H18N4O4, Solubility: DMSO : 250 mg/mL (705.50 mM; Need ultrasonic), Clinical_Informat: Phase 2, Pathway: Autophagy;Membrane Transporter/Ion Channel, Target: Autophagy;CFTR, Biological_Activity: PTI-428 is a specific cystic fibrosis transmembrane conductance regulator (CFTR) amplifier[1].
IC50 & Target: CFTR[1]

Name: DFP00173, CAS: 672286-03-2, stock 11.8g, assay 98.4%, MWt: 332.16, Formula: C11H7Cl2N3O3S, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: DFP00173 is a potent and selective aquaporin-3 (AQP3) inhibitor. DFP00173 inhibits mouse and human AQP3 with an IC50 of ∼0.1-0.4 μM. DFP00173 is selective for AQP3 over the homologous AQP isoforms AQP7 and AQP9[1].
In Vitro: DFP00173 inhibits the glycerol permeability of human erythrocytes with an IC50 of ~0.2 µM[1].

Name: Z433927330, CAS: 1005883-72-6, stock 0.3g, assay 98.3%, MWt: 364.40, Formula: C20H20N4O3, Solubility: DMSO : ≥ 280 mg/mL (768.39 mM), Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: Z433927330 is a potent and selective inhibitor of Aquaporin-7 (AQP7), less potently inhibits AQP3 and AQPs9, with IC50s of ~0.2 µM, ~0.7 µM and ~1.1 µM for mAQP7, mAQP3 and mAQP9, respectively[1].
IC50 & Target: IC50: ~0.2 µM (mAQP7), ~0.7 µM (mAQP3), ~1.1 µM (mAQP9)[1]
In Vitro: Z433927330 inhibits glycerol permeability, with an IC50 of ~0.6 µM[1].

Name: DRF-1042, CAS: 200619-13-2, stock 0.2g, assay 98.5%, MWt: 408.40, Formula: C22H20N2O6, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Cell Cycle/DNA Damage;Antibody-drug Conjugate/ADC Related, Target: Topoisomerase;ADC Cytotoxin, Biological_Activity: DRF-1042 is an orally active derivative of Camptothecin. DRF-1042 acts to inhibit DNA topoisomerase I. DRF-1042 shows good anticancer activity against a panel of human cancer cell lines including multi-drug resistance (MDR) phenotype[1][2].
IC50 & Target: DNA topoisomerase I[1]
In Vitro: DRF-1042 demonstrates superior lactone stability and good in vitro anticancer activity against a panel of human cancer cell lines including multi-drug resistance (MDR) phenotype[2].
In Vivo: In clonogenic assay against murine, canine and human bone marrow cells, DRF-1042 treatment shows less mylosupression that supports the possibility of protracted dose schedule in both experimental and clinical studies[2].

Name: GSK2593074A GSK'074, CAS: 1337531-06-2, stock 1.4g, assay 98.1%, MWt: 465.57, Formula: C27H23N5OS, Solubility: DMSO : 41.67 mg/mL (89.50 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Apoptosis, Target: RIP kinase, Biological_Activity: GSK2593074A (GSK’074) is a necroptosis inhibitor with dual targeting ability to both RIP1 and RIP3[1].
IC50 & Target: RIP1, RIP3[1]
In Vitro: GSK2593074A (GSK’074; 0.01, 0.1, 1, 10, and 100 nM; 6 hours for MOVAS cells; 3 hours for L929 cells) completely rescues cells from necroptosis under different stimuli in both human and murine cells at IC50~3 nM. In multiple cell types including mouse SMCs, fibroblasts (L929), bone marrow derived macrophages (BMDM), and human colon epithelial cells (HT29), GSK2593074A inhibits necroptosis with an IC50 of ~3 nM[1].
In Vivo: GSK2593074A (GSK’074; 0.93 mg/kg/day; i.p. injection; 14 or 28 days) is administrated to Apoe-/- mice immediately following pump implantation. Compared to the DMSO group, GSK2593074A-treated mice show significantly alleviated aneurysm formation, reflected by a much smaller aortic dilatation (DMSO 85.39±15.76% vs GSK2593074A 36.28±5.76%; P<0.05) as well as a reduced abdominal aortic aneurysm (AAA) incidence (from 83.3 to 16.7%). GSK2593074A significantly decreases the extent of aortic expansion (DMSO 66.06±9.17% vs GSK2593074A 27.36±8.25%; P<0.05) [1].

Name: Borussertib, CAS: 1800070-77-2, stock 21.9g, assay 98.8%, MWt: 596.68, Formula: C36H32N6O3, Solubility: DMSO : 25 mg/mL (41.90 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: PI3K/Akt/mTOR, Target: Akt, Biological_Activity: Borussertib is a covalent-allosteric and first-in-class inhibitor of protein kinase Akt, with an IC50 of 0.8 nM and a Ki of 2.2 nM for Aktwt[1].
IC50 & Target: IC50: 0.8 nM (Aktwt)[1].
In Vitro: Borussertib exhibits excellent cellular activity in the nanomolar range with superior profile against clinical candidate Akt inhibitors as well as the cytostatic drug doxorubicin. The EC50 values are 191±90 nM, 48±15 nM, 5±1 nM, 277±90 nM, 373±54 nM, 7770±641 nM in AN3CA (endometrium), T47D (breast), ZR-75-1 (breast), MCF-7 (breast), BT-474 (breast) and KU-19-19 (bladder) cell lines, respectively[1].

Name: (R,S)-Anatabine, CAS: 2743-90-0, stock 23.6g, assay 98.8%, MWt: 160.22, Formula: C10H12N2, Solubility: DMSO : 125 mg/mL (780.18 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: (R,S)-Anatabine is a a minor tobacco alkaloid found in the Solanaceae family of plants that can be used as a specific marker for the detection of tobacco use[1].

Name: Tyk2-IN-5, CAS: 1797432-62-2, stock 27.1g, assay 98.5%, MWt: 434.43, Formula: C21H19FN8O2, Solubility: DMSO : 43.33 mg/mL (99.74 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Epigenetics;Stem Cell/Wnt;JAK/STAT Signaling, Target: JAK;JAK;JAK, Biological_Activity: Tyk2-IN-5 (compound 6) is a highly potent, selective and orally active Tyk2 inhibitor and targets the JH2 domain, with a Ki of 0.086 nM for Tyk2 JH2 and an IC50 of 25 nM for IFNα. Highly effective in inhibiting IFNγ production in a rat pharmacodynamics model and fully efficacious in a rat adjuvant arthritis model[1].
IC50 & Target: Ki: 0.086 nM (0.086 nM) 
IC50: 25 nM (IFNα)[1].

Name: TBAJ-587, CAS: 2252316-16-6, stock 3.3g, assay 98.7%, MWt: 614.50, Formula: C30H33BrFN3O5, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Anti-infection, Target: Bacterial, Biological_Activity: TBAJ-587, a potent anti-tuberculosis agent, inhibits M.tb strain H37Rv growth with MIC90s of 0.006 and <0.02 µg/mL in MABA and LORA assay, respectively. TBAJ-587 inhibits hERG channel minimally, attenuates inhibition of the cardiac potassium channel protein coded by the hERG, which is important for cardiac repolarization[1].
IC50 & Target: Anti-tuberculosis[1]
In Vitro: Bedaquiline is a drug of the diarylquinoline class that has proven to be clinically effective against drug-resistant tuberculosis, but has a cardiac liability due to its potent inhibition of the cardiac potassium channel protein hERG. TBAJ-587, an analogue of Bedaquiline, demonstrates more potent anti-tubercular activity, with greatly attenuated hERG blockade. TBAJ-587 inhibits hERG channel with an IC50 of 13 μM[1].

Name: LysRs-IN-2, CAS: 2170696-76-9, stock 31.3g, assay 98.4%, MWt: 355.31, Formula: C17H16F3NO4, Solubility: DMSO : ≥ 60 mg/mL (168.87 mM), Clinical_Informat: No Development Reported, Pathway: Metabolic Enzyme/Protease, Target: Aminoacyl-tRNA Synthetase, Biological_Activity: LysRs-IN-2 is a lysyl-tRNA synthetase (KRS) inhibitor with IC50s of 0.015 μM and 0.13 μM for Plasmodium falciparum lysyl-tRNA synthetase (PfKRS) and Cryptosporidium parvum lysyl-tRNA synthetase (CpKRS), respectively[1].
IC50 & Target: IC50: 0.015 μM (PfKRS), 0.13 μM (CpKRS)[1]
In Vitro: LysRs-IN-2 is active against whole-cell bloodstream P. falciparum 3D7 (EC50=0.27 μM), HsKRS (IC50=1.8 μM), HepG2 cells (EC50=49 μM), and Cryptosporidium parvum (EC50=2.5 µM)[1].
In Vivo: LysRs-IN-2 (1.5 mg/kg; orally once a day for 4 days) reduces parasitemia by 90% in the murine P. falciparum SCID model. LysRs-IN-2 (20 mg/kg; orally once a day for 7 days) reduces parasite shedding in NOD SCID gamma mice and INF-γ-knockout mice (Cryptosporidium mouse models)[1].

Name: HPGDS inhibitor 2, CAS: 2101626-26-8, stock 29.5g, assay 98.8%, MWt: 378.41, Formula: C20H24F2N2O3, Solubility: DMSO : ≥ 150 mg/mL (396.40 mM), Clinical_Informat: No Development Reported, Pathway: Immunology/Inflammation, Target: PGE synthase, Biological_Activity: HPGDS inhibitor 2 is a highly potent and selective hematopoietic prostaglandin D synthase (H-PGDS) inhibitor with an IC50 of 9.9 nM[1].
IC50 & Target: IC50: 9.9 nM (H-PGDS)[1]

Name: ML303, CAS: 1638211-04-7, stock 13.7g, assay 98.7%, MWt: 399.37, Formula: C21H16F3N3O2, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Anti-infection, Target: Influenza Virus, Biological_Activity: ML303 is a pyrazolopyridine influenza virus nonstructural protein 1 (NS1) antagonist (IC90 = 155 nM), with an EC50 of 0.7 μM for Influenza A virus H1N1[1].
IC50 & Target: EC50: 0.7 μM (H1N1)[1].
In Vitro: ML303 (20 μM, 6 h) treatment restore IFN-β mRNA levels in MDCK cells[1].

Name: JNJ-61432059, CAS: 2035814-50-5, stock 19.8g, assay 98.3%, MWt: 443.47, Formula: C25H22FN5O2, Solubility: DMSO : 50 mg/mL (112.75 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Membrane Transporter/Ion Channel;Neuronal Signaling, Target: iGluR;iGluR, Biological_Activity: JNJ-61432059 is an oral active and selective negative modulator of AMPAR associated with trans-membrane AMPAR regulatory protein (TARP) γ-8, with a pIC50 of 9.7 for GluA1/γ-8. Exhibits time- and dose-dependent AMPAR/γ-8 receptor occupancy in mouse hippocampus, resulting in robust seizure protection in corneal kindling and pentylenetetrazole (PTZ) anticonvulsant models[1].
IC50 & Target: pIC50: 9.7 (AMPAR)[1].

Name: Rebaudioside B, CAS: 58543-17-2, stock 13.7g, assay 99%, MWt: 804.87, Formula: C38H60O18, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: Rebaudioside B is the minor constituent isolated from the leaves of Stevia rebaudiana Bertoni. Rebaudioside B tastes about 150 times sweeter than sucrose [1].

Name: DMX-5804, CAS: 2306178-56-1, stock 37.6g, assay 98.4%, MWt: 361.39, Formula: C21H19N3O3, Solubility: DMSO : 125 mg/mL (345.89 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: MAPK/ERK Pathway, Target: MAP4K, Biological_Activity: DMX-5804 is a potent, orally active and selective MAP4K4 inhibitor, with an IC50 of 3 nM, a pIC50 of 8.55 for human MAP4K4, less potent on MINK1/MAP4K6 (pIC50, 8.18), and TNIK/MAP4K7 (pIC50, 7.96). DMX-5804 enhances cardiomyocyte survival, and reduces ischemia-reperfusion injury in mice[1].
IC50 & Target: IC50: 3 nM (MAP4K4)[1] 
pIC50: 8.55 (MAP4K4), 8.18 (MINK1/MAP4K6), 7.96 (TNIK/MAP4K7)[1]
In Vitro: DMX-5804 exhibits great selectivity at MAP4K4 over other kinases, such as GCK/MAP4K2 (pIC50, 6.50), GLK/MAP4K3 (pIC50, 4.95), KHS/MAP4K5 (pIC50, 6.36), ABL1 (pIC50, 5.80), Aurora B (pIC50, 5.49), FLT3 (pIC50, 5.31), GSK3β (pIC50, 4.66), MLK1/MAP3K9 (pIC50, 7.19), MLK3/MAP3K11 (pIC50, 6.99), NUAK (pIC50, 6.88) and VEGFR (pIC50, 5.72)[1].

Name: Mogroside IIe, CAS: 88901-38-6, stock 19.8g, assay 98.9%, MWt: 801.01, Formula: C42H72O14, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: Mogroside IIe, a triterpenoid glycoside isolated from the extracts of Luo Han Guo, is a nonsugar sweetener. Mogrosides are sweeter than sucrose. Mogrosides exhibit antioxidant, antidiabetic and anticancer activities[1].

Name: JAK/HDAC-IN-1, CAS: 2284621-75-4, stock 32.6g, assay 98.6%, MWt: 450.32, Formula: C19H21Cl2N7O2, Solubility: DMSO : 20.83 mg/mL (46.26 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Epigenetics;Stem Cell/Wnt;JAK/STAT Signaling;Epigenetics;Cell Cycle/DNA Damage, Target: JAK;JAK;JAK;HDAC;HDAC, Biological_Activity: JAK/HDAC-IN-1 is a potent JAK2/HDAC dual inhibitor, exhibits antiproliferative and proapoptotic activities in several hematological cell lines. JAK/HDAC-IN-1 shows IC50s of 4 and 2 nM for JAK2 and HDAC, respectively[1].
In Vitro: JAK/HDAC-IN-1 (Compound 8m) exhibits IC50s of 4.8, 7.4 and 49 nM for JAK1, JAK3 and TYK2, and 14, 120, 2470 nM for HDAC2, HDAC6 and HDAC8, respectively[1].

Name: Jaspamycin 7-CN-7-C-Ino, CAS: 22242-96-2, stock 35.4g, assay 98.8%, MWt: 292.25, Formula: C12H12N4O5, Solubility: DMSO : 41.67 mg/mL (142.58 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Stem Cell/Wnt;Protein Tyrosine Kinase/RTK;Anti-infection, Target: PKA;PKA;Parasite, Biological_Activity: Jaspamycin (7-CN-7-C-Ino) is a potent activator of PKA, binding to the R site (PKAR), with an EC50 of 6.5 nM and Kd of 8 nM in Trypanosoma brucei. Jaspamycin (7-CN-7-C-Ino) does not bind with purified human PKARIα. Anti-parasite activity[1].
IC50 & Target: Kd: 8 nM (Trypanosoma brucei PKAR(199-499))[1] 
EC50: 6.5 nM (Trypanosoma brucei PKA holoenzyme)[1]

Name: J22352, CAS: 2252395-44-9, stock 20.2g, assay 99%, MWt: 415.44, Formula: C24H21N3O4, Solubility: DMSO : 125 mg/mL (300.89 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Epigenetics;Cell Cycle/DNA Damage, Target: HDAC;HDAC, Biological_Activity: J22352 is a PROTAC (proteolysis-targeting chimeras)-like and highly selective HDAC6 inhibitor with an IC50 value of 4.7 nM. J22352 promotes HDAC6 degradation and induces anticancer effects by inhibiting autophagy and eliciting the antitumor immune response in glioblastoma cancers, and leading to the restoration of host antitumor activity by reducing the immunosuppressive activity of PD-L1[1].
IC50 & Target: IC50: 4.7 nM (HDAC6)[1]
In Vitro: J22352 (0.1-20 μM; 72 hours) decreases U87MG cell viability in a dose-dependent manner[1]. 
J22352 (10 μM; 24 hours) shows a dose-dependent decrease in HDAC6 protein abundance[1].
In Vivo: J22352 (10 mg/kg; given i.p. per day for 14 days in male nude mice) results in a >80% tumor growth inhibition (TGI) rate. J22352 is well tolerated in mice[1].

Name: BAY-545, CAS: 1699717-32-2, stock 6.3g, assay 98.2%, MWt: 433.45, Formula: C18H22F3N3O4S, Solubility: DMSO : ≥ 150 mg/mL (346.06 mM), Clinical_Informat: No Development Reported, Pathway: GPCR/G Protein, Target: Adenosine Receptor, Biological_Activity: BAY-545 is a potent and selective A2B adenosine receptor antagonist, with an IC50 of 59 nM. BAY-545 also exhibits IC50s of 66, 400, 280 nM for human, mouse, rat A2B adenosine receptor in cells, respectively, and a Ki of 97 nM for human A2B adenosine receptor, with more selectivity over A1, A2A, and A3 adenosine receptor[1].
IC50 & Target: IC50: 59 nM (A2B adenosine receptor), 66 nM (Human A2B adenosine receptor), 400 nM (Mouse A2B adenosine receptor), 280 nM (Rat A2B adenosine receptor), 1300 nM (Human A1 adenosine receptor), 820 nM (Human A2A adenosine receptor), 470 nM (Mouse A2A adenosine receptor) and 750 nM (Rat A2A adenosine receptor)[1] 
Ki: 97 nM (A2B adenosine receptor)[1]
In Vitro: BAY-545 is selective at A2B adenosine receptor over A1, A2A, and A3 adenosine receptor, with IC50s of 1300 nM (Human A1 adenosine receptor), 820 nM (Human A2A adenosine receptor), 470 nM (Mouse A2A adenosine receptor) and 750 nM (Rat A2A adenosine receptor)[1].

Name: Levamlodipine besylate (S)-Amlodipine besylate;Levoamlodipine besylate, CAS: 150566-71-5, stock 19.7g, assay 98.7%, MWt: 567.05, Formula: C26H31ClN2O8S, Solubility: DMSO : ≥ 150 mg/mL (264.53 mM), Clinical_Informat: Phase 4, Pathway: Membrane Transporter/Ion Channel;Neuronal Signaling, Target: Calcium Channel;Calcium Channel, Biological_Activity: Levamlodipine besylate ((S)-Amlodipine besylate) is a powerful dihydropyridine calcium channel blocker, possessing vasodilation properties and used in the treatment of hypertension and angina[1].
IC50 & Target: Calcium channel[1].

Name: Elexacaftor VX-445, CAS: 2216712-66-0, stock 8.4g, assay 98.1%, MWt: 597.65, Formula: C26H34F3N7O4S, Solubility: DMSO : 125 mg/mL (209.15 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Autophagy;Membrane Transporter/Ion Channel, Target: Autophagy;CFTR, Biological_Activity: Elexacaftor (VX-445, Compound 1) is a modulator of cystic fibrosis transmembrane conductance regulator (CFTR). Elexacaftor (VX-445, Compound 1) facilitates the processing and trafficking of CFTR to increase the amount of CFTR at the cell surface[1].
IC50 & Target: CFTR[1].
In Vitro: Elexacaftor (VX-445) is a next-generation cystic fibrosis transmembrane conductance regulator (CFTR) corrector designed to restore Phe508del CFTR protein function. Elexacaftor (VX-445) has the potential to treat cystic fibrosis. VX-445-Tezacaftor-VX-770 significantly improves Phe508del CFTR protein processing, trafficking, and chloride transport to a greater extent than any two of these agents in dual combination[2].

Name: AZ 628, CAS: 878739-06-1, stock 33.8g, assay 98.9%, MWt: 451.52, Formula: C27H25N5O2, Solubility: DMSO : ≥ 50 mg/mL (110.74 mM); H2O : < 0.1 mg/mL (insoluble), Clinical_Informat: No Development Reported, Pathway: Apoptosis;MAPK/ERK Pathway, Target: Apoptosis;Raf, Biological_Activity: AZ 628 is a pan-Raf kinase inhibitor with IC50s of 105, 34 and 29 nM for B-Raf, B-RafV600E, and c-Raf-1, respectively.
IC50 & Target: IC50: 105 nM (B-Raf), 34 nM (B-RafV600E), 29 nM (c-Raf-1)[1]
In Vitro: AZ 628 reduces activities of preactivated B-Raf, B-RafV600E, and c-Raf-1 in in vitro kinase assays, with IC50 values of 105, 34 and 29 nM, respectively. AZ 628 also inhibits activation of number of tyrosine protein kinases including VEGFR2, DDR2, Lyn, Flt1, FMS and others. AZ 628 inhibits anchorage-dependent and -independent growth, causes cell cycle arrest, and induces apoptosis in colon and melanoma cell lines harboring B-RafV600E mutation[1]. AZ 628 suppresses growth in cells expressing K-RASG13D. Inhibition of RAF with AZ 628 suppresses MEK and ERK phosphorylation. AZ 628 selectively affects viability in K-RAS mutant cells[2].

Name: Larotaxel XRP9881, CAS: 156294-36-9, stock 37.9g, assay 98.4%, MWt: 831.90, Formula: C45H53NO14, Solubility: DMSO : ≥ 50 mg/mL (60.10 mM), Clinical_Informat: No Development Reported, Pathway: Apoptosis, Target: Apoptosis, Biological_Activity: Larotaxel (XRP9881) is a taxane analogue with preclinical activity against taxane-resistant breast cancer. Larotaxel (XRP9881) exerts its cytotoxic effect by promoting tubulin assembly and stabilizing microtubules, ultimately leading to cell death by apoptosis. It presents the ability to cross the blood brain barrier and has a much lower affinity for P-glycoprotein 1 than Docetaxel[1][2][3].

Name: CFTR corrector 2, CAS: 1628416-28-3, stock 13.7g, assay 98.7%, MWt: 486.49, Formula: C27H23FN4O4, Solubility: DMSO : 62.5 mg/mL (128.47 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Autophagy;Membrane Transporter/Ion Channel, Target: Autophagy;CFTR, Biological_Activity: CFTR corrector 2 is a cystic fibrosis transmembrane conductance corrector (CFTR), extracted from patent US20140274933[1].
IC50 & Target: CFTR[1].

Name: Xanthopterin (hydrate), CAS: 5979-01-1, stock 14.9g, assay 98.4%, MWt: 197.15, Formula: C6H7N5O3, Solubility: DMSO : 5 mg/mL (25.36 mM; ultrasonic and warming and heat to 80°C), Clinical_Informat: No Development Reported, Pathway: Cell Cycle/DNA Damage, Target: DNA/RNA Synthesis, Biological_Activity: Xanthopterin hydrate, an unconjugated pteridine compound, is the main component of the yellow granule in the Oriental hornet bear wings, produces a characteristic excitation/emission maximum at 386/456 nm[2]. Xanthopterin hydrate(XPT) causes renal growth and hypertrophy in rat[1].
Xanthopterin hydrate inhibits RNA synthesis[4].
In Vitro: Xanthopterin (7.8-250 mM; 24 hours) show a significant reduction in mitochondrial activity with respect to controls (IC50=109 mM)[2].

Name: GSK-843 GSK'843, CAS: 1601496-05-2, stock 11.1g, assay 98.3%, MWt: 377.49, Formula: C19H15N5S2, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Apoptosis, Target: RIP kinase, Biological_Activity: GSK-843 (GSK'843) is a receptor-interacting protein kinase 3 (RIP3 or RIPK3) inhibitor, which binds RIP3 kinase domain with an IC50 of 8.6 nM, and inhibits kinase activity with an IC50 of 6.5 nM[1].
IC50 & Target: IC50: 6.5 nM (RIP3)[1]

Name: Lenalidomide-Br, CAS: 2093387-36-9, stock 33.3g, assay 99%, MWt: 323.14, Formula: C13H11BrN2O3, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: PROTAC, Target: Ligand for E3 Ligase, Biological_Activity: Lenalidomide-Br (Compound 41) is an analog of cereblon (CRBN) ligand Lenalidomide for E3 ubiquitin ligase, and is used in the recruitment of CRBN protein. Lenalidomide-Br can be connected to the ligand for protein by a linker to form PROTACs, such as the PROTAC STAT3 degrader SD-36 (HY-129602)[1][2].
In Vitro: Lenalidomide-Br can be connected to the ligand for protein by a linker to form PROTACs. PROTACs are inducers of ubiquitination-mediated degradation of cancer-promoting proteins[1][2].

Name: 6-Hydroxypyridin-2(1H)-one hydrochloride, CAS: 10357-84-3, stock 11.3g, assay 98.8%, MWt: 147.56, Formula: C5H6ClNO2, Solubility: , Clinical_Informat: No Development Reported, Pathway: Metabolic Enzyme/Protease, Target: Endogenous Metabolite, Biological_Activity:

Name: PROTAC BET-binding moiety 2, CAS: 916493-82-8, stock 3.3g, assay 98.4%, MWt: 444.89, Formula: C20H17ClN4O4S, Solubility: DMSO : 42.86 mg/mL (96.34 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: PROTAC, Target: Ligand for Target Protein for PROTAC, Biological_Activity: PROTAC BET-binding moiety 2 is an inhibitor of BET bromodomain[1].

Name: FASN-IN-1, CAS: 1808260-84-5, stock 1.5g, assay 99%, MWt: 395.54, Formula: C18H25N3O3S2, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Metabolic Enzyme/Protease, Target: Fatty Acid Synthase (FAS), Biological_Activity: FASN-IN-1 is a fatty acid synthase (FASN) inhibitor extracted from patent WO2015134790A1, compound 56[1].

Name: EHMT2-IN-1, CAS: 2230849-55-3, stock 18g, assay 98.8%, MWt: 353.42, Formula: C18H23N7O, Solubility: DMSO : 55 mg/mL (155.62 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Epigenetics, Target: Histone Methyltransferase, Biological_Activity: EHMT2-IN-1 is a potent EHMT inhibitor, with IC50s of all <100 nM for EHMT1 peptide, EHMT2 peptide and cellular EHMT2. Used in the research of blood disorder or cancer[1].
In Vitro: EHMT2-IN-1 (Compound 108) potent EHMT inhibitor, with IC50s of all <100 nM for EHMT1 peptide, EHMT2 peptide and cellular EHMT2[1].

Name: Apraglutide FE 203799, CAS: 1295353-98-8, stock 21.4g, assay 98.4%, MWt: 3765.25, Formula: C172H263N43O52, Solubility: 10 mM in DMSO, Clinical_Informat: Phase 2, Pathway: Others, Target: Others, Biological_Activity: Apraglutide (FE 203799), a synthetic 33-amino-acid peptide and a long-acting GLP-2 analogue, enhances adaptation and linear intestinal growth in a neonatal piglet model of short bowel syndrome with total resection of the ileum[1].
In Vivo: Apraglutide (FE 203799; 5 mg/kg/dose, subcutaneously, twice on days 0 and 4 postsurgery) treated piglets are healthy, have significant lower fecal fat and energy losses and exhibite intestinal lengthening, greater small-intestinal weight, longer villus height, and greater crypt depth on day 7[1].

Name: AZD-7648, CAS: 2230820-11-6, stock 24.3g, assay 98.7%, MWt: 380.40, Formula: C18H20N8O2, Solubility: DMSO : 5 mg/mL (13.14 mM; ultrasonic and warming and heat to 80°C), Clinical_Informat: Phase 2, Pathway: PI3K/Akt/mTOR;Cell Cycle/DNA Damage, Target: DNA-PK;DNA-PK, Biological_Activity: AZD-7648 is a potent and selective DNA-PK inhibitor. Anti-tumor activity[1].
IC50 & Target: DNA-PK[1]

Name: CBP-IN-1, CAS: 2222941-37-7, stock 19.7g, assay 98.8%, MWt: 534.60, Formula: C30H32F2N4O3, Solubility: DMSO : 100 mg/mL (187.06 mM; Need ultrasonic), Clinical_Informat: Phase 2, Pathway: Epigenetics, Target: Epigenetic Reader Domain, Biological_Activity: CBP-IN-1 is a potent p300/CBP bromodomain inhibitor[1].
IC50 & Target: p300/CBP[1]

Name: CSF1R-IN-2, CAS: 2271119-26-5, stock 14.2g, assay 98.7%, MWt: 409.42, Formula: C20H20FN7O2, Solubility: DMSO : 25 mg/mL (61.06 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK, Target: Src;c-Met/HGFR;c-Fms, Biological_Activity: CSF1R-IN-2 (compound 5) is an oral-active inhibitor of SRC, MET and c-FMS, with IC50 values of 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively[1].
IC50 & Target: IC50: 0.12 nM (SRC), 0.14 nM (MET), 0.76 nM (c-FMS)[1].
In Vitro: CSF1R-IN-2 (compound 5) causes the suppression of MET autophosphorylation as well as the downstream STAT3, ERK and AKT phosphorylation at IC50 values of around 1-3 nM in SNU-5 and MKN-45 cell lines[1].
In Vivo: CSF1R-IN-2 (compound 5: p.o., BID, 13 days) treatment results in an 85% tumor regression and no body weight loss is observed after 21 days treatment in mice[1]. 
CSF1R-IN-2 (compound 5: p.o., BID, 10 days) demonstrates the ability to inhibit tumor growth at 44% and 67% at the dose of 5 mg/kg, BID and 15 mg/kg, BID, respectively in SCID/Beige mice[1]. 
CSF1R-IN-2 (compound 5) inhibits MET activity in MKN-45 tumors following oral administration in mice[1].

Name: LMP7-IN-1, CAS: 2285330-15-4, stock 36.4g, assay 98.2%, MWt: 329.16, Formula: C17H20BNO5, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Metabolic Enzyme/Protease, Target: Proteasome, Biological_Activity: LMP7-IN-1 is an inhibitor of immunoproteasome (LMP7), may used in the research of inflammatory and autoimmune diseases, neurodegenerative diseases, proliferative diseases and cancer[1].
IC50 & Target: LMP7[1]
In Vitro: LMP7-IN-1 (Example 2) is an inhibitor of immunoproteasome (LMP7), may used in the research of inflammatory and autoimmune diseases, neurodegenerative diseases, proliferative diseases and cancer[1].

Name: AMG-510 racemate, CAS: 2252403-56-6, stock 25.4g, assay 98.6%, MWt: 560.59, Formula: C30H30F2N6O3, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: GPCR/G Protein, Target: Ras, Biological_Activity: AMG-510 racemate is the racemate of AMG-510. AMG-510 is a potent, orally bioavailable, and selective KRAS G12C covalent inhibitor with anti-tumor activity.

Name: Endomorphin 2 (TFA), CAS: 1276124-00-5, stock 17.9g, assay 98.1%, MWt: 685.69, Formula: C34H38F3N5O7, Solubility: DMSO : < 1 mg/mL (insoluble or slightly soluble); H2O : 62.5 mg/mL (91.15 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: GPCR/G Protein;Neuronal Signaling, Target: Opioid Receptor;Opioid Receptor, Biological_Activity: Endomorphin 2 TFA, a high affinity, highly selective agonist of the μ-opioid receptor, displays reasonable affinities for kappa3 binding sites, with Ki value between 20 and 30 nM[1].
IC50 & Target: Ki: 20-30 nM (kappa3 opioid receptor)[1]

Name: GW 5074, CAS: 220904-83-6, stock 31.6g, assay 98.2%, MWt: 520.94, Formula: C15H8Br2INO2, Solubility: DMSO : ≥ 100 mg/mL (191.96 mM), Clinical_Informat: No Development Reported, Pathway: Apoptosis;MAPK/ERK Pathway, Target: Apoptosis;Raf, Biological_Activity: GW 5074 is a potent and selective c-Raf inhibitor with IC50 of 9 nM, and has no effect on the activities of JNK1/2/3, MEK1, MKK6/7, CDK1/2, c-Src, p38 MAP, VEGFR2 or c-Fms.
IC50 & Target: IC50: 9 nM (c-Raf)
In Vitro: GW5074 is a potent and specific inhibitor of c-Raf with IC50 of 9 nM and has no effect of MKK6, MKK7, p38 MAP kinase and cdks in vitro. However, treatment of neuronal cultures with GW5074 permits accumulation of activating modifications on c-Raf and also B-Raf. The inhibition of LK-induced apoptosis by GW5074 in cerebellar granule neurons is not MEK-ERK-dependent. GW5074 delays down-regulation of Akt activity but inhibits apoptosis by an Akt-independent mechanism. GW5074 affects Ras, nuclear factor-kappa B and c-jun. GW5074 inhibits cell death caused by neurotoxins in granule cells and other neuronal types[1].
In Vivo: GW5074 (5 mg/Kg) completely prevents extensive bilateral striatal lesions induced by 3-NP in mice[1]. GW5074 suppresses sidestream smoke-induced airway hyperresponsiveness in mice[2]. GW5074 completely abolishes chronic morphine-mediated AC superactivation I in CHO cells stably expressing the humanμ-opioid receptor[3].

Name: ACY-1083, CAS: 1708113-43-2, stock 29.9g, assay 98.1%, MWt: 348.35, Formula: C17H18F2N4O2, Solubility: DMSO : 125 mg/mL (358.83 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Epigenetics;Cell Cycle/DNA Damage, Target: HDAC;HDAC, Biological_Activity: ACY-1083 is a selective and brain-penetrating HDAC6 inhibitor with an IC50 of 3 nM and is 260-fold more selective for HDAC6 than all other classes of HDAC isoforms. ACY-1083 effectively reverses chemotherapy-induced peripheral neuropathy[1].

Name: UNC2541, CAS: 1612782-86-1, stock 31.9g, assay 98.3%, MWt: 471.57, Formula: C24H34FN7O2, Solubility: DMSO : 10 mg/mL (21.21 mM; ultrasonic and warming and heat to 60°C), Clinical_Informat: No Development Reported, Pathway: Protein Tyrosine Kinase/RTK, Target: TAM Receptor, Biological_Activity: UNC2541 is a potent and Mer tyrosine kinase (MerTK)-specific inhibitor, binds in the MerTK ATP pocket, with an IC50 of 4.4 nM, more selective over Axl, Tyro3 and Flt3. UNC2541 inhibits phosphorylated MerTK (pMerTK; EC50, 510 nM)[1].
IC50 & Target: UNC2541 is a potent and Mer tyrosine kinase (MerTK)-specific inhibitor, binds in the MerTK ATP pocket, with an IC50 of 4.4 nM, more selective over Axl (IC50, 120 nM), Tyro3 (IC50, 220 nM) and Flt3 (IC50, 320 nM). UNC2541 inhibits phosphorylated MerTK (pMerTK; EC50, 510 nM)[1].

Name: Cauloside C, CAS: 20853-58-1, stock 17.4g, assay 99%, MWt: 766.95, Formula: C41H66O13, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: Cauloside C is a triterpene glycoside isolated from Caulophyllum robustum Max. Cauloside C exerts anti-inflammatory effects through the inhibition of expression of iNOS and proinflammatory cytokines[1].

Name: Tat-NR2B9c (TFA) NA-1 (TFA), CAS: 1834571-04-8, stock 37.7g, assay 98.7%, MWt: 114.02, Formula: C2HF3O2, Solubility: H2O : ≥ 50 mg/mL (438.52 mM), Clinical_Informat: No Development Reported, Pathway: Membrane Transporter/Ion Channel;Neuronal Signaling;Immunology/Inflammation, Target: iGluR;iGluR;NO Synthase, Biological_Activity: Tat-NR2B9c TFA (NA-1 TFA) is a 20-aa peptide, which acts as a postsynaptic density-95 (PSD-95) inhibitor, with an EC50 of 6.7 nM for PSD-95d2 (PSD-95 PDZ domain 2), and 670 nM for PSD-95d1[1]. Tat-NR2B9c also reduces NMDA-induced p38 activation, inhibits neuronal nitric oxide synthase (nNOS)/PSD-95 interaction, and possesses neuroprotective efficacy[1][2].
IC50 & Target: EC50: 6.7 nM (PSD-95d2), 670 nM (PSD-95d1)[1] 
NO synthase[1]

Name: Epertinib (hydrochloride) S-22611 (hydrochloride), CAS: 2071195-74-7, stock 38.4g, assay 98.9%, MWt: 596.48, Formula: C30H28Cl2FN5O3, Solubility: DMSO : 125 mg/mL (209.56 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: JAK/STAT Signaling;Protein Tyrosine Kinase/RTK, Target: EGFR;EGFR, Biological_Activity: Epertinib hydrochloride is a potent, orally active, reversible, and selective tyrosine kinase inhibitor of EGFR, HER2 and HER4, with IC50s of 1.48 nM, 7.15 nM and 2.49 nM, respectively. Epertinib shows potent antitumor activity[1].
IC50 & Target: IC50: 1.48 nM (EGFR), 7.15 nM (HER2), 2.49 nM (HER4)[1]

Name: Zidebactam sodium salt WCK-5107 sodium salt, CAS: 1706777-46-9, stock 36.1g, assay 98.3%, MWt: 413.38, Formula: C13H20N5NaO7S, Solubility: 10 mM in DMSO, Clinical_Informat: Phase 1, Pathway: Anti-infection, Target: Bacterial, Biological_Activity: Zidebactam sodium salt (WCK-5107 sodium salt) is a potent β-lactamase inhibitor[1]. Zidebactam also is a penicillin-binding protein2 (PBP2) inhibitor with an IC50 of 0.26 μg/mL[2].
IC50 & Target: IC50: 0.26±0.06 μg/mL (P. aeruginosa PAO1 PBP2)[2].
In Vitro: Zidebactam sodium salt (WCK-5107 sodium salt) inhibits WT Enterobacteriaceae with a MIC50 of 0.25 mg/L[1].Zidebactam sodium salt (WCK-5107 sodium salt) alone exhibits variable activity when tested against E. coli (MIC50/90 0.12/0.12 mg/L) and Enterobacter spp. (MIC50/90 0.12/0.25 mg/L)[1].

Name: HO-1-IN-1 hydrochloride, CAS: 1092851-70-1, stock 28.8g, assay 98.7%, MWt: 315.64, Formula: C13H16BrClN2, Solubility: DMSO : 125 mg/mL (396.02 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Metabolic Enzyme/Protease;NF-κB;Immunology/Inflammation, Target: Reactive Oxygen Species;Reactive Oxygen Species;Reactive Oxygen Species, Biological_Activity: HO-1-IN-1 hydrochloride (Compound 2) is a heme oxygenase 1 (HO-1) inhibitor with an IC50 of 250 nM[1].

Name: HO-1-IN-1, CAS: 1093058-52-6, stock 26.7g, assay 98.7%, MWt: 279.18, Formula: C13H15BrN2, Solubility: DMSO : 125 mg/mL (447.74 mM; Need ultrasonic); H2O : < 0.1 mg/mL (insoluble), Clinical_Informat: No Development Reported, Pathway: Metabolic Enzyme/Protease;NF-κB;Immunology/Inflammation, Target: Reactive Oxygen Species;Reactive Oxygen Species;Reactive Oxygen Species, Biological_Activity: HO-1-IN-1 (Compound 2) is a heme oxygenase 1 (HO-1) inhibitor with an IC50 of 250 nM[1].

Name: Chromium picolinate Chromium (III) picolinate;Cr(Pic)3, CAS: 14639-25-9, stock 19.4g, assay 98.2%, MWt: 418.30, Formula: C18H12CrN3O6, Solubility: DMSO : 7.81 mg/mL (18.67 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: Chromium picolinate (Chromium (III) picolinate) reduces insulin resistance and is widely used in prevention and treatment of type 2 diabetes mellitus[1].

Name: EIPA (hydrochloride) L593754 hydrochloride;MH 12-43 hydrochloride, CAS: 1345839-28-2, stock 36.6g, assay 98.8%, MWt: 336.22, Formula: C11H19Cl2N7O, Solubility: DMSO : 130 mg/mL (386.65 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Membrane Transporter/Ion Channel;Membrane Transporter/Ion Channel;Neuronal Signaling, Target: TRP Channel;Sodium Channel;TRP Channel, Biological_Activity: EIPA hydrochloride (L593754 hydrochloride) is a TRPP3 channel inhibitor with an IC50 of 10.5 μM[1]. EIPA also inhibits Na+/H+-exchanger (NHE)[2] and macropinocytosis[3].
IC50 & Target: IC50: 10.5 μM (TRPP3 channel)[1] 
NHE[2] 
Macropinocytosis[3]

Name: 3,4'-Dihydroxyflavone 3,4'-DHF, CAS: 14919-49-4, stock 35.8g, assay 98.3%, MWt: 254.24, Formula: C15H10O4, Solubility: H2O : < 0.1 mg/mL (insoluble); DMSO : ≥ 155 mg/mL (609.66 mM), Clinical_Informat: No Development Reported, Pathway: Anti-infection, Target: Influenza Virus, Biological_Activity: 3,4'-Dihydroxyflavone (3,4'-DHF) is an oral active flavonoid with antiviral activity against Influenza A virus[1].
In Vivo: 3,4'-Dihydroxyflavone (3,4'-DHF; PO, 1 mg/kg per 30 μL, daily, 5 days) significantly decreases virus titers and pathological changes in the lung and reduced body weight loss and death[1].

Name: 4'-Methoxyflavonol, CAS: 6889-78-7, stock 0.9g, assay 98.4%, MWt: 268.26, Formula: C16H12O4, Solubility: H2O : < 0.1 mg/mL (insoluble); DMSO : 6.4 mg/mL (23.86 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: 4'-Methoxyflavonol is a synthesized flavone/flavonol with 1, 2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) bilayers[1].

Name: 3',4'-Dihydroxyflavonol DiOHF, CAS: 6068-78-6, stock 17.5g, assay 98.9%, MWt: 270.24, Formula: C15H10O5, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Immunology/Inflammation, Target: NO Synthase, Biological_Activity: 3',4'-Dihydroxyflavonol (DiOHF) is an effective antioxidant, which reduces superoxide and improves nitric oxide (NO) function in diabetic rat mesenteric arteries[1].
In Vitro: 3',4'-Dihydroxyflavonol (DiOHF) acutely preserves nitric oxide (NO) activity in the presence of elevated reactive oxygen species (ROS). DiOHF improves NO activity in diabetes by reducing Nox2-dependent superoxide production and preventing eNOS uncoupling to improve endothelial function[1]. 
3',4'-Dihydroxyflavonol reduces vascular contraction through Ca²⁺ desensitization in permeabilized third-order branches of rat mesenteric arteries[2].

Name: 3,7,4'-Trihydroxyflavone 5-Deoxykampferol, CAS: 2034-65-3, stock 39g, assay 98.2%, MWt: 270.24, Formula: C15H10O5, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Cell Cycle/DNA Damage, Target: DNA/RNA Synthesis, Biological_Activity: 3,7,4'-Trihydroxyflavone, isolated from Rhus javanica var. roxburghiana, is a flavonoid with DNA strand-scission activity[1].

Name: N6-Ethyladenosine, CAS: 14357-08-5, stock 18.9g, assay 98.7%, MWt: 295.29, Formula: C12H17N5O4, Solubility: DMSO : ≥ 83.33 mg/mL (282.20 mM), Clinical_Informat: No Development Reported, Pathway: GPCR/G Protein, Target: Adenosine Receptor, Biological_Activity: N6-Ethyladenosine is an adenosine derivative, acts as a Adenosine receptor agonist, with Kis of 4.9 and 4.7 nM for hA1AR and hA3AR, respectively[1].
IC50 & Target: Ki: 4.9 nM (hA1AR), 4.7 nM (hA3AR)[1]
In Vitro: N6-Ethyladenosine (Compound 28) exhibits more selectivity at hA1AR and hA3AR over hA2AR (Ki, 8900±770 nM)[1].

Name: Pseudouridimycin PUM, CAS: 1566586-52-4, stock 31.2g, assay 98.3%, MWt: 486.44, Formula: C17H26N8O9, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Anti-infection;Cell Cycle/DNA Damage, Target: Bacterial;DNA/RNA Synthesis, Biological_Activity: Pseudouridimycin (PUM), an antibiotic, is a selective bacterial RNA polymerase (RNAP) inhibitor. Pseudouridimycin is a C-nucleoside analogue that is effective against both Gram-negative and Gram-positive bacteria[1].

Name: Pexidartinib (hydrochloride) PLX-3397 (hydrochloride), CAS: 2040295-03-0, stock 12.5g, assay 98.5%, MWt: 454.28, Formula: C20H16Cl2F3N5, Solubility: DMSO : 60 mg/mL (132.08 mM; Need ultrasonic), Clinical_Informat: Launched, Pathway: Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK, Target: c-Fms;c-Kit, Biological_Activity: Pexidartinib hydrochloride (PLX-3397 hydrochloride) is a potent, orally active, selective, and ATP-competitive colony stimulating factor 1 receptor (CSF1R or M-CSFR) and c-Kit inhibitor, with IC50s of 20 and 10 nM, respectively. Pexidartinib exhibits 10- to 100-fold selectivity for c-Kit and CSF1R over other related kinases. Anti-cancer activity[1].
IC50 & Target: IC50: 10 nM (c-Kit), 20 nM (cFMS), 160 nM (FLT3), 350 nM (KDR), 860 nM (LCK), 880 nM (FLT1), 890 nM (NTRK3)[1]
In Vitro: Pexidartinib hydrochloride (PLX-3397 hydrochloride) is a potent, selective and ATP-competitive CSF1R (cFMS) and c-Kit inhibitor, shows 10- to 100-fold selectivity for c-Kit and CSF1R over other related kinases, such as FLT3, KDR (VEGFR2), LCK, FLT1 (VEGFR1) and NTRK3 (TRKC), with IC50s of 160, 350, 860, 880, and 890 nM, respectively[1].
In Vivo: Pexidartinib (PLX3397; 0.25, 1 mg/kg, i.p., twice daily for 8 days) inhibits the proliferation of microglia and BrdU-positive cells in neonatal mice[2]. 
Pexidartinib (1 mg/kg, twice daily for 8 day) shows no obvious effect on the cleaved caspase-3-positive cells in mice[2].

Name: Netropsin (dihydrochloride), CAS: 18133-22-7, stock 0.3g, assay 98.8%, MWt: 503.39, Formula: C18H28Cl2N10O3, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Cell Cycle/DNA Damage, Target: DNA Stain, Biological_Activity: Netropsin (dihydrochloride) is a small-molecule MGB (minor-groove binder), inhibits the catalytic activity of isolated topoisomerase and interferes with the stabilization of the cleavable complexes of topoisomerase II and I in nuclei[1]. Netropsin (dihydrochloride) has potential antibiotic and antiviral properties by binding to dsDNA in a non-intercalative manner, it improves survival from murine endotoxaemia by attenuating NOS2 induction through interference with HMGA1 DNA binding to the core NOS2 promoter[2]. Netropsin (dihydrochloride) in solutions of DNA has radioprotective ability against radiation-induced damage due to its high binding affinity and high structural stabilization, hydroxyl radical (OH*) generated by ionizing radiation cannot radiolyse the netropsin-DNA complex[3].

Name: TH34, CAS: 2196203-96-8, stock 14.8g, assay 98.4%, MWt: 256.30, Formula: C15H16N2O2, Solubility: DMSO : 150 mg/mL (585.25 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Epigenetics;Cell Cycle/DNA Damage, Target: HDAC;HDAC, Biological_Activity: TH34, an HDAC6/8/10 inhibitor with IC50s of 4.6 μM, 1.9 μM, and 7.7 μM respectively, shows high selectivity over HDAC1/2/3[1].
IC50 & Target: IC50: 4.6 μM (HDAC6), 1.9 μM (HDAC8), 7.7 μM (HDAC10)[1]
In Vitro: TH34 induces caspase-dependent programmed cell death and cell cycle arrest in neuroblastoma cells[1].

Name: Lysergol, CAS: 602-85-7, stock 28.7g, assay 98.8%, MWt: 254.33, Formula: C16H18N2O, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Anti-infection, Target: Bacterial, Biological_Activity: Lysergol, a clavine alkaloid isolated from seeds of Ipomoea muricata, is a bioenhancer for the drugs and nutrients and has antibacterial activity. Lysergol has been used as hypotensive, psychotropic analgesic and uterus- and intestine-stimulating drug[1][2].

Name: CK1-IN-1, CAS: 1784751-20-7, stock 15.6g, assay 98.7%, MWt: 383.39, Formula: C24H15F2N3, Solubility: DMSO : 62.5 mg/mL (163.02 mM; Need ultrasonic); H2O : < 0.1 mg/mL (insoluble), Clinical_Informat: No Development Reported, Pathway: Stem Cell/Wnt;Cell Cycle/DNA Damage, Target: Casein Kinase;Casein Kinase, Biological_Activity: CK1-IN-1 is a casein kinase 1 (CK1) inhibitor extracted from patent WO2015119579A1, compound 1c, has IC50s of 15 nM, 16 nM, 73 nM for CK1δ, and CK1ε, p38σ MAPK, respectively[1].
IC50 & Target: IC50: 15 nM (CK1δ), 16 nM (CK1ε), 73 nM (p38σ MAPK)[1]

Name: (Rac)-BAY1238097, CAS: 1564268-19-4, stock 3.8g, assay 98.8%, MWt: 451.56, Formula: C25H33N5O3, Solubility: DMSO : 150 mg/mL (332.18 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Epigenetics, Target: Epigenetic Reader Domain, Biological_Activity: (Rac)-BAY1238097 is a BET inhibitor, with an IC50 of 1.02 μM for BRD4. Used in cancer research[1].
IC50 & Target: IC50: 1.02 μM (BRD4)[1]

Name: Cefotetan, CAS: 69712-56-7, stock 0.4g, assay 99%, MWt: 575.62, Formula: C17H17N7O8S4, Solubility: DMSO : 250 mg/mL (434.31 mM; Need ultrasonic), Clinical_Informat: Launched, Pathway: Anti-infection, Target: Bacterial, Biological_Activity: Cefotetan is a semisynthetic cephamycin antibiotic that exerts its bactericidal effects by inhibition of cell-wall synthesis[1].

Name: MMV008138, CAS: 1679333-73-3, stock 35.4g, assay 98.8%, MWt: 361.22, Formula: C18H14Cl2N2O2, Solubility: DMSO : 125 mg/mL (346.05 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Anti-infection, Target: Parasite, Biological_Activity: MMV008138 is a species-selective IspD (enzyme 2-C-methyl-d-erythritol 4-phosphate cytidylyltransferase)-targeting antimalarial agent, with an IC50 of 44 nM for PfIspD (P. falciparum IspD). MMV008138 inhibits the growth of P. falciparum Dd2 strain with an IC50 of 250 nM[1][2].
IC50 & Target: IC50: 44 nM (PfIspD)[1]
In Vitro: MMV008138 targets the enzyme IspD in the MEP pathway of P. falciparum[1]. 
MMV008138 does not target human IspD[1].

Name: MBC-11 (trisodium), CAS: 387877-45-4, stock 29.1g, assay 98.2%, MWt: 577.15, Formula: C11H17N3Na3O14P3, Solubility: H2O : 125 mg/mL (216.58 mM; Need ultrasonic), Clinical_Informat: Phase 1, Pathway: Others, Target: Others, Biological_Activity: MBC-11 trisodium is a first-in-class conjugate of the bone-targeting bisphosphonate HEDP covalently linked to the antimetabolite Ara-C. Has potential to treat tumor-induced bone disease (TIBD)[1].
In Vitro: MBC-11 shows similar activity profiles and significantly inhibits growth of all three cell lines between 10-8 and 10-4 M. MBC-11 decreases KAS-6/1 cell growth from approximately 56% at 10-8 M to 6% at 10-5 M[1]
In Vivo: MBC-11 (0.04 μg/day, s.c.) has a lower incidence of bone metastases of 40% compared to those treated with PBS (90%) or 0.04 μg/day zoledronate (100%). MBC-11 also significantly decreases bone tumor burden compared to PBS- or zoledronate-treated mice[1]. 
Weight gained in mice treated with up to 500 μg/day of MBC-11 is similar to the PBS treated group[1]. 
These results demonstrate that MBC-11 decreases bone tumor burden, maintains bone structure, and may increase overall survival, warranting further investigation as a treatment for tumor-induced bone disease (TIBD)[1].

Name: VH032 thiol VHL ligand 6, CAS: 2098836-54-3, stock 34.1g, assay 98.1%, MWt: 490.64, Formula: C23H30N4O4S2, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: PROTAC, Target: Ligand for E3 Ligase, Biological_Activity: VH032 thiol (VHL ligand 6) is a VHL ligand, which binds to pan-BET inhibitor JQ1 via a linker to form PROTAC[1].

Name: Biotinyl tyramide, CAS: 41994-02-9, stock 10.5g, assay 98.6%, MWt: 363.47, Formula: C18H25N3O3S, Solubility: DMSO : 250 mg/mL (687.81 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: Biotinyl tyramide is a biotin derivative used for tyramide signal amplification (TSA), as a reagent to amplify both immunohistochemical signals and in situ hybridization protocols[1][2][3][4].

Name: SB-590885, CAS: 405554-55-4, stock 14.2g, assay 98.7%, MWt: 453.54, Formula: C27H27N5O2, Solubility: DMSO : 33.33 mg/mL (73.49 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: MAPK/ERK Pathway, Target: Raf, Biological_Activity: SB-590885 is a potent B-Raf inhibitor with Ki of 0.16 nM, and has 11-fold greater selectivity for B-Raf over c-Raf, without inhibition to other human kinases.
IC50 & Target: IC50: 0.16 nM (B-Raf)
In Vitro: SB-590885 displays significant selectivity for B-Raf over c-Raf with Ki of 0.16 nM over 1.72 nM. SB-590885 is a more potent inhibitor than the previously described Raf/VEGFR kinase inhibitor BAY 439006 (Ki=38 nM for mutant B-Raf, 6 nM for c-Raf). SB-590885 displays potent selectivity over 46 other kinases. Unlike the multi-kinase inhibitor BAY43-9006, SB-590885 stabilizes the oncogenic B-Raf kinase domain in an active configuration. In Colo205, HT29, A375P, SKMEL28, and MALME-3M cells expressing oncogenic B-RafV600E, SB-590885 treatment potently inhibits ERK phosphorylation with EC50 of 28 nM, 58 nM, 290 nM, 58 nM, and 190 nM, respectively, and consistently, inhibits the proliferation with EC50 of 0.1 μM, 0.87 μM, 0.37 μM, 0.12 μM, and 0.15 μM, respectively. SB-590885 decreases anchorage-independent growth of melanoma cell lines in a BRAF mutant-selective manner[1]. SB-590885 displays high affinity for B-Raf with Kd of 0.3 nM[2]. Most of the melanoma cell lines that harbor the BRAF V600E mutation and lack CDK4 mutations (451Lu, WM35, and WM983) are highly sensitive to SB-590885 with IC50 of <1 μM. Increased levels of cyclin D1 resulting from genomic amplification mediate SB-590885 resistance in B-Raf V600E-mutated melanomas[3].
In Vivo: Administration of SB-590885 potently decreases tumorigenesis in murine xenografts established from mutant B-Raf-expressing A375P melanoma cells, and modestly inhibits tumor growth[1].

Name: Lignine Lignin, CAS: 9005-53-2, stock 12.1g, assay 98.9%, MWt: 1000, Formula: N/A, Solubility: DMSO : ≥ 50 mg/mL; H2O : < 0.1 mg/mL (insoluble), Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: Lignine (Lignin) is a complex organic polymer, which plays an important role in plant cell wall structure.

Name: 1,2,3,6-Tetragalloylglucose TeGG, CAS: 79886-50-3, stock 18.4g, assay 98.4%, MWt: 788.57, Formula: C34H28O22, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: 1,2,3,6-Tetragalloylglucose is a potent UDP glucuronosyltransferase 1 family, polypeptide A1 (UGT1A1) inhibitor, with a Ki of 1.68 μM[1].
IC50 & Target: Ki: 1.68 μM (UGT1A1)[1].

Name: Eplivanserin (mixture) SR-46349 (mixture), CAS: 130581-13-4, stock 14.3g, assay 98.3%, MWt: 328.38, Formula: C19H21FN2O2, Solubility: DMSO : 125 mg/mL (380.66 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Neuronal Signaling;Neuronal Signaling;GPCR/G Protein, Target: Serotonin Transporter;5-HT Receptor;5-HT Receptor, Biological_Activity: Eplivanserin mixture is a selective serotonin reuptake inhibitor and a 5-HT2A receptor antagonist, extracted from patent WO 2005/002578 A1[1].
IC50 & Target: 5-HT2A receptor[1].

Name: FB23-2, CAS: 2243736-45-8, stock 11.7g, assay 98.8%, MWt: 392.24, Formula: C18H15Cl2N3O3, Solubility: DMSO : 62.5 mg/mL (159.34 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: FB23-2 is a potent and selective inhibitor of mRNA N6-methyladenosine (m6A) demethylase FTO, with an IC50 of 2.6 μM[1].
IC50 & Target: IC50: 2.6 μM (FTO)[1]
In Vitro: FB23-2 dramatically suppresses proliferation and promotes the differentiation/apoptosis of human acute myeloid leukemia (AML) cell line cells and primary blast AML cells[1]. 
FB23 inhibits the proliferation of NB4 and MONOMAC6 cells, with IC50 values of 0.8 μM and 1.5 μM[1]. 
In Vivo: FB23-2 significantly inhibits the progression of human AML cell lines and primary cells in xeno-transplanted mice[1].

Name: FMF-04-159-2, CAS: 2364489-81-4, stock 39.1g, assay 98.6%, MWt: 683.01, Formula: C28H30Cl3N7O5S, Solubility: DMSO : 250 mg/mL (366.03 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Cell Cycle/DNA Damage, Target: CDK, Biological_Activity: FMF-04-159-2 is a covalent CDK14 inhibitor. FMF-04-159-2 inhibits CDK14 and CDK2 with IC50s of 39.6 nM and 256 nM in NanoBRET assay, respectively[1].
In Vitro: FMF-04-159-2 inhibits HCT116 proliferation with an IC50 of 1,144±190 nM[1].

Name: NDI-091143, CAS: 2375840-87-0, stock 5.6g, assay 98.4%, MWt: 453.84, Formula: C20H14ClF2NO5S, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Metabolic Enzyme/Protease, Target: ATP Citrate Lyase, Biological_Activity: NDI-091143 is a potent and high-affinity human ATP-citrate lyase (ACLY) inhibitor with an IC50 of 2.1 nM (ADP-Glo assay), a Ki of 7.0 nM and a Kd of 2.2 nM. NDI-091143 inhibits ACLY catalysis allosterically, by stabilizing large conformational changes in the citrate domain that indirectly block the binding and recognition of citrate[1].
IC50 & Target: IC50: 2.1 nM (human ATP-citrate lyase); Ki: 7.0 nM (human ATP-citrate lyase); Kd: 2.2 nM (human ATP-citrate lyase)[1]
In Vitro: Thermal shift assays shows that NDI-091143 gives rise to considerable stabilization of both full-length ACLY and the N-terminal segment. The thermal shift data are consistent with limited proteolysis experiments using full-length ACLY, in which NDI-091143 together with Mg-ATP provided the greatest protection against digestion by chymotrypsin[1].

Name: PROTAC ERα Degrader-2, CAS: 1351169-29-3, stock 1.9g, assay 98.9%, MWt: 763.96, Formula: C42H61N5O8, Solubility: DMSO : 200 mg/mL (261.79 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Others;PROTAC;PROTAC, Target: Estrogen Receptor/ERR;PROTAC;SNIPER, Biological_Activity: PROTAC ERα Degrader-2 comprises a cIAP1 ligand binding group, a linker and an estrogen receptor α (ERα) binding group. PROTAC ERα Degrader-2 is an ERα degrader. Maximal ERα degradation at 30 μM concentration in human mammary tumor MCF7 cells. Degradation inducers based on cIAP1 are called specific and non-genetic IAP-dependent protein erasers (SNIPERs)[1].

Name: Glycodeoxycholic Acid, CAS: 360-65-6, stock 38.4g, assay 98%, MWt: 449.62, Formula: C26H43NO5, Solubility: DMSO : 250 mg/mL (556.03 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Metabolic Enzyme/Protease, Target: Endogenous Metabolite, Biological_Activity:

Name: Macropa-NH2, CAS: 2146095-13-6, stock 26.2g, assay 98.9%, MWt: 547.60, Formula: C26H37N5O8, Solubility: DMSO : 83.33 mg/mL (152.17 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: Macropa-NH2 is the precursor of Macropa-NCS. Macropa-NCS is conjugated to trastuzumab as well as to the prostate-specific membrane antigen-targeting compound RPS-070 and is a promising therapeutic radionuclide applied in the treatment of soft-tissue metastases[1][2].

Name: (R)-Ketorolac (+)-Ketorolac, CAS: 66635-93-6, stock 24.8g, assay 98.9%, MWt: 255.27, Formula: C15H13NO3, Solubility: DMSO : ≥ 100 mg/mL (391.74 mM), Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: (R)-Ketorolac is the R-enantiomer of Ketorolac, shows potent analgesic activity, reduces ulcerogenic potential. (R)-Ketorolac is inactive on COX[1].

Name: (E/Z)-BCI (hydrochloride) NSC 150117 (hydrochloride), CAS: 95130-23-7, stock 4.5g, assay 98.7%, MWt: 353.89, Formula: C22H24ClNO, Solubility: DMSO : 15.62 mg/mL (44.14 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Metabolic Enzyme/Protease, Target: Phosphatase, Biological_Activity: (E/Z)-BCI hydrochloride (NSC 150117 hydrochloride) is a dual-specificity phosphatase 6 (DUSP6) inhibitor with anti-inflammatory activities. (E/Z)-BCI hydrochloride attenuates LPS-induced inflammatory mediators and ROS production in macrophage cells via activating the Nrf2 signaling axis and inhibiting the NF-κB pathway[1].
IC50 & Target: DUSP6[1]
In Vitro: (E/Z)-BCI hydrochloride (2-10 μM; 72 hours) significantly decreases cell viability in a time and dose-dependent manner in gastric epithelial cell GES1, GC cell lines, and AGS cell lines[2]. 
(E/Z)-BCI hydrochloride (0.5-4 μM; 24 hours) significantly inhibits DUSP6 expression in LPS-activated macrophages[1]. 
(E/Z)-BCI hydrochloride (0.5-2 μM; 24 hours) treatment significantly inhibits the expression of IL-1β, TNF-α and IL-6 mRNA in LPS-activated macrophages[1]. 
(E/Z)-BCI hydrochloride decreases ROS production and activates the Nrf2 pathway in LPS-activated macrophages[1].
(E/Z)-BCI hydrochloride inhibits cell proliferation, migration and invasion in a receptor-independent manner and enhances Cisplatin (CDDP) cytotoxicity (enhances CDDP-induced cell death and apoptosis) at pharmacological concentrations in the gastric cancer (GC) cells[2]. 
In Vivo: (E/Z)-BCI hydrochloride (35 mg/kg; intraperitoneal injection; every 7 days; for four weeks) treatment enhances cisplatin efficacy in PDX models[2].

Name: Ulixertinib (hydrochloride) BVD-523 (hydrochloride);VRT752271 (hydrochloride), CAS: 1956366-10-1, stock 1.1g, assay 99%, MWt: 469.79, Formula: C21H23Cl3N4O2, Solubility: DMSO : 125 mg/mL (266.08 mM; Need ultrasonic), Clinical_Informat: Phase 2, Pathway: Stem Cell/Wnt;MAPK/ERK Pathway, Target: ERK;ERK, Biological_Activity: Ulixertinib hydrochloride (BVD-523 hydrochloride) is a potent, orally active, highly selective, ATP-competitive and reversible covalent inhibitor of ERK1/2 kinases, with an IC50 of <0.3 nM against ERK2. Ulixertinib hydrochloride inhibits the phosphorylated ERK2 (pERK) and downstream kinase RSK (pRSK) in an A375 melanoma cell line[1][2].

Name: EHMT2-IN-2, CAS: 2230850-47-0, stock 10.9g, assay 98.2%, MWt: 374.44, Formula: C21H22N6O, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Epigenetics, Target: Histone Methyltransferase, Biological_Activity: EHMT2-IN-2 is a potent EHMT inhibitor, with IC50s of all <100 nM for EHMT1 peptide, EHMT2 peptide and cellular EHMT2. Used in the research of blood disease or cancer[1].
In Vitro: EHMT2-IN-2 (Compound 200) is a potent EHMT inhibitor, with IC50s of all < 100 nM for EEHMT1 peptide, EHMT2 peptide and cellular EHMT2[1].

Name: M-2420 Methoxycoumarin-Ser-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Lys-dinitrophenyl, CAS: 310427-95-3, stock 39.6g, assay 98.4%, MWt: 1574.56, Formula: C70H91N15O27, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: M-2420 is a fluorogenic substrate containing β-secretase site of the Swedish mutation of amyloid precursor protein (APP)[1].

Name: 3-Nitrocoumarin, CAS: 28448-04-6, stock 4.6g, assay 98.8%, MWt: 191.14, Formula: C9H5NO4, Solubility: DMSO : ≥ 100 mg/mL (523.18 mM), Clinical_Informat: No Development Reported, Pathway: Metabolic Enzyme/Protease, Target: Phospholipase, Biological_Activity: 3-Nitrocoumarin (3-NC) is a potent and selective Phospholipase C-γ (PLC-γ) inhibitor[1].
IC50 & Target: PLC-γ[1].

Name: PLX-4720, CAS: 918505-84-7, stock 30.5g, assay 98.6%, MWt: 413.83, Formula: C17H14ClF2N3O3S, Solubility: DMSO : ≥ 50 mg/mL (120.82 mM), Clinical_Informat: No Development Reported, Pathway: MAPK/ERK Pathway, Target: Raf, Biological_Activity: PLX-4720 is a potent and selective inhibitor of B-RafV600E with IC50 of 13 nM in a cell-free assay, equally potent to c-Raf-1(Y340D and Y341D mutations), and 10-fold selectivity for B-RafV600E than wild-type B-Raf.
IC50 & Target: IC50: 13 nM (B-RafV600E)
In Vitro: PLX-4720 displays >10 times selectivity against wild type B-Raf, and >100 times selectivity over other kinases such as Frk, Src, Fak, FGFR, and Aurora A with IC50 of 1.3-3.4 μM. PLX-4720 significantly inhibits the ERK phosphorylation in cell lines bearing B-RafV600E with IC50 of 14-46 nM, but not the cells with wild-type B-Raf. PLX-4720 significantly inhibits the growth of tumor cell lines bearing the B-RafV600E oncogene, such as COLO205, A375, WM2664, and COLO829 with GI50 of 0.31 μM, 0.50 μM, 1.5 μM, and 1.7 μM, respectively. In addition, PLX-4720 treatment at 1 μM induces cell cycle arrest and apoptosis exclusively in the B-RafV600E-positive 1205Lu cells, but not in the B-Raf wild-type C8161 cells[1]. PLX-4720 treatment (10 μM) significantly induces > 14-fold expression of BIM in the PTEN+ cells, compared with the PTEN- cell lines (4-fold), giving an explanation of the resistance of PTEN- cells to PLX-4720-induced apoptosis[2].
In Vivo: Oral administration of PLX-4720 at 20 mg/kg/day induces significant tumor growth delays and regressions in B-RafV600E-dependent COLO205 tumor xenografts, without obvious adverse effects in mice even at dose of 1 g/kg. PLX-4720 at 100 mg/kg twice daily almost completely eliminates the 1205Lu xenografts bearing B-RafV600E, while has no activity against C8161 xenografts bearing wild-type B-Raf. The anti-tumor effects of PLX-4720 correlate with the blockade of MAPK pathway in those cells harboring the V600E mutation[1]. PLX-4720 treatment at 30 mg/kg/day significant inhibits the tumor growth of 8505c xenografts by >90%, and dramatically decreases distant lung metastases[3].

Name: Pimethixene maleate Pimetixene maleate, CAS: 13187-06-9, stock 12.9g, assay 98.8%, MWt: 409.50, Formula: C23H23NO4S, Solubility: 10 mM in DMSO, Clinical_Informat: Launched, Pathway: Immunology/Inflammation;GPCR/G Protein;Neuronal Signaling;GPCR/G Protein;Neuronal Signaling, Target: Histamine Receptor;Histamine Receptor;5-HT Receptor;5-HT Receptor;Histamine Receptor, Biological_Activity: Pimethixene maleate is antihistamine and antiserotonergic compound, acts as an antimigraine agent.
Pimethixene maleate is a highly potent antagonist of 5-HT1A, 5-HT2A, 5-HT2B, 5-HT2C, histamine H1, dopamine D2 and D4.4 as well as muscarinic M1 and M2 receptors, with pKis of 7.63, 10.22, 10.44, 8.42, 10.14, 8.19, 7.54, 8.61 and 9.38, respectively[1].
IC50 & Target: pKi: 7.63 (5-HT1A receptor), 10.22 (5-HT2A receptor), 10.44 (5-HT2B receptor), 8.42 (5-HT2C receptor), 10.14 (histamine H1 receptor), 8.19 (D2 receptor), 7.54 (DD4.4 receptor), 8.61 (M1 receptor), 9.38 (M2 receptor)[1]

Name: Molibresib (besylate) GSK 525762C; I-BET 762 (besylate), CAS: 1895049-20-3, stock 32.8g, assay 98.4%, MWt: 582.07, Formula: C28H28ClN5O5S, Solubility: DMSO : 25 mg/mL (42.95 mM; Need ultrasonic), Clinical_Informat: Phase 1, Pathway: Epigenetics, Target: Epigenetic Reader Domain, Biological_Activity: Molibresib besylate (GSK 525762C; I-BET 762 besylate) is a BET bromodomain inhibitor with IC50 of 32.5-42.5 nM.
IC50 & Target: IC50: 32.5-42.5 nM (BET)[1]

Name: Pteridine-2,4(1H,3H)-dione, CAS: 487-21-8, stock 31.5g, assay 98%, MWt: 164.12, Formula: C6H4N4O2, Solubility: , Clinical_Informat: No Development Reported, Pathway: Metabolic Enzyme/Protease, Target: Endogenous Metabolite, Biological_Activity:

Name: H-Gly-Gly-Pro-OH Glycyl-glycyl-L-proline, CAS: 14379-76-1, stock 18.3g, assay 98.7%, MWt: 229.23, Formula: C9H15N3O4, Solubility: H2O, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: H-Gly-Gly-Pro-OH is a peptide with 3 amino acid.

Name: Tauroursodeoxycholate dihydrate TUDCA dihydrate;UR 906 dihydrate;Taurolite dihydrate, CAS: 117609-50-4, stock 7.2g, assay 98%, MWt: 535.73, Formula: C26H49NO8S, Solubility: DMSO : 83.33 mg/mL (155.54 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Apoptosis;Apoptosis;Stem Cell/Wnt;MAPK/ERK Pathway, Target: Apoptosis;Caspase;ERK;ERK, Biological_Activity: Tauroursodeoxycholate dihydrate (TUDCA dihydrate; UR 906 dihydrate; Taurolite dihydrate) is an endoplasmic reticulum (ER) stress inhibitor. Tauroursodeoxycholate significantly reduces expression of apoptosis molecules, such as caspase-3 and caspase-12. Tauroursodeoxycholate also inhibits ERK[1][2].
IC50 & Target: ERK[1] 
Caspase-3, Caspase-12[2]

Name: mAChR-IN-1 (hydrochloride), CAS: 119391-73-0, stock 1.8g, assay 98.4%, MWt: 524.82, Formula: C23H26ClIN2O2, Solubility: DMSO : 65 mg/mL (123.85 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Neuronal Signaling;GPCR/G Protein, Target: mAChR;mAChR, Biological_Activity: mAChR-IN-1 hydrochloride is a potent muscarinic cholinergic receptor (mAChR) antagonist, with an IC50 of 17 nM[1].
IC50 & Target: IC50: 17 nM (mAChR)[1].

Name: BI-749327, CAS: 2361241-23-6, stock 4.9g, assay 98.7%, MWt: 442.43, Formula: C23H21F3N4O2, Solubility: DMSO : 31.25 mg/mL (70.63 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Membrane Transporter/Ion Channel;Neuronal Signaling, Target: TRP Channel;TRP Channel, Biological_Activity: BI-749327 is a potent, high selectivity and orally bioavailable TRPC6 antagonist, with IC50s of 13 nM, 19 nM and 15 nM for mouse, human and guinea pig TRPC6, respectively. BI-749327 is 85-fold more selective for mouse TRPC6 than TRPC3 and 42-fold versus TRPC7[1].
IC50 & Target: IC50: 13 nM (mouse TRPC6), 19 nM (human TRPC6), 15 nM (guinea pig TRPC6)[1]
In Vitro: BI-749327 suppresses NFAT activation in HEK293T cells expressing wild-type or gain-of-function TRPC6 mutants and blocks associated signaling and expression of prohypertrophic genes in isolated myocytes[1]. 
In Vivo: BI-749327 (30 mg/kg/day; i.g.) improves left heart function, reduces volume/mass ratio, and blunts expression of profibrotic genes and interstitial fibrosis in mice subjected to sustained pressure overload[1]. 
BI-749327 dose dependently reduces renal fibrosis and associated gene expression in mice with unilateral ureteral obstruction[1]. 
BI-749327 has long terminal half-life (t1/2 8.5-13.5 hours) for mice (3-30 mg/kg; p.o.)[1].

Name: LUT014, CAS: 2274819-46-2, stock 33.7g, assay 98.6%, MWt: 528.49, Formula: C27H19F3N8O, Solubility: DMSO : 50 mg/mL (94.61 mM; Need ultrasonic); H2O : < 0.1 mg/mL (insoluble), Clinical_Informat: Phase 1, Pathway: MAPK/ERK Pathway, Target: Raf, Biological_Activity: LUT014 is a B-Raf inhibitor with an IC50 of 11.7 nM, and developed to reduce dose-limiting acneiform lesions associated EGFR Inhibitors treatment. Extracted from patent WO 2019026065A2 [1].
IC50 & Target: IC50: 11.7 nM (B-Raf)[1]

Name: GSK8612, CAS: 2361659-62-1, stock 14.5g, assay 98.9%, MWt: 520.33, Formula: C17H17BrF3N7O2S, Solubility: DMSO : ≥ 125 mg/mL (240.23 mM), Clinical_Informat: No Development Reported, Pathway: NF-κB, Target: IKK, Biological_Activity: GSK8612 is a highly selective and potent Tank-binding Kinase-1 (TBK1) inhibitor, with a pIC50 of 6.8 for recombinant TBK1[1].
IC50 & Target: pIC50: 6.8 (recombinant TBK1)[1].
In Vitro: GSK8612 inhibits toll-like receptor (TLR)3-induced IRF3 phosphorylation in Ramos cells and type I IFN secretion in primary human mononuclear cells. In THP1 cells, GSK8612 is able to inhibit secretion of IFNβ in response to dsDNA and cGAMP, the natural ligand for STING[1].

Name: MW-150 dihydrochloride dihydrate MW01-18-150SRM dihydrochloride dihydrate, CAS: 1661020-92-3, stock 3.1g, assay 98.8%, MWt: 490.43, Formula: C24H29Cl2N5O2, Solubility: DMSO : 20.83 mg/mL (42.47 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: MAPK/ERK Pathway;Autophagy, Target: p38 MAPK;Autophagy, Biological_Activity: MW-150 dihydrochloride dihydrate (MW01-18-150SRM dihydrochloride dihydrate) is a selective, CNS penetrant, and orally active inhibitor of p38α MAPK with a Ki of 101 nM. MW-150 dihydrochloride dihydrate (MW01-18-150SRM dihydrochloride dihydrate) inhibits the ability of the endogenous p38α MAPK to phosphorylate an endogenous substrate MK2 in activated glia[1].
IC50 & Target: Ki: 101nM (p38α MAPK)[1]
In Vitro: MW-150 dihydrochloride dihydrate inhibits in a concentration-dependent manner the ability of the endogenous p38αMAPK to phosphorylate an endogenous substrate MK2 in activated glia[1]. 
MW-150 dihydrochloride dihydrate blocks in a concentration-dependent manner the increased IL-1β production by activated glia. The IC50 values are 332 nM and 936 nM for MK2 and IL-1β, respectively[1].
In Vivo: MW-150 dihydrochloride dihydrate (2.5 mg/kg; oral daily for 3−4 months) improves the APP/PS1 transgenic (Tg) mice performance in radial arm water maze (RAWM) and contextual fear conditioning tests[1]. 
MW-150 dihydrochloride dihydrate (2.5 mg/kg; given i.p.; daily for 14 days) treatment in APPNLh/NLh × PSP264L/P264L knock-in mouse (with no overexpression of the amyloid precursor protein) exhibits RAWM behavior indistinguishable from WT mice[1].

Name: TAK-448 (acetate) MVT-602 (acetate), CAS: 1470374-22-1, stock 7.8g, assay 98.7%, MWt: 1285.41, Formula: C60H84N16O16, Solubility: 10 mM in DMSO, Clinical_Informat: Phase 2, Pathway: Others, Target: Others, Biological_Activity: TAK-448 acetate (MVT-602 acetate) is a potent and full KISS1R agonist with an IC50 of 460 pM and an EC50 of 632 pM[1].
IC50 & Target: IC50: 460 pM (KISS1R)[1] 
EC50: 632 pM (KISS1R)[1]
In Vivo: TAK-448 acetate (0.01-3 mg/kg; given i.h.; dosings on day 0 and 28) has greater anti-tumor effects in VCaP xenograft model[2].

Name: NVP-BHG712 BHG712, CAS: 940310-85-0, stock 25.4g, assay 98.7%, MWt: 503.48, Formula: C26H20F3N7O, Solubility: DMSO : 31.25 mg/mL (62.07 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Protein Tyrosine Kinase/RTK, Target: Ephrin Receptor, Biological_Activity: NVP-BHG712 is an oral active EphB4 kinase autophosphorylation inhibitor, with IC50 values of 3.3 nM and 3.0 nM for EphA2 and EphB4, respectively[1][2].
IC50 & Target: IC50: 3.3 nM (EphA2), 3 nM (EphB4)[2].
In Vitro: NVP-BHG712 inhibits VEGF driven vessel formation, while it has only little effects on VEGF receptor (VEGFR) activity. The data suggests a close cross talk between the VEGFR and EphR signaling during vessel formation[2].
In Vivo: NVP-BHG712 (3, 10 and 30 mg/kg, p.o., daily) inhibits VEGF driven tissue growth and angiogenesis[2].

Name: GSK3145095, CAS: 1622849-43-7, stock 23.9g, assay 98.7%, MWt: 397.38, Formula: C20H17F2N5O2, Solubility: DMSO : 250 mg/mL (629.12 mM; Need ultrasonic), Clinical_Informat: Phase 2, Pathway: Apoptosis, Target: RIP kinase, Biological_Activity: GSK3145095 is a RIP1 kinase inhibitor with an IC50 of 6.3 nM [1].
IC50 & Target: IC50: 6.3 nM (RIP1 kinase )[1]
In Vitro: GSK3145095 potently blocks the TNF response as shown by determination of overall cell viability as measured by cellular ATP levels (IC50 = 1.6 nM), cell death as measured by LDH release (IC50 = 0.5 nM) and RIP1-dependent inflammatory cytokine MIP-1β production, either as absolute levels for protein, or fold changes in mRNA expression (IC50 = 0.4 nM) [1].

Name: (1S,2S,3R)-DT-061, CAS: 1809427-20-0, stock 9.2g, assay 98.3%, MWt: 520.52, Formula: C25H23F3N2O5S, Solubility: Methanol : 25 mg/mL (48.03 mM; Need ultrasonic); DMSO : 125 mg/mL (240.14 mM; Need ultrasonic); H2O : < 0.1 mg/mL (insoluble), Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: (1S,2S,3R)-DT-061 is an enantiomer of DT-061. DT-061 is an orally bioavailable activator of protein phosphatase 2A (PP2A) and could be applied in the therapy of KRAS-mutant and MYC-driven tumorigenesis[1].

Name: UAMC-3203 hydrochloride, CAS: 2271358-65-5, stock 40g, assay 98.5%, MWt: 508.12, Formula: C25H38ClN5O2S, Solubility: DMSO : 50 mg/mL (98.40 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Apoptosis, Target: Ferroptosis, Biological_Activity: UAMC-3203 hydrochloride is a potent and selective Ferroptosis inhibitor with an IC50 of 12 nM[1].
IC50 & Target: IC50: 12 nM (Ferroptosis)[1]
In Vivo: No toxicity is observed in mice after repeated injections of UAMC-3203 (20 µmol/kg; injected intraperitoneally; daily, over a period of 4 weeks)[1].

Name: GS-6207, CAS: 2189684-44-2, stock 30.6g, assay 98.2%, MWt: 968.28, Formula: C39H32ClF10N7O5S2, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Anti-infection, Target: HIV, Biological_Activity: GS-6207 is a HIV-1 capsid inhibitor. GS-6207 shows anti-HIV activity with an EC50 of 100 pM in MT-4 cells. GS-6207 displays a mean EC50 of 50 pM (20-160 pM) against 23 HIV-1 clinical isolates from different subtypes in peripheral blood mononuclear cells (PBMCs)[1].

Name: Tirzepatide LY3298176, CAS: 2023788-19-2, stock 6.1g, assay 99%, MWt: 4813.45, Formula: C225H348N48O68, Solubility: 10 mM in DMSO, Clinical_Informat: Phase 3, Pathway: GPCR/G Protein, Target: Glucagon Receptor, Biological_Activity: Tirzepatide (LY3298176) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that is being developed for the treatment of type 2 diabetes[1].
In Vivo: Tirzepatide (LY3298176) shows significantly better efficacy with regard to glucose control and weight loss than do Dulaglutide[1].

Name: GSK429286A, CAS: 864082-47-3, stock 0.4g, assay 98.6%, MWt: 432.37, Formula: C21H16F4N4O2, Solubility: DMSO : ≥ 51 mg/mL (117.95 mM), Clinical_Informat: No Development Reported, Pathway: TGF-beta/Smad;Stem Cell/Wnt;Cell Cycle/DNA Damage, Target: ROCK;ROCK;ROCK, Biological_Activity: GSK429286A is a selective inhibitor of ROCK1 with an IC50 value of 14 nM.
IC50 & Target: IC50: 14 nM (ROCK1)[1].
In Vitro: GSK429286A at 1 μM reduces ROCK2 activity over 20-fold, under conditions in which the only other kinase tested that is significantly inhibited is MSK1 whose activity is reduced ~5-fold. GSK429286A is a more selective ROCK2 inhibitor than the widely utilized ROCK inhibitor Y-27632 as assessed on kinase-specificity panel, and does not significantly inhibit LRRK2 even at doses as high as 30 μM (500-fold higher than IC50 of inhibition of ROCK2). GSK429286A slightly inhibits RSK and p70S6K with IC50 of 0.78 μM and 1.94 μM, respectively. GSK429286A significantly inhibits rat aortic ring dilation with IC50 of 190 nM[2].
In Vivo: GSK429286A has 61% oral bioavailability in male Sprague-Dawley rats. Oral administration of GSK429286A at single doses of 3-30 mg/kg dramatically reduces mean arterial pressure in the spontaneously hypertensive rats (SHRs) in a dose-dependent manner, with a maximum decrease of 50 mmHg after approximately 2 hours treatment at dose of 30 mg/kg[1].

Name: Apelin-13, CAS: 217082-58-1, stock 24.5g, assay 98.2%, MWt: 1550.83, Formula: C69H111N23O16S, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: Apelin-13 is the endogenous ligand of the orphan G protein-coupled receptor APJ, activates APJ receptor with an EC50 value of 0.37 nM in CHO cells[1][2].

Name: Neurokinin B (TFA), CAS: 101536-55-4, stock 12.8g, assay 98%, MWt: 1438.47, Formula: C55H79N13O14S2.2C2HF3O2, Solubility: H2O, Clinical_Informat: No Development Reported, Pathway: Neuronal Signaling;GPCR/G Protein, Target: Neurokinin Receptor;Neurokinin Receptor, Biological_Activity: Neurokinin B TFA belongs to the tachykinin family of peptides. Neurokinin B binds a family of GPCRs-including neurokinin receptor 1 (NK1R), NK2R, and NK3R-to mediate their biological effect[1].
IC50 & Target: Neurokinin receptor[1]

Name: RGD peptide (GRGDNP), CAS: 114681-65-1, stock 9.8g, assay 98.1%, MWt: 614.61, Formula: C23H38N10O10, Solubility: H2O, Clinical_Informat: No Development Reported, Pathway: Cytoskeleton;Apoptosis, Target: Integrin;Apoptosis, Biological_Activity: RGD peptide (GRGDNP) acts as an inhibitor of integrin-ligand interactions and plays an important role in cell adhesion, migration, growth, and differentiation[1]. RGD peptide (GRGDNP) promote apoptosis through activation of conformation changes that enhance pro-caspase-3 activation and autoprocessing[2][3].

Name: Adenosine amine congener ADAC, CAS: 96760-69-9, stock 8.2g, assay 98.6%, MWt: 576.60, Formula: C28H32N8O6, Solubility: DMSO : 31.25 mg/mL (54.20 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: GPCR/G Protein, Target: Adenosine Receptor, Biological_Activity: Adenosine amine congener (ADAC) is a selective A1 adenosine receptor agonist, can ameliorate noise- and Cisplatin-induced cochlear injury. Adenosine amine congener also has neuroprotective effects[1][2].
IC50 & Target: A1 adenosine receptor[1][2]
In Vitro: Adenosine amine congener can reduce oxidative stress in the noise-exposed cochlea, leading to protection of sensory hair cells. Adenosine amine congener also can reduce cisplatin-induced apoptosis in cochlear tissues, particularly in sensory hair cells and strial marginal cells. The mechanisms of otoprotection by Adenosine amine congener include inhibition of glutamate release via presynaptic A1 receptors and inhibition of voltage-gated Ca2+ channels, which can prevent activation of apoptotic and necrotic cell death pathways[1].
In Vivo: Adenosine amine congener (25-300 μg/kg/day; intraperitoneal injection; daily; for 5 days; male Wistar rats) treatment is most effective in the first 24 hours after noise exposure at doses >50 μg/kg, providing up to 21 dB protection. Adenosine amine congener mitigates noise-induced hearing loss in a dose- and time-dependent manner[1].

Name: 5-(N,N-Hexamethylene)-amiloride Hexamethylene amiloride;HMA, CAS: 1428-95-1, stock 38.6g, assay 98.3%, MWt: 311.77, Formula: C12H18ClN7O, Solubility: 10 mM in DMSO, Clinical_Informat: Phase 1, Pathway: Apoptosis;Anti-infection;Membrane Transporter/Ion Channel, Target: Apoptosis;HIV;Sodium Channel, Biological_Activity: 5-(N,N-Hexamethylene)-amiloride (Hexamethylene amiloride) derives from an amiloride and is a potent Na+/H+ exchanger inhibitor, which decreases the intracellular pH (pHi) and induces apoptosis in leukemic cells. 5-(N,N-Hexamethylene)-amiloride (Hexamethylene amiloride) is also an inhibitor of the HIV-1 Vpu virus ion channel and inhibits mouse hepatitis virus (MHV) replication and human coronavirus 229E (HCoV229E) replication in cultured L929 cells with EC50s of 3.91 μM and 1.34 μM, respectively[1][2].
IC50 & Target: Na+/H+ exchanger[1] 
EC50: 3.91 μM (MHV replication), 1.34 μM (HCoV229E replication)[2]

Name: ELX-02 disulfate NB-124 disulfate, CAS: 2244622-33-9, stock 21.3g, assay 98.5%, MWt: 678.68, Formula: C19H42N4O18S2, Solubility: H2O : 125 mg/mL (184.18 mM; Need ultrasonic); DMSO : < 1 mg/mL (insoluble or slightly soluble), Clinical_Informat: Phase 1, Pathway: Others, Target: Others, Biological_Activity: ELX-02 disulfate (NB-124 disulfate) is an investigational, advanced synthetic eukaryotic ribosome selective glycoside (ERSG). ELX-02 disulfate is being developed as a therapy for genetic diseases caused by nonsense mutations[1].

Name: ELX-02 sulfate NB-124 sulfate, CAS: 1375073-94-1, stock 1.1g, assay 98.6%, MWt: 580.60, Formula: C19H40N4O14S, Solubility: 10 mM in DMSO, Clinical_Informat: Phase 1, Pathway: Others, Target: Others, Biological_Activity: ELX-02 sulfate (NB-124 sulfate) is an investigational, advanced synthetic eukaryotic ribosome selective glycoside (ERSG). ELX-02 sulfate is being developed as a therapy for genetic diseases caused by nonsense mutations[1].

Name: PROTAC ER Degrader-3, CAS: 2158322-29-1, stock 33.1g, assay 98.3%, MWt: 1220.41, Formula: C71H77N7O12, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others;PROTAC, Target: Estrogen Receptor/ERR;PROTAC, Biological_Activity: PROTAC ER Degrader-3 is an intermediate for synthesis of PAC. PAC, consists the ADCs linker and PROTACs, conjugated to an antibody. PAC extracts from patent WO2017201449A1, compound LP2. PAC conjugated to an antibody is a more marked estrogen receptor-alpha (ERα) degrader compared to PROTAC (without Ab)[1].

Name: Taltirelin (acetate) TA-0910 (acetate), CAS: 1549593-23-8, stock 9.7g, assay 98.2%, MWt: 465.46, Formula: C19H27N7O7, Solubility: DMSO : 125 mg/mL (268.55 mM; Need ultrasonic), Clinical_Informat: Launched, Pathway: Others, Target: Thyroid Hormone Receptor, Biological_Activity: Taltirelin acetate (TA-0910 acetate) is a superagonist at thyrotropin-releasing hormone receptor (TRH-R) with an IC50 of 910 nM and EC50 of 36 nM for stimulating an increase in cytosolic Ca2+ concentration (Ca2+ release)[1].
IC50 & Target: IC50: 910 nM (Thyrotropin-releasing hormone receptor)[1]

Name: Adrenocorticotropic Hormone (ACTH) (18-39), human (TFA) CLIP (human) (TFA), CAS: 73724-75-1, stock 19.6g, assay 98%, MWt: 2579.69, Formula: C114H166F3N27O38, Solubility: H2O, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: Adrenocorticotropic Hormone (ACTH) (18-39), human TFA is a corticotropinlike intermediate lobe peptide, which is is produced in the melanotrophs of the intermediate lobe of the pituitary[1].

Name: OVA G4 peptide, CAS: 148274-82-2, stock 4.8g, assay 98.9%, MWt: 906.08, Formula: C43H71N9O12, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: OVA G4 peptide is a variant of the agonist ovalbumin (OVA) peptide SIINFEKL (257-264). SIINFEKL is routinely used to stimulate ovalbumin-specific T cells and to test new vaccine adjuvants can form a stable hydrogel[1][2].

Name: N-Boc-Phe-Leu-Phe-Leu-Phe Boc-FLFLF, CAS: 148182-34-7, stock 10.1g, assay 98.2%, MWt: 785.97, Formula: C44H59N5O8, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: N-Boc-Phe-Leu-Phe-Leu-Phe (Boc-FLFLF) is a formyl peptide receptor 1 (FPR1) antagonist, which increases pain effects and inhibits antinociceptive activity of annexin[1][2].
IC50 & Target: FPR1[1]

Name: Platelet Factor 4 (58-70), human, CAS: 82989-21-7, stock 7g, assay 98.6%, MWt: 1572.97, Formula: C76H133N17O18, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: Platelet Factor 4 (58-70), human, a peptide based on the amino acid sequence corresponding to residues 58-70 of platelet factor-4 (PF-4), contains the major heparin-binding domain, which is not sufficient for full antiangiogenic activity[1].

Name: (Rac)-Antineoplaston A10, CAS: 77658-84-5, stock 37.1g, assay 98.7%, MWt: 246.26, Formula: C13H14N2O3, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Apoptosis;GPCR/G Protein, Target: Apoptosis;Ras, Biological_Activity: (rac)-Antineoplaston A10 is the racemate of Antineoplaston A10. Antineoplaston A10 is a Ras inhibitor potentially for the treatment of glioma, lymphoma, astrocytoma and breast cancer[1].

Name: N-Desethyl amodiaquine, CAS: 79352-78-6, stock 35.4g, assay 98.6%, MWt: 327.81, Formula: C18H18ClN3O, Solubility: DMSO : 125 mg/mL (381.32 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Anti-infection, Target: Parasite, Biological_Activity: N-Desethyl amodiaquine is the major biologically active metabolite of Amodiaquine. N-Desethyl amodiaquine is an antiparasitic agent. IC50 values for strains V1/S and 3D7 are 97 nM and 25 nM, respectively[1].

Name: Tiagabine hydrochloride hydrate NO050328 hydrochloride hydrate;NO328 hydrochloride hydrate;TGB hydrochloride hydrate, CAS: 145821-57-4, stock 29.9g, assay 98.7%, MWt: 430.02, Formula: C20H28ClNO3S2, Solubility: 10 mM in DMSO, Clinical_Informat: Launched, Pathway: Neuronal Signaling;Membrane Transporter/Ion Channel, Target: GABA Receptor;GABA Receptor, Biological_Activity: Tiagabine hydrochloride hydrate is a potent and selective GABA uptake inhibitor, used as an anticonvulsant agent, with IC50s of 67, 446 and 182 nM for [3H]GABA uptake in Synaptosomes, Neurons and Glia, respectively[1].

Name: Antineoplaston A10, CAS: 91531-30-5, stock 10.7g, assay 99%, MWt: 246.26, Formula: C13H14N2O3, Solubility: DMSO : 250 mg/mL (1015.19 mM; Need ultrasonic), Clinical_Informat: Phase 2, Pathway: Apoptosis;GPCR/G Protein;Metabolic Enzyme/Protease, Target: Apoptosis;Ras;Endogenous Metabolite, Biological_Activity: Antineoplaston A10, a naturally occurring substance in human body, is a Ras inhibitor potentially for the treatment of glioma, lymphoma, astrocytoma and breast cancer[1].
IC50 & Target: Ras[1].

Name: Gastrin I (1-14), human, CAS: 100940-57-6, stock 19.4g, assay 98.9%, MWt: 1705.73, Formula: C79H100N16O27, Solubility: H2O, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: Gastrin I (1-14), human is 1-14 fragment of human gastrin I peptide. Gastrin I is an endogenous, gastrointestinal peptide hormone. Gastrin is the major hormonal regulator of gastric acid secretion[1].

Name: Vipivotide tetraxetan Linker PSMA-617 Linker, CAS: 1703768-74-4, stock 29.1g, assay 98.1%, MWt: 655.74, Formula: C33H45N5O9, Solubility: DMSO : 270 mg/mL (411.75 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Antibody-drug Conjugate/ADC Related, Target: ADC Linker, Biological_Activity: Vipivotide tetraxetan Linker (PSMA-617 Linker) is a nonclaevable peptide linker for synthesis of Vipivotide tetraxetan (PSMA-617). Vipivotide tetraxetan (PSMA-617) is a ligand used to synthesize 177Lu-PSMA-617, which is a radioactive molecule for the treatment of prostate cancer[1].

Name: KPLH1130, CAS: 906669-07-6, stock 22g, assay 98.4%, MWt: 283.28, Formula: C15H13N3O3, Solubility: DMSO : 135 mg/mL (476.56 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Metabolic Enzyme/Protease, Target: PDHK, Biological_Activity: KPLH1130 is a specific pyruvate dehydrogenase kinase (PDK) inhibitor, blocks macrophage polarization and attenuates proinflammatory responses. KPLH1130 improves glucose tolerance in HFD-fed mice[1].
IC50 & Target: PDK[1]

Name: TAS4464, CAS: 1848959-10-3, stock 14.8g, assay 98.4%, MWt: 506.51, Formula: C21H23FN6O6S, Solubility: 10 mM in DMSO, Clinical_Informat: Phase 2, Pathway: Metabolic Enzyme/Protease, Target: NEDD8-activating Enzyme, Biological_Activity: TAS4464 is a highly potent and selective inhibitor of NEDD8 activating enzyme (NAE), with an IC50 of 0.955 nM[1].
IC50 & Target: IC50：0.955 nM (NAE)[1]
In Vitro: TAS4464 treatment inhibits cullin neddylation and subsequently induces the accumulation of CRL substrates such as CDT1, p27, and phosphorylates IκBα in 47 human cancer cell lines.

Name: SY-1365, CAS: 1816989-16-8, stock 8.2g, assay 98.4%, MWt: 587.12, Formula: C31H35ClN8O2, Solubility: 10 mM in DMSO, Clinical_Informat: Phase 1, Pathway: Cell Cycle/DNA Damage, Target: CDK, Biological_Activity: SY-1365 is a highly selective covalent inhibitor of CDK7. SY-1365 possesses therapeutic potential in both hematological and solid tumors[1].
IC50 & Target: CDK7[1]

Name: STAT3-IN-3, CAS: 2361304-26-7, stock 1.2g, assay 98.3%, MWt: 600.48, Formula: C27H26BrN3O6S, Solubility: DMSO : 5 mg/mL (8.33 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: JAK/STAT Signaling;Stem Cell/Wnt, Target: STAT;STAT, Biological_Activity: STAT3-IN-3 is a potent and selective inhibitor of signal transducer and activator of transcription 3 (STAT3)[1].
IC50 & Target: STAT3[1]

Name: Y-33075 (dihydrochloride), CAS: 173897-44-4, stock 7.3g, assay 98%, MWt: 353.25, Formula: C16H18Cl2N4O, Solubility: DMSO : 100 mg/mL (283.09 mM; Need ultrasonic); H2O : 50 mg/mL (141.54 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: TGF-beta/Smad;Stem Cell/Wnt;Cell Cycle/DNA Damage, Target: ROCK;ROCK;ROCK, Biological_Activity: Y-33075 dihydrochloride is a selective ROCK inhibitor with an IC50 of 3.6 nM.
IC50 & Target: IC50: 3.6 nM (ROCK), 420 nM (PKC), 810 nM (CaMKII)[1]
In Vitro: Y-33075 (Y-39983) is a potent ROCK inhibitor, with an IC50 of 3.6 nM. Y-33075 also inhibits PKC and CaMKII more potently than Y-27632, and the IC50s of Y-27632 and Y-33075 for PKC are 9.0 μM and 0.42 μM, respectively, whereas the IC50s of Y-27632 and Y-33075 for CaMKII are 26 μM and 0.81 μM, respectively. The IC50s of Y-27632 and Y-33075 for PKC is 82 and 117 times those for ROCK, respectively, whereas the IC50s of Y-27632 and Y-33075 for CaMKII is 236 and 225 times those for ROCK, respectively[1]. Y-33075 (Y-39983, 10 μM) extends neurites in the retinal ganglion cells (RGCs) compared with those in RGCs treated without Y-39983[2]. Y-33075 (Y-39983, 1 μM) inhibits the contraction of rabbit ciliary artery segments evoked by histamine in Ca2+-free solutions. Y-33075 (10 μM) shows no effect on the [Ca2+]i increase with the high-potassium (high-K) solution[3].
In Vivo: In rabbits, Y-39983 (≥0.01%) significantly lowers intraocular pressure (IOP) at 2 hours after topical administration. In monkeys, Y-39983 (0.05%)-treated eyes show significant reduction of IOP between 2 and 7 hours after topical administration[1]. Y-39983 (100 μM) increases the regenerating axons of retinal ganglion cells (RGCs) in the eyes of the rats[2].

Name: NP-12, CAS: 1353563-85-5, stock 18.7g, assay 98.7%, MWt: 3261.55, Formula: C142H226N40O48, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Immunology/Inflammation, Target: PD-1/PD-L1, Biological_Activity: NP-12 is a peptide antagonist of the PD-1 signaling pathway, which acts as an immunomodulatory agent for cancer therapy[1].
IC50 & Target: PD-1[1]
In Vitro: NP-12 displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions [1]. 
NP-12 rescues the proliferation in the mouse splenocyte assay system, with average EC50 values of 17 nM and 16.6 nM against rmPD-L1 and rmPD-L2 respectively[1]. 
NP-12 is also able to significantly rescue recombinant human PD-L1 and PD-L2 mediated inhibition of in vitro human PBMC proliferation, with average EC50 values of 63.3 nM and 44.1 nM against PD-L1 and PD-L2 respectively[1].

Name: MD2-TLR4-IN-1, CAS: 2249801-12-3, stock 38.4g, assay 98%, MWt: 421.28, Formula: C22H14Cl2N4O, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Immunology/Inflammation, Target: Toll-like Receptor (TLR), Biological_Activity: MD2-TLR4-IN-1 (compound 22m) is an inhibitor of myeloid differentiation protein 2/toll-like receptor 4 (MD2-TLR4) complex, inhibiting lipopolysaccharides (LPS)-induced expression of tumor necrosis factor alpha (TNF-α) and interleukin-6 (IL-6) in macrophages with IC50 values of 0.89 μM and 0.53 μM, respectively[1].
IC50 & Target: MD2-TLR4[1].

Name: Methylnitronitrosoguanidine MNNG, CAS: 70-25-7, stock 12.7g, assay 98.1%, MWt: 147.09, Formula: C2H5N5O3, Solubility: DMSO : 125 mg/mL (849.82 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Cell Cycle/DNA Damage, Target: DNA Alkylator/Crosslinker, Biological_Activity: Methylnitronitrosoguanidine (MNNG) is an alkylating agent with toxic and mutagenic effects[1].
IC50 & Target: DNA Alkylator/Crosslinker[1]

Name: (R)-Simurosertib (R)-TAK-931, CAS: 1330782-69-8, stock 13.6g, assay 98.6%, MWt: 341.43, Formula: C17H19N5OS, Solubility: DMSO : 75 mg/mL (219.66 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: (R)-Simurosertib ((R)-TAK-931) is the (R)-enantiomer of Simurosertib, Simurosertib (TAK-931) is a selective cycle 7 (CDC7) kinase inhibitor, with an IC50<0.3 nM[1].

Name: LML134, CAS: 1542135-76-1, stock 6.3g, assay 98.6%, MWt: 375.47, Formula: C19H29N5O3, Solubility: DMSO : 12.5 mg/mL (33.29 mM; Need ultrasonic), Clinical_Informat: Phase 2, Pathway: Immunology/Inflammation;GPCR/G Protein;Neuronal Signaling, Target: Histamine Receptor;Histamine Receptor;Histamine Receptor, Biological_Activity: LML134 (compound 18b) is an orally active and high selective Histamine 3 receptor (H3R) inverse agonist with Kis of 0.3 nM and 12 nM for hH3R cAMP and hH3R bdg. LML134 penetrates the brain rapidly, leading to high H3R occupancy, and disengages its target with a fast kinetic profile. LML134 is for the treatment of excessive sleep disorders[1].
IC50 & Target: Ki: 0.3 nM (hH3R cAMP) and 12 nM (hH3R bdg)[1]
In Vivo: LML134 (compound 18b) (oral; 10 mg/kg) indicates rapid oral absorption, with a Tmax of 0.5 hours, t1/2 of 1.54 hours and a fraction absorbed of 44%, as well as a rapid clearance in male Sprague-Dawley rats[1]. 
LML134 (i.v.; 1 mg/kg) has t1/2 of 0.44 hours, CL of 28 mL/min/kg and the low plasma protein binding in male Sprague-Dawley rat (Fu =39.0%)[1].

Name: 6-Thioinosine 6TI;6-Mercaptopurine riboside, CAS: 574-25-4, stock 24.2g, assay 98.2%, MWt: 284.29, Formula: C10H12N4O4S, Solubility: DMSO : 50 mg/mL (175.88 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Cell Cycle/DNA Damage, Target: Nucleoside Antimetabolite/Analog, Biological_Activity: 6-Thioinosine (6TI) is a purine antimetabolite, acts as an anti-adipogenesis agent, downregulates mRNA levels of PPAR γ and C/EBPα, as well as PPAR γ target protein such as LPL, CD36, aP2, and LXRα[1][2].

Name: Chemerin-9 (149-157), CAS: 676367-27-4, stock 19.6g, assay 99%, MWt: 1063.16, Formula: C54H66N10O13, Solubility: H2O, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: Chemerin-9 (149-157), the nonapeptide (149)YFPGQFAFS(157) (chemerin-9), corresponding to the C terminus of processed chemerin, retains most of the activity of the full-size protein, with regard to agonism toward the chemerinR[1].

Name: PACAP-38 (31-38), human, mouse, rat, CAS: 138764-85-9, stock 34.7g, assay 98.9%, MWt: 1062.27, Formula: C47H83N17O11, Solubility: H2O, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: PACAP-38 (31-38), human, mouse, rat demonstrates potent, efficacious, and sustained stimulatory effects on sympathetic neuronal NPY and catecholamine production[1]. PACAP is a potent activator of cAMP formation[2].

Name: TNF-α (31-45), human, CAS: 144796-71-4, stock 16.9g, assay 98.7%, MWt: 1667.87, Formula: C69H122N26O22, Solubility: H2O, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: TNF-α (31-45), human is a peptide of tumor necrosis factor-α.

Name: Deltasonamide 2 (TFA), CAS: 2235358-74-2, stock 24.4g, assay 98.3%, MWt: 761.27, Formula: C32H40ClF3N6O6S2, Solubility: DMSO : 125 mg/mL (164.20 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Metabolic Enzyme/Protease, Target: Phosphodiesterase (PDE), Biological_Activity: Deltasonamide 2 TFA is competitive, high affinity PDEδ inhibitor with a Kd of ~385 pM[1].
IC50 & Target: Kd: ~385 pM (PDEδ)[1]

Name: Y-33075 Y 39983, CAS: 199433-58-4, stock 21.5g, assay 99%, MWt: 280.32, Formula: C16H16N4O, Solubility: H2O : < 0.1 mg/mL (insoluble); DMSO : 50 mg/mL (178.37 mM; Need ultrasonic and warming), Clinical_Informat: No Development Reported, Pathway: TGF-beta/Smad;Stem Cell/Wnt;Cell Cycle/DNA Damage, Target: ROCK;ROCK;ROCK, Biological_Activity: Y-33075 is a selective ROCK inhibitor derived from Y-27632, and is more potent than Y-27632, with an IC50 of 3.6 nM.
IC50 & Target: IC50: 3.6 nM (ROCK), 420 nM (PKC), 810 nM (CaMKII)[1]
In Vitro: Y-33075 (Y-39983) is a potent ROCK inhibitor, with an IC50 of 3.6 nM. Y-33075 also inhibits PKC and CaMKII more potently than Y-27632, and the IC50s of Y-27632 and Y-33075 for PKC are 9.0 μM and 0.42 μM, respectively, whereas the IC50s of Y-27632 and Y-33075 for CaMKII are 26 μM and 0.81 μM, respectively. The IC50s of Y-27632 and Y-33075 for PKC is 82 and 117 times those for ROCK, respectively, whereas the IC50s of Y-27632 and Y-33075 for CaMKII is 236 and 225 times those for ROCK, respectively[1]. Y-33075 (Y-39983, 10 μM) extends neurites in the retinal ganglion cells (RGCs) compared with those in RGCs treated without Y-39983[2]. Y-33075 (Y-39983, 1 μM) inhibits the contraction of rabbit ciliary artery segments evoked by histamine in Ca2+-free solutions. Y-33075 (10 μM) shows no effect on the [Ca2+]i increase with the high-potassium (high-K) solution[3].
In Vivo: In rabbits, Y-39983 (≥0.01%) significantly lowers intraocular pressure (IOP) at 2 hours after topical administration. In monkeys, Y-39983 (0.05%)-treated eyes show significant reduction of IOP between 2 and 7 hours after topical administration[1]. Y-39983 (100 μM) increases the regenerating axons of retinal ganglion cells (RGCs) in the eyes of the rats[2].

Name: ORM-10103, CAS: 488847-28-5, stock 38.3g, assay 98.6%, MWt: 348.35, Formula: C20H16N2O4, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Membrane Transporter/Ion Channel, Target: Na+/Ca2+ Exchanger, Biological_Activity: ORM-10103 is a specific inhibitor of the Na+/Ca2+ exchanger (NCX), which decreases the NCX current with estimated IC50s of 55 and 67 nM at -80 and at 20 mV, respectively[1][2].
IC50 & Target: IC50: 55 (NCX -80 mV ), 67 nM (NCX 20 mV)[2]

Name: TBK1/IKKε-IN-5, CAS: 1893397-65-3, stock 17.7g, assay 98.7%, MWt: 513.59, Formula: C28H31N7O3, Solubility: DMSO : 7.81 mg/mL (15.21 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: NF-κB, Target: IKK, Biological_Activity: TBK1/IKKε-IN-5 (compound 1) is a dual TBK1 and IKKε inhibitor, with IC50 values of 1 nM and 5.6 nM for TBK1 and IKKε, respectively[1].
IC50 & Target: IC50: 1 nM (TBK1), 5.6 nM (IKKε)[1].

Name: α2β1 Integrin Ligand Peptide, CAS: 134580-64-6, stock 19.7g, assay 98.5%, MWt: 390.35, Formula: C14H22N4O9, Solubility: H2O, Clinical_Informat: No Development Reported, Pathway: Cytoskeleton, Target: Integrin, Biological_Activity: α2β1 Integrin Ligand Peptide interacts with the α2β1 integrin receptor on the cell membrane and mediates extracellular signals into cells. It is a potential antagonist of collagen receptors[1].

Name: Cardiotoxin Analog (CTX) IV (6-12), CAS: 115722-23-1, stock 13.4g, assay 98.9%, MWt: 899.13, Formula: C48H70N10O7, Solubility: H2O, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: Cardiotoxin Analog (CTX) IV (6-12) is a part peptide of Cardiotoxin Analog (CTX) IV. Cardiotoxin analogues IV isolated from the venom of Taiwan Cobra. CTX IV is an unique snake venom cardiotoxin[1].

Name: Todralazine (hydrochloride) Ecarazine (hydrochloride), CAS: 3778-76-5, stock 21.7g, assay 98.7%, MWt: 268.70, Formula: C11H13ClN4O2, Solubility: DMSO : 125 mg/mL (465.20 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: GPCR/G Protein;Neuronal Signaling, Target: Adrenergic Receptor;Adrenergic Receptor, Biological_Activity: Todralazine hydrochloride (Ecarazine hydrochloride) is an anti-hypertensive agent, acts as a β2AR blocker, with antioxidant and free radical scavenging activity[1].
IC50 & Target: β2AR[1]

Name: Oleanolic acid hemiphthalate disodium salt, CAS: 168770-31-8, stock 4.9g, assay 98.4%, MWt: 648.78, Formula: C38H50Na2O6, Solubility: DMSO : 20.83 mg/mL (32.11 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: Oleanolic acid hemiphthalate disodium salt is an anti-inflammatory agent[1].

Name: Stanolone benzoate Androstanolone benzoate;Dihydrotestosterone benzoate;DHTB, CAS: 1057-07-4, stock 11.6g, assay 98.4%, MWt: 394.55, Formula: C26H34O3, Solubility: Ethanol : 2.5 mg/mL (6.34 mM; Need ultrasonic); DMSO : 5 mg/mL (12.67 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Others, Target: Androgen Receptor, Biological_Activity: Stanolone benzoate (Androstanolone benzoate) is a synthetic androgen and anabolic steroid[1].

Name: D-Desthiobiotin, CAS: 533-48-2, stock 24.5g, assay 98.2%, MWt: 214.26, Formula: C10H18N2O3, Solubility: DMSO : 62.5 mg/mL (291.70 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: D-Desthiobiotin is a biotin derivative used in affinity chromatography and protein chromatography, also can be used for protein and cell labeling, detection and isolation[1].

Name: Nicotinamide riboside (chloride), CAS: 23111-00-4, stock 14.2g, assay 98.6%, MWt: 290.70, Formula: C11H15ClN2O5, Solubility: DMSO : 50 mg/mL (172.00 mM; Need ultrasonic); H2O : 125 mg/mL (430.00 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Epigenetics;Cell Cycle/DNA Damage, Target: Sirtuin;Sirtuin, Biological_Activity: Nicotinamide riboside chloride is a crystal form of Nicotinamide riboside (NR) chloride. Nicotinamide riboside chloride increases NAD[+] levels and activates SIRT1 and SIRT3, culminating in enhanced oxidative metabolism and protection against high fat diet-induced metabolic abnormalities. Nicotinamide riboside chloride is used in dietary supplements[1].
IC50 & Target: NAD[+], SIRT1 and SIRT3[1]
In Vitro: Nicotinamide riboside chloride (0.5 nM; 24 hours) reduces the acetylation status of Ndufa9 and SOD2[1].
In Vivo: Chronic Nicotinamide riboside chloride (p.o.; 400 mg/kg/day; for 16 weeks) supplementation increases plasma and intracellular NAD[+] content in a tissue-specific manner[1].

Name: Bromodomain inhibitor-8, CAS: 1300031-70-2, stock 23.5g, assay 98.4%, MWt: 448.94, Formula: C26H25ClN2O3, Solubility: DMSO : 100 mg/mL (222.75 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Epigenetics, Target: Epigenetic Reader Domain, Biological_Activity: Bromodomain inhibitor-8 (Intermediate 21) is a BET bromodomain inhibitor for treating autoimmune and inflammatory diseases[1].

Name: c-Kit-IN-3, CAS: 2363169-01-9, stock 32.2g, assay 99%, MWt: 516.90, Formula: C26H20ClF3N2O4, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Protein Tyrosine Kinase/RTK, Target: c-Kit, Biological_Activity: c-Kit-IN-3 (Compound 18) is a potent and selective c-KIT kinase inhibitor with an IC50s of 4 nM, 8 nM for c-KIT wt and c-KIT T670I, respectively. c-Kit-IN-3 displays great potencies against most of the gain-offunction mutations in the juxtamembrane domain, drugresistant mutations in the ATP binding pocket, and activation loops[1].
IC50 & Target: IC50: 4 nM (c-KIT w) and 8 nM (c-KIT T670I)[1]
In Vitro: c-Kit-IN-3 (Compound 18; 0.1-10 μM; 6 days; primary GIST patient cells) exhibits dose-dependent antiproliferative effects[1].
c-Kit-IN-3 (0.01-1 μM; 24 hours; GIST-T1, GIST-T1-T670I, and GIST-5R cells) treatment induces dose-dependent cell apoptotic death (by examining the cleaved PARP and cleaved caspase 3)[1]. 
c-Kit-IN-3 (0.01-1 μM; 24 hours; GIST-T1, GIST-T1-T670I, and GIST-5R cells) treatment arrests the cell cycle into the G0/G1 phase in all of these three cell lines[1]. 
c-Kit-IN-3 (0-1 μM; 24 hours) blocks the autophosphorylation of c-KIT pY703, pY719, and pY823 in GIST-T1, GIST-T1-T670I, and GIST-5R, respectively, cells at a concentration of 30 nM and inhibits the downstream signaling mediators pAKT (T308/S473), pS6 (S235/236), and pERK (T202/204)[1]. 
c-Kit-IN-3 potently inhibits the activity of CSF1R (IC50: 18 nM), PDGFRα (IC50: 25 nM), RET (IC50: 34 nM), and it relatively less potently inhibits DDR1 (IC50: 135 nM), FLT4 (IC50: 121 nM), and PDGFRβ (IC50: 97 nM)[1]. 
c-Kit-IN-3 (0.006 μM-1.37 μM) potently inhibits the growth of c-KIT-dependent GIST cancer cells, such as GIST-T1 (IC50: 0.006 μM); GIST-882 (IC50: 0.013 μM); GIST-T1-T670I (IC50
: 0.011 μM); GIST-5R (IC50: 0.073 μM); GIST-48B (IC50: 1.37 μM), respectively[1].
In Vivo: c-Kit-IN-3 (Compound 18; oral gavage; 20-100 mg/kg/day; for 11 days; female BALB/C-nu mice) treatment dose dependently inhibits the tumor progression[1]. 
c-Kit-IN-3 (1 mg/kg (iv for mice, rats, dog); 10 mg/kg (p.o. for mice, rats ) and 5 mg/kg (p.o. for dog)) has T1/2 of 4.5 h, 6.4 h, 19.4 h for mice, rats and dogs, respectively. And it possesses acceptable bioavailability in mice (F = 43%), rats (F = 50%), and dogs (F = 81%)[1].

Name: Nucleozin, CAS: 341001-38-5, stock 17.6g, assay 98.9%, MWt: 426.85, Formula: C21H19ClN4O4, Solubility: DMSO : 28.66 mg/mL (67.14 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Anti-infection, Target: Influenza Virus, Biological_Activity: Nucleozin targets influenza A nucleoprotein (NP), a multifunctional, RNA-binding protein necessary for virus replication.
IC50 Value:
Target: Influenza Virus NP
Nucleozin targets influenza A nucleoprotein, a multifunctional, RNA-binding protein necessary for virus replication. It induces the formation of nucleoptotein aggregates and inhibits its accumulation, interfering with viral replication. EC50 is in the nM range. Nucleozin is effective in H1N1, H3N2, and H5N1 flu virus strains.

Name: ERK5-IN-2, CAS: 1888305-96-1, stock 17g, assay 99%, MWt: 388.19, Formula: C17H11BrFN3O2, Solubility: DMSO : 250 mg/mL (644.01 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Stem Cell/Wnt;MAPK/ERK Pathway, Target: ERK;ERK, Biological_Activity: ERK5-IN-2 is an orally active, sub-micromolar, selective ERK5 inhibitor with IC50s of 0.82 μM, 3 μM for ERK5 and ERK5 MEF2D, respectively. ERK5-IN-2 does not interact with the BRD4 bromodomain. ERK5-IN-2 suppresses both tumor xenograft growth and basic fibroblast growth factor (bFGF) driven Matrigel plug angiogenesis[1].
IC50 & Target: IC50: 0.82 μM (ERK5) and 3 μM (ERK5 MEF2D)[1]
In Vivo: ERK5-IN-2 (compound 46) (p.o.; 100 mg/kg; CD1 mice for 7 days and CD1 nude (nu/nu) mice for 10 days) has an anti-angiogenic effect and low concentrations of haemoglobin[1]. 
ERK5-IN-2 (i.v. or p.o.; 10 mg/kg for 0.083-24 hours) exhibits low intrinsic clearance and has high flux and a low efflux ratio (ER) in a caco-2 cell permeability assay in both human and mouse[1].

Name: FGTI-2734, CAS: 1247018-19-4, stock 36g, assay 98%, MWt: 510.63, Formula: C26H31FN6O2S, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Metabolic Enzyme/Protease, Target: Farnesyl Transferase, Biological_Activity: FGTI-2734 is a RAS C-terminal mimetic dual farnesyl transferase (FT) and geranylgeranyl transferase-1 (GGT) inhibitor with IC50s of 250 nM and 520 nM for FT and GGT, respectively. FGTI-2734 can prevent membrane localization of KRAS, hence solving KRAS resistance problem and thwarting mutant KRAS patient-derived pancreatic tumors[1].
IC50 & Target: IC50: 250 nM (FT) and 520 nM (GGT)[1]
In Vitro: FGTI-2734 (1-30 μM; 72 hours) induces CASPASE-3 and PARP cleavage in MiaPaCa2, L3.6pl and Calu6 cells[1]. 
FGTI-2734 (3-30 μM; 72 hours) inhibits both protein prenylation of HDJ2, RAP1A, KRAS and NRAS. FGTI-2734 inhibits KRAS membrane localization in RAS-transformed murine NIH3T3 cells and in mutant KRAS human cancer cells[1]. 
In Vivo: FGTI-2734 (intraperitoneally; 100 mg/kg/daily for 18 to 25 days) only inhibits tumor growth in mutant KRAS-dependent tumors but not in mutant KRAS-independent tumors[1].

Name: Dimethyl trisulfide, CAS: 3658-80-8, stock 11.9g, assay 99%, MWt: 126.26, Formula: C2H6S3, Solubility: H2O : 1 mg/mL (7.92 mM; Need ultrasonic); DMSO : 100 mg/mL (792.02 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Metabolic Enzyme/Protease, Target: Endogenous Metabolite, Biological_Activity: Dimethyl trisulfide is an organic chemical compound and the simplest organic trisulfide found in garlic, onion, broccoli, and similar plants. Dimethyl trisulfide is a cyanide antidote[1].

Name: Allyl methyl sulfide, CAS: 10152-76-8, stock 11.5g, assay 98.4%, MWt: 88.17, Formula: C4H8S, Solubility: DMSO : ≥ 250 mg/mL (2835.43 mM), Clinical_Informat: No Development Reported, Pathway: Anti-infection, Target: Bacterial, Biological_Activity: Allyl methyl sulfide is a bioactive organosulfur compound found in garlic. Allyl methyl sulfide exhibits antibacterial, antioxidant and anticancer properties[1].

Name: alpha-D-glucose, CAS: 492-62-6, stock 25.1g, assay 98.7%, MWt: 180.16, Formula: C6H12O6, Solubility: , Clinical_Informat: No Development Reported, Pathway: Metabolic Enzyme/Protease, Target: Endogenous Metabolite, Biological_Activity:

Name: 16-Dehydroprogesterone, CAS: 1096-38-4, stock 14.4g, assay 98.4%, MWt: 312.45, Formula: C21H28O2, Solubility: DMSO : 25 mg/mL (80.01 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Metabolic Enzyme/Protease, Target: Endogenous Metabolite, Biological_Activity: 16-Dehydroprogesterone is a steroidal progestin.

Name: N-Carbamoyl-DL-aspartic acid Ureidosuccinic Acid, CAS: 923-37-5, stock 32.6g, assay 98.2%, MWt: 176.13, Formula: C5H8N2O5, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Metabolic Enzyme/Protease, Target: Endogenous Metabolite, Biological_Activity: N-Carbamoyl-DL-aspartic acid (Ureidosuccinic acid) is a precursor of nucleic acid pyrimidines[1].

Name: GSK3368715 EPZ019997, CAS: 1629013-22-4, stock 13.9g, assay 98.5%, MWt: 366.54, Formula: C20H38N4O2, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Epigenetics, Target: Histone Methyltransferase, Biological_Activity: GSK3368715 (EPZ019997) is an orally active, reversible, and S-adenosyl-L-methionine (SAM) uncompetitive type I protein arginine methyltransferases (PRMTs) inhibitor (IC50=3.1 nM (PRMT1), 48 nM (PRMT3), 1148 nM (PRMT4), 5.7 nM (PRMT6), 1.7 nM (PRMT8)). GSK3368715 (EPZ019997) produces a shift in arginine methylation states, alters exon usage, and has strong anti-cancer activity[1].
IC50 & Target: IC50: 3.1 nM (PRMT1), 48 nM (PRMT3), 1148 nM (PRMT4), 5.7 nM (PRMT6), 1.7 nM (PRMT8)[1] 
Kiapp: 1.5 nM (PRMT1), 81 nM (PRMT3), 19 nM (PRMT4), 2.4 nM (PRMT6), 2 nM (PRMT8)[1]
In Vitro: GSK3368715 (EPZ019997) shows 50% or more growth inhibition relative to DMSO-treated cells in the majority of 249 cancer cell lines, representing 12 tumor types[1].
In Vivo: GSK3368715 (EPZ019997) significantly effects on the growth of BxPC3 xenografts at all doses tested, reducing tumor growth by 78% and 97% in the 150- and 300-mg/kg dose groups, respectively[1].

Name: JNJ-37822681 (dihydrochloride), CAS: 2108806-02-4, stock 32g, assay 98.7%, MWt: 445.26, Formula: C17H19Cl2F5N4, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: GPCR/G Protein;Neuronal Signaling, Target: Dopamine Receptor;Dopamine Receptor, Biological_Activity: JNJ-37822681 dihydrochloride is a potent, specific, centrally active, fast-dissociating dopamine D2 receptor antagonist with a moderate binding affinity for the dopamine D2L receptor (Ki =158 nM), which has potential for the treatment of schizophrenia and bipolar disorder[1].
IC50 & Target: Ki: 158 nM (dopamine D(2))[1]

Name: Fumonisin B2, CAS: 116355-84-1, stock 39.6g, assay 98%, MWt: 705.83, Formula: C34H59NO14, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Metabolic Enzyme/Protease, Target: Acyltransferase, Biological_Activity: Fumonisin B2, a mycotoxin produced by Fusarium moniliforme in various grains, is a potent inhibitor of sphingosine N-acyltransferase (ceramide synthase) and disrupts de novo sphingolipid biosynthesis[1][2].
IC50 & Target: Sphingosine N-acyltransferase[2]

Name: E3 ligase Ligand 8, CAS: 1225383-33-4, stock 9.2g, assay 98.1%, MWt: 530.61, Formula: C31H34N2O6, Solubility: DMSO : 100 mg/mL (188.46 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: PROTAC, Target: Ligand for E3 Ligase, Biological_Activity: E3 ligase Ligand 8 is a ligand for E3 ubiquitin ligase. E3 ligase Ligand 8 can be connected to the ligand for protein by a linker to form PROTACs. PROTACs are inducers of ubiquitination-mediated degradation of cancer-promoting proteins[1].

Name: BIIL-260 (hydrochloride), CAS: 192581-24-1, stock 38g, assay 98.1%, MWt: 503.03, Formula: C30H31ClN2O3, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: GPCR/G Protein, Target: Leukotriene Receptor, Biological_Activity: BIIL-260 hydrochloride is a potent and long-acting orally active leukotriene B(4) receptor LTB4 antagonist, with anti-inflammatory activity. BIIL-260 hydrochloride interacts with the LTB4 receptor in a saturable, reversible, and competitive manner, has high affinity to the LTB4 receptor on isolated human neutrophil cell membranes with Ki values of 1.7 nM[1].
IC50 & Target: Ki: 1.7 nM (LTB4 receptor)[1]
In Vitro: BIIL-260 hydrochloride potently inhibits LTB4-induced intracellular Ca2+ release in human neutrophils with IC50 value of 0.82 nM

Name: KX-01-191, CAS: 2211903-84-1, stock 7.6g, assay 98.6%, MWt: 552.34, Formula: C28H39N3OSn, Solubility: DMSO : ≥ 100 mg/mL (181.05 mM), Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: KX-01-191 (compound 5c′) is a tin-precursor[1].

Name: Dapagliflozin impurity, CAS: 960404-86-8, stock 18.4g, assay 98.7%, MWt: 424.87, Formula: C21H25ClO7, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: Dapagliflozin impurity is an enantiomer of Dapagliflozin which is a sodium-glucose transporter 2 inhibitor[1].

Name: JH-RE-06, CAS: 1361227-90-8, stock 26.4g, assay 98.2%, MWt: 468.72, Formula: C20H16Cl3N3O4, Solubility: DMSO : 5 mg/mL (10.67 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Cell Cycle/DNA Damage, Target: DNA/RNA Synthesis, Biological_Activity: JH-RE-06, a potent REV1-REV7 interface inhibitor (IC50=0.78 μM; Kd=0.42 μM), targets REV1 that interacts with the REV7 subunit of POLζ. JH-RE-06 disrupts mutagenic translesion synthesis (TLS) by preventing recruitment of mutagenic POLζ. JH-RE-06 improves chemotherapy[1][2].
IC50 & Target: IC50: 0.78 μM (REV1-REV7)[1] 
Kd: 0.42 μM (REV1-REV7)[1]
In Vitro: JH-RE-06 unexpectedly induces dimerization of the REV1 CTD at its REV7-binding surface and blocks the REV1-REV7 interaction[1].
In Vivo: JH-RE-06 inhibits mutagenic TLS and enhances cisplatin-induced toxicity in cultured human and mouse cell lines[1]. 
Co-administration of JH-RE-06 with cisplatin suppresses the growth of xenograft human melanomas in mice[1].

Name: Cortistatin-14, CAS: 186901-48-4, stock 31.5g, assay 98.3%, MWt: 1720.03, Formula: C81H114N20O18S2, Solubility: H2O, Clinical_Informat: No Development Reported, Pathway: GPCR/G Protein;Neuronal Signaling, Target: Somatostatin Receptor;Somatostatin Receptor, Biological_Activity: Cortistatin-14, a neuropeptide have structural similarity to somatostatin-14, binds and exerts its function via the somatostatin receptors (sst1-sst5). Cortistatin-14 shows anticonvulsive, neuroprotective effect and remarkable anti-inflammatory properties[1][2][3][4].

Name: (Rac)-PT2399, CAS: 1672662-07-5, stock 15.4g, assay 98.7%, MWt: 419.32, Formula: C17H10F5NO4S, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Metabolic Enzyme/Protease, Target: HIF/HIF Prolyl-Hydroxylase, Biological_Activity: (Rac)-PT2399 (Compound 10e), the racemate of PT2399, acts as a potent and specific hypoxia-inducible factor 2a (HIF-2α) inhibitor with an IC50 of 0.01 μM[1].
IC50 & Target: IC50: 0.01 μM (HIF-2α)[1]

Name: Dasatinib BMS-354825, CAS: 302962-49-8, stock 19.7g, assay 98%, MWt: 488.01, Formula: C22H26ClN7O2S, Solubility: DMSO : 35.35 mg/mL (72.44 mM; Need ultrasonic and warming), Clinical_Informat: Launched, Pathway: Protein Tyrosine Kinase/RTK;Apoptosis;Protein Tyrosine Kinase/RTK;Autophagy, Target: Src;Apoptosis;Bcr-Abl;Autophagy, Biological_Activity: Dasatinib (BMS-354825) is a dual Bcr-Abl and Src family tyrosine kinase inhibitor with IC50s of 0.6, 0.8, 79 and 37 nM for Abl, Src, c-Kit and c-KitD816V, respectively.
IC50 & Target: IC50: 0.6 nM/0.8 nM (AblWT/Src)[1] 
IC50: 79 nM/37 nM (c-KitWT/c-KitD816V)[2]
In Vitro: Dasatinib potently inhibits wild-type Abl kinase and all mutants except T315I over a narrow range (IC50≤1.7 nM). Dasatinib (IC50: 0.8 nM) displays 325-fold greater potency compared with STI571 against cells expressing wild-type Bcr-Abl in Ba/F3 cells[1].
In Vivo: Daily treatment with Dasatinib (50 mg/kg) is initiated on day 10. Using this approach, a significant inhibition of BCPAP orthotopic tumor growth is observed 6 days after treatment (day 16, P=0.014), which is sustained through days 23 and 29 (P=0.0003), compared with vehicle-treated mice[3]. Metabolism studies of Dasatinib (50 mg/kg) in rat suggested that Dasatinib is the major circulating component, whereas multiple metabolites contributed to the remaining 40-60% of the sample radioactivity at 4 h post dose[4].

Name: Reactive Blue 4, CAS: 13324-20-4, stock 17g, assay 98.8%, MWt: 637.43, Formula: C23H14Cl2N6O8S2, Solubility: DMSO : 83.33 mg/mL (130.73 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: Reactive Blue 4 is an anthraquinone dye, as a single colorimetric chemosensor for sequential determination of multiple analytes with different optical responses in aqueous media. Reactive Blue 4 is phytotoxic, cytotoxic and genotoxic. Reactive Blue 4 [1][2].

Name: BI-3406, CAS: 2230836-55-0, stock 31.8g, assay 98.8%, MWt: 462.46, Formula: C23H25F3N4O3, Solubility: Ethanol : 100 mg/mL (216.23 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: BI-3406 (compound I-6) is a Son of Sevenless 1 (SOS1) inhibitor with an IC50 of 6 nM[1]. BI-3406 has anticancer activity.
IC50 & Target: IC50: 6 nM (SOS1)[1]

Name: NH2-PEG3-C1-Boc PROTAC Linker 5, CAS: 189808-70-6, stock 16g, assay 98.3%, MWt: 263.33, Formula: C12H25NO5, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: PROTAC, Target: PROTAC Linker, Biological_Activity: NH2-PEG3-C1-Boc (PROTAC Linker 5) is a PROTAC linker, which refers to the PEG composition. NH2-PEG3-C1-Boc can be used in the synthesis of a series of PROTACs. PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins[1].

Name: TAM-IN-2, CAS: 2135642-56-5, stock 33g, assay 98.4%, MWt: 583.59, Formula: C31H27F2N7O3, Solubility: DMSO : 5 mg/mL (8.57 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Protein Tyrosine Kinase/RTK, Target: TAM Receptor, Biological_Activity: TAM-IN-2 is a TAM inhibitor extracted from patent US 20170275290 A1, pyrrolotriazine compound 0904[1].

Name: cIAP1 ligand 1 E3 ligase Ligand 12, CAS: 2095244-42-9, stock 30.2g, assay 98.6%, MWt: 598.75, Formula: C31H42N4O6S, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: PROTAC, Target: Ligand for E3 Ligase, Biological_Activity: cIAP1 ligand 1 is the LCL161 derivative based IAP ligand. cIAP1 ligand 1 can be connected to the ABL ligand for protein by a linker to form SNIPER.

Name: Tigloylgomisin H, CAS: 66069-55-4, stock 38.7g, assay 98.7%, MWt: 500.58, Formula: C28H36O8, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: Tigloylgomisin H is a lignan isolated from the fruits of S. chinensis, can induce quinone reductase (QR) activity in Hepa1c1c7 mouse hepatocarcinoma cells. Tigloylgomisin H functions as a monofunctional inducer that specifically upregulates phase II detoxification enzyme NQO1 through the NF-E2-related factor 2 (Nrf2)-ARE pathway, thus represents a potential liver cancer prevention agent[1].

Name: Polygalaxanthone XI, CAS: 857859-82-6, stock 7.9g, assay 98.7%, MWt: 568.48, Formula: C25H28O15, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: Polygalaxanthone XI, a xanthone glycoside isolated from the cortexes of Polygala tenuifolia, can be used in the study of expectorant, sedative, and tranquilizing agent[1].

Name: Sigma-1 receptor antagonist 2, CAS: 1639220-15-7, stock 21.5g, assay 98.8%, MWt: 375.89, Formula: C20H26ClN3O2, Solubility: DMSO : 86.67 mg/mL (230.57 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Neuronal Signaling;GPCR/G Protein, Target: Sigma Receptor;Sigma Receptor, Biological_Activity: Sigma-1 receptor antagonist 2 is a potent and selective sigma 1 receptor (σ1 R) antagonist with Kis of 3.88 and 1288 nM for σ1 and σ2 receptor, respectively[1].
IC50 & Target: Ki: 3.88 nM (σ1 receptor), 1288 nM (σ2 receptor)[1]

Name: Sigma-1 receptor antagonist 3, CAS: 1639220-17-9, stock 23g, assay 98.8%, MWt: 363.86, Formula: C19H23ClFN3O, Solubility: DMSO : 12.5 mg/mL (34.35 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Membrane Transporter/Ion Channel;Neuronal Signaling;GPCR/G Protein, Target: Potassium Channel;Sigma Receptor;Sigma Receptor, Biological_Activity: Sigma-1 receptor antagonist 3 (compound135) is a potent and selective Sigma-1 (σ1) receptor antagonist with a Ki of 1.14 nM. Sigma-1 receptor antagonist 3 inhibits Human Ether-a-go-go-Related Gene (hERG) with an IC50 of 1.54 μM. Sigma-1 receptor antagonist 3 is for treating neuropathic pain[1].
IC50 & Target: IC50: 1.54μM (hERG)[1]. 
Ki : 1.14 nM (Sigma-1 receptor); 1239 nM (Sigma-2 receptor) [1]

Name: PF-06882961, CAS: 2230198-02-2, stock 19.5g, assay 98.3%, MWt: 555.60, Formula: C31H30FN5O4, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: GPCR/G Protein, Target: Glucagon Receptor, Biological_Activity: PF-06882961 is a potent, orally bioavailable agonist of the glucagon-like peptide-1 receptor (GLP-1R)[1][2].
IC50 & Target: GLP-1R[1][2]
In Vivo: PF-06882961 (3-240 mg per day) shows mild to moderate damage to the heart, moderate to severe effects on the thymus gland (which helps with managing infection), mild to moderate stomach ulcers at the highest dose level given in the rat[3]. 
PF-06882961 (3-240 mg per day) results one death in an earlier 2-week monkey study at the highest PF-06882961 dose given in that study. No deaths are seen in the 6-week monkey study or any other monkey studies at any of the doses given[3].

Name: Sigma-1 receptor antagonist 1, CAS: 1639220-19-1, stock 17.1g, assay 98.4%, MWt: 380.31, Formula: C19H23Cl2N3O, Solubility: DMSO : 6.25 mg/mL (16.43 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Neuronal Signaling;GPCR/G Protein, Target: Sigma Receptor;Sigma Receptor, Biological_Activity: Sigma‑1 receptor antagonist 1 (compound 137) is a potent and selective sigma-1 receptor (σ1R) antagonist, with a high binding affinity to σ1R receptor (Ki = 1.06 nM). Sigma‑1 receptor antagonist 1 exhibits antineuropathic pain activity and acts as a promising agent for the treatment of neuropathic pain[1].
IC50 & Target: Ki: 1.06 nM (σ1R)[1]
In Vitro: Sigma‑1 receptor antagonist 1 exhibits a high binding affinity to σ1R receptor (Ki = 1.06 nM) and good σ-1/2 selectivity (1344-fold)[1]. 
In Vivo: Sigma‑1 receptor antagonist 1 exerts dose-dependent antinociceptive effects in mice formalin model and rats CCI models of neuropathic pain[1].

Name: Ludaconitine, CAS: 82144-72-7, stock 14.8g, assay 98.1%, MWt: 587.70, Formula: C32H45NO9, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Anti-infection, Target: Parasite, Biological_Activity: Ludaconitine, isolated from Aconitum spicatum (Bruhl) Stapf, exhibits antileishmanial activity with an IC50 of 36.10 μg/mL[1].

Name: Isoagarotetrol, CAS: 104060-61-9, stock 26.2g, assay 98.9%, MWt: 318.32, Formula: C17H18O6, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: Isoagarotetrol is a natural product isolated from agalwood[1].

Name: 5,7,4'-Trimethoxyflavone, CAS: 5631-70-9, stock 34.3g, assay 98.6%, MWt: 312.32, Formula: C18H16O5, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Apoptosis;Epigenetics;Cell Cycle/DNA Damage;Apoptosis, Target: Apoptosis;PARP;PARP;Caspase, Biological_Activity: 5,7,4'-Trimethoxyflavone is isolated from Kaempferia parviflora (KP) that is a famous medicinal plant from Thailand. 5,7,4'-Trimethoxyflavone induces apoptosis, as evidenced by increments of sub-G1 phase, DNA fragmentation, annexin-V/PI staining, the Bax/Bcl-xL ratio, proteolytic activation of caspase-3, and degradation of poly (ADP-ribose) polymerase (PARP) protein.5,7,4'-Trimethoxyflavone is significantly effective at inhibiting proliferation of SNU-16 human gastric cancer cells in a concentration dependent manner[1].
IC50 & Target: Apoptosis,Caspase,PARP[1]

Name: Iristectorin B, CAS: 94396-09-5, stock 29.1g, assay 98.9%, MWt: 492.43, Formula: C23H24O12, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: Iristectorin B is an isoflavone from Iris tectorum, has anti-cancer activities in breast cancer[1].

Name: Iristectorin A, CAS: 37744-61-9, stock 32.9g, assay 98.5%, MWt: 492.43, Formula: C23H24O12, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: Iristectorin A, a natural product from Iris tectorum, has anti-cancer activities in breast cancer[1].

Name: 2-O-α-D-Glucopyranosyl-L-ascorbic Acid, CAS: 129499-78-1, stock 15.3g, assay 98.3%, MWt: 338.26, Formula: C12H18O11, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: 2-O-α-D-Glucopyranosyl-L-ascorbic Acid is a glucoside derivative of ascorbic acid, shows anti-cancer activity after enzymatic hydrolysis to ascorbic acid[1].

Name: Triglochinic acid, CAS: 31795-12-7, stock 23.5g, assay 98.5%, MWt: 188.13, Formula: C7H8O6, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: Triglochinic acid is a monomeric compound isolated from tubers of Pinellia pedatisecta Schott[1].

Name: Hydroxy-γ-sanshool, CAS: 78886-66-5, stock 14.7g, assay 98.4%, MWt: 289.41, Formula: C18H27NO2, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: Hydroxy-γ-sanshool is an alkylamide exists in Zanthoxylum bungeanum oil and Zanthoxylum schinifolium oil[1].

Name: Hydroxy-β-sanshool, CAS: 97465-69-5, stock 19.3g, assay 98.3%, MWt: 263.38, Formula: C16H25NO2, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: Hydroxy-β-sanshool is an alkylamide exists in Zanthoxylum bungeanum oil and Zanthoxylum schinifolium oil[1].

Name: Hydroxy-α-sanshool, CAS: 83883-10-7, stock 4.5g, assay 98.8%, MWt: 263.38, Formula: C16H25NO2, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Membrane Transporter/Ion Channel;Neuronal Signaling, Target: TRP Channel;TRP Channel, Biological_Activity: Hydroxy-α-sanshool is an alkylamide isolated from pepper, acts as a TRPA1 covalent and TRPV1 non-covalent agonist, with EC50s of 69 and 1.1 µM, respectively[1].
IC50 & Target: EC50: 69 µM (TRPA1), 1.1 µM (TRPV1)[1]

Name: GSK3368715 (dihydrochloride) EPZ019997 (dihydrochloride), CAS: 1628925-77-8, stock 6.1g, assay 98.5%, MWt: 439.46, Formula: C20H40Cl2N4O2, Solubility: DMSO : 250 mg/mL (568.88 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Epigenetics, Target: Histone Methyltransferase, Biological_Activity: GSK3368715 dihydrochloride (EPZ019997 dihydrochloride) is an orally active, reversible, and S-adenosyl-L-methionine (SAM) uncompetitive type I protein arginine methyltransferases (PRMTs) inhibitor (IC50=3.1 nM (PRMT1), 48 nM (PRMT3), 1148 nM (PRMT4), 5.7 nM (PRMT6), 1.7 nM (PRMT8)). GSK3368715 dihydrochloride (EPZ019997 dihydrochloride) produces a shift in arginine methylation states, alters exon usage, and has strong anti-cancer activity[1].
IC50 & Target: IC50: 3.1 nM (PRMT1), 48 nM (PRMT3), 1148 nM (PRMT4), 5.7 nM (PRMT6), 1.7 nM (PRMT8)[1] 
Kiapp: 1.5 nM (PRMT1), 81 nM (PRMT3), 19 nM (PRMT4), 2.4 nM (PRMT6), 2 nM (PRMT8)[1]
In Vitro: GSK3368715 dihydrochloride (EPZ019997 dihydrochloride) shows 50% or more growth inhibition relative to DMSO-treated cells in the majority of 249 cancer cell lines, representing 12 tumor types[1].
In Vivo: GSK3368715 dihydrochloride (EPZ019997 dihydrochloride) significantly effects on the growth of BxPC3 xenografts at all doses tested, reducing tumor growth by 78% and 97% in the 150- and 300-mg/kg dose groups, respectively[1].

Name: Asatone, CAS: 38451-63-7, stock 30.5g, assay 98.6%, MWt: 448.51, Formula: C24H32O8, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: NF-κB, Target: NF-κB, Biological_Activity: Asatone is an active component isolated from Radix et Rhizoma Asari, with anti-inflammatory effect via activation of NF-κB and donwn regulation of p-MAPK (ERK, JNK and p38) pathways[1].
IC50 & Target: NF-κB[1]

Name: Dehydroandrographolide succinate (potassium sodium salt), CAS: 863319-40-8, stock 21.8g, assay 98.8%, MWt: 594.67, Formula: C28H36KNaO10, Solubility: 10 mM in DMSO, Clinical_Informat: Launched, Pathway: Others, Target: Others, Biological_Activity: Dehydroandrographolide succinate (potassium sodium salt), extracted from herbal medicine Andrographis paniculata (Burm f) Nees, is widely used for the treatment of viral pneumonia and viral upper respiratory tract infections because of its immunostimulatory, anti-infective and anti-inflammatory effect[1][2].

Name: Usaramine N-oxide, CAS: 117020-54-9, stock 5.4g, assay 98.9%, MWt: 367.39, Formula: C18H25NO7, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: Usaramine N-oxide, a flavonoid isolated from Crotalaria pallida, possesses anti-inflammatory activities[1].

Name: Monocrotaline N-Oxide, CAS: 35337-98-5, stock 0.7g, assay 98.9%, MWt: 341.36, Formula: C16H23NO7, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: Monocrotaline N-Oxide, a monocrotaline metabolite, leads to DNA adduct formation in vivo[1].

Name: Retusin Quercetin-3,3',4',7-tetramethylether, CAS: 1245-15-4, stock 7.9g, assay 98.1%, MWt: 358.34, Formula: C19H18O7, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: Retusin (Quercetin-3,3',4',7-tetramethylether), a natural compound isolated from the leaves of Talinum triangulare, possesses antiviral and anti-inflammatory activities[1].

Name: Heptasaccharide Glc4Xyl3, CAS: 121591-98-8, stock 23g, assay 98.4%, MWt: 1062.92, Formula: C39H66O33, Solubility: , Clinical_Informat: No Development Reported, Pathway: , Target: , Biological_Activity: Heptasaccharide Glc4Xyl3, a covalent inhibitor of endo-xyloglucanases, is used for the identification and analysis of diverse xyloglucan-active enzymes in nature[1].

Name: Xylohexaose, CAS: 49694-21-5, stock 9.7g, assay 98%, MWt: 810.70, Formula: C30H50O25, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: Xylohexaose is a hexasaccharide consisting of six xylose residues.

Name: Rebaudioside N, CAS: 1220616-46-5, stock 14.3g, assay 98%, MWt: 1275.29, Formula: C56H90O32, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: Rebaudioside N is a minor steviol glycoside isolated from the leaves of Stevia rebaudiana Bertoni[1].

Name: Rebaudioside M, CAS: 1220616-44-3, stock 22.5g, assay 98.8%, MWt: 1291.29, Formula: C56H90O33, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: Rebaudioside M, a glycoside of the ent-kaurene diterpenoid aglycone, is a natural non-calorie sweetener isolated from Stevia rebaudiana Bertoni[1].

Name: Fructo-oligosaccharide DP10/GF9, CAS: 118150-64-4, stock 38.3g, assay 98.4%, MWt: 1641.44, Formula: C60H104O51, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: Fructo-oligosaccharide DP10/GF9 belongs to fructooligosaccharides (FOS) with degree of polymerization (DP=10). Fructo-oligosaccharides (FOS) are composed of 9 fructose units linked by (2→1)-β-glycosidic bonds and having a single D-glucosyl unit at the non-reducing end[1].

Name: Fructo-oligosaccharide DP9/GF8, CAS: 143625-74-5, stock 9.9g, assay 98.8%, MWt: 1477.28, Formula: C54H92O46, Solubility: 10 mM in DMSO; H2O, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: Fructo-oligosaccharide DP9/GF8 belongs to fructooligosaccharides (FOS) with degree of polymerization (DP=9). Fructo-oligosaccharides (FOS) are composed of 8 fructose units linked by (2→1)-β-glycosidic bonds and having a single D-glucosyl unit at the non-reducing end[1].

Name: Fructo-oligosaccharide DP8/GF7, CAS: 62512-21-4, stock 8.9g, assay 98.4%, MWt: 1315.14, Formula: C48H82O41, Solubility: H2O; 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: Fructo-oligosaccharide DP8/GF7 belongs to fructooligosaccharides (FOS) with degree of polymerization (DP=8). Fructo-oligosaccharides (FOS) are composed of 7 fructose units linked by (2→1)-β-glycosidic bonds and having a single D-glucosyl unit at the non-reducing end[1].

Name: Fructo-oligosaccharide DP7/GF6, CAS: 62512-20-3, stock 11.5g, assay 98.8%, MWt: 1153.00, Formula: C42H72O36, Solubility: H2O; 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: Fructo-oligosaccharide DP7/GF6 belongs to fructooligosaccharides (FOS) with degree of polymerization (DP=7). Fructo-oligosaccharides (FOS) are composed of 6 fructose units linked by (2→1)-β-glycosidic bonds and having a single D-glucosyl unit at the non-reducing end[1].

Name: 1,1,1,1-Kestohexaose, CAS: 62512-19-0, stock 4.4g, assay 98.5%, MWt: 990.86, Formula: C36H62O31, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: 1,1,1,1-Kestohexaose is a fructan oligomer isolated from Poa ampla[1].

Name: 1,4-b-D-Xylopentaose, CAS: 49694-20-4, stock 5.4g, assay 98.6%, MWt: 678.59, Formula: C25H42O21, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: 1,4-b-D-Xylopentaose (Xylopentaose) consists of five b-1,4 xylose sugars[1].

Name: Xylotetraose, CAS: 22416-58-6, stock 39.8g, assay 98.7%, MWt: 546.47, Formula: C20H34O17, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: Xylotetraose is a hydrolysis product of Xylan[1]. Xylan is a polysaccharide made from units of xylose and contains predominantly β-D-xylose units linked as in cellulose[2]. Xylotetraose can be used for enzyme biochemical analysis[1][3][4].

Name: Rhodiolin, CAS: 86831-53-0, stock 0.3g, assay 98.3%, MWt: 480.42, Formula: C25H20O10, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: Rhodiolin is a flavonoid isolated from Rhodiola fastigita[1].

Name: ArnicolideC, CAS: 34532-67-7, stock 17g, assay 99%, MWt: 334.41, Formula: C19H26O5, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: ArnicolideC is a sesquiterpene lactone isolated Centipeda minima[1]. ArnicolideC exertes a cytotoxic effect on the panel of Nasopharyngeal carcinoma (NPC) cells, significantly inhibiting cell growth in a dose- and time- dependent manner. ArnicolideC also exhibits inhibitory effects on NPC proliferation[2].

Name: Arnicolide D, CAS: 34532-68-8, stock 0.3g, assay 98.9%, MWt: 332.39, Formula: C19H24O5, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: PI3K/Akt/mTOR;Apoptosis;PI3K/Akt/mTOR;PI3K/Akt/mTOR;JAK/STAT Signaling;Stem Cell/Wnt, Target: PI3K;Caspase;mTOR;Akt;STAT;STAT, Biological_Activity: Arnicolide D is a sesquiterpene lactone isolated from Centipeda minima. Arnicolide D modulates the cell cycle, activates the caspase signaling pathway and inhibits the PI3K/AKT/mTOR and STAT3 signaling pathways. Arnicolide D inhibits Nasopharyngeal carcinoma (NPC) cell viability in a concentration- and time-dependent manner[1].
IC50 & Target: caspase; PI3K/AKT/mTOR and STAT3[1]

Name: 8,9-Epoxy-3-isobutyryloxy-10-(2-methylbutanoyl)thymol, CAS: 22518-07-6, stock 29g, assay 98.1%, MWt: 334.41, Formula: C19H26O5, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: 8,9-Epoxy-3-isobutyryloxy-10-(2-methylbutanoyl)thymol is a chemical composition of essential oils from Telekia speciosa. 8,9-Epoxy-3-isobutyryloxy-10-(2-methylbutanoyl)thymol also shows marked antipro-liferative activity against human cancer cell lines in vitro[1].

Name: 10-Isobutyryloxy-8,9-epoxythymol isobutyrate, CAS: 22518-06-5, stock 35.3g, assay 98.1%, MWt: 320.38, Formula: C18H24O5, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Anti-infection, Target: Bacterial, Biological_Activity: 10-Isobutyryloxy-8,9-epoxythymol isobutyrate is a major constituent of Inula helenium and Inula royleana root cultures. 10-Isobutyryloxy-8,9-epoxythymol isobutyrate shows moderate antimicrobial activity against Staphylococcus aureus FDA 209 P, Staphylococcus aureus, Enterococcus faecalis, Candida albicans and Pseudomonas aeruginosa with MICs of 50, 250, 250, 250, and 1000 μg/mL, respectively[1].

Name: 5,6,7,40-Tetrahydroxyisoflavone-6,7-di-o-b-D-glucopyranoside, CAS: 1219001-04-3, stock 19.7g, assay 98.6%, MWt: 610.52, Formula: C27H30O16, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: 5,6,7,40-Tetrahydroxyisoflavone-6,7-di-o-b-D-glucopyranoside is an isoflavonoid glycoside isolated from Pueraria lobata[1].

Name: Acetylseneciphylline N-oxide, CAS: 123844-00-8, stock 29.8g, assay 98.8%, MWt: 391.42, Formula: C20H25NO7, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: Acetylseneciphylline N-oxide is a pyrrolizine alkaloid that is seneciphylline in which the hydroxy hydrogen is replaced by an acetyl group and the tertiary amino function is oxidised to the corresponding N-oxide[1].

Name: InteriotherinA, CAS: 181701-06-4, stock 18.1g, assay 98.8%, MWt: 504.53, Formula: C29H28O8, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Anti-infection, Target: HIV, Biological_Activity: Interiotherin A is a lignan with a dibenzocyclooctadiene skeleton isolated from Kadsura interior. Interiotherin A inhibits HIV replication to exhibit anti-HIV activity, it has a role as a metabolite and an anti-HIV agent[1].
In Vitro: Interiotherin A (Compounds 1) (0.8-100µg/mL; 4 hours) inhibits HIV replication with EC50 values of 3.1 µg/mL[1].

Name: Calenduloside E, CAS: 26020-14-4, stock 5.6g, assay 98.5%, MWt: 632.82, Formula: C36H56O9, Solubility: Methanol : 10 mg/mL (15.80 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Metabolic Enzyme/Protease;Cell Cycle/DNA Damage, Target: HSP;HSP, Biological_Activity: Calenduloside E (CE) is a natural pentacyclic triterpenoid saponin extracted from Aralia elata. Calenduloside E (CE) has anti-apoptotic potent by targeting heat shock protein 90 (Hsp90)[1].

Name: Glycyrrhetic acid 3-O-β-D-glucuronide, CAS: 34096-83-8, stock 4.3g, assay 98.3%, MWt: 646.81, Formula: C36H54O10, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: Glycyrrhetic acid 3-O-β-D-glucuronide, isolated from glycyrrhiza, is an important derivative of glycyrrhizin (GL) with an anti -allergic activity[1]. Glycyrrhetic acid 3-O-β-D-glucuronide (GAMG) shows that β‐glucuronidases (β‐GUS) are key GAMG-producing enzymes, displaying a high potential to convert GL directly into GAMG[2].Glycyrrhetic acid 3-O-β-D-glucuronide is valuable as a sweetener.
In Vitro: Glycyrrhetic acid 3-O-β-D-glucuronide can inhibit the release of β‐hexosaminidase from RBL‐2H3 cells with an IC50 value of 0.28 mM[2].
Glycyrrhetic acid 3-O-β-D-glucuronide (GAMG) significantly reduces the nitrite concentration in a dose-dependent manner with an IC50 value of 120 μM in LPS‐induced RAW264.7 cells[2].

Name: 11-Oxomogroside IIe, CAS: 918972-06-2, stock 17.7g, assay 98.9%, MWt: 799.00, Formula: C42H70O14, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: 11-Oxomogroside IIe is a triterpene glycoside isolated from Siraitia grosvenori[1].

Name: Mogroside I E1, CAS: 88901-39-7, stock 15.9g, assay 98%, MWt: 638.87, Formula: C36H62O9, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: Mogroside I E1, a triterpenoid glycoside isolated from the extracts of Luo Han Guo, is a nonsugar sweetener. Mogrosides are sweeter than sucrose. Mogrosides exhibit antioxidant, antidiabetic and anticancer activities[1].

Name: Mogroside I A1, CAS: 88901-46-6, stock 30.5g, assay 98.9%, MWt: 638.87, Formula: C36H62O9, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: Mogroside I A1, a triterpenoid glycoside isolated from the extracts of Luo Han Guo, is a nonsugar sweetener. Mogrosides are sweeter than sucrose. Mogrosides exhibit antioxidant, antidiabetic and anticancer activities[1].

Name: Mogroside IIA1, CAS: 88901-44-4, stock 14g, assay 98.8%, MWt: 801.01, Formula: C42H72O14, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: Mogroside IIA1, a triterpenoid glycoside isolated from the extracts of Luo Han Guo, is a nonsugar sweetener. Mogrosides are sweeter than sucrose. Mogrosides exhibit antioxidant, antidiabetic and anticancer activities[1].

Name: SJA710-6, CAS: 1397255-09-2, stock 13.8g, assay 98.1%, MWt: 439.32, Formula: C22H20BrFN4, Solubility: H2O : < 0.1 mg/mL (insoluble); DMSO : 250 mg/mL (569.06 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: SJA710-6 is a small molecule able to selectively differentiate MSCs toward hepatocyte-like cells[1].

Name: GL3, CAS: 60037-39-0, stock 8.5g, assay 98.2%, MWt: 1073.01, Formula: C48H64O27, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: GL3, the major component of O. fragrans seeds, is a derivative based on both phenylethanoid and methyloleoside[1].

Name: Ilorasertib (hydrochloride) ABT-348 (hydrochloride), CAS: 1847485-91-9, stock 33.8g, assay 98.4%, MWt: 525.00, Formula: C25H22ClFN6O2S, Solubility: DMSO : 41.67 mg/mL (79.37 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK;Cell Cycle/DNA Damage;Epigenetics;Protein Tyrosine Kinase/RTK, Target: VEGFR;PDGFR;Aurora Kinase;Aurora Kinase;RET, Biological_Activity: Ilorasertib hydrochloride (ABT-348 hydrochloride) is a potent and ATP-competitive multitargeted kinase inhibitor, which inhibits Aurora C, Aurora B, and Aurora A with IC50s of 1 nM, 7 nM, 120 nM, respectively. Ilorasertib hydrochloride (ABT-348 hydrochloride) also suppresses RET tyrosine kinase, PDGFRβ and Flt1 with IC50s of 7 nM, 3 nM and 32 nM, respectively[1].

Name: Secologanoside, CAS: 59472-23-0, stock 19.1g, assay 98.3%, MWt: 390.34, Formula: C16H22O11, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Metabolic Enzyme/Protease, Target: Elastase, Biological_Activity: Secologanoside is a triterpenoid isolated from Poraqueiba sericea, weakly inhibits elastase with an IC50 of 164 μg/mL. Secologanoside is moderate cytotoxic to fibroblasts[1].

Name: Cauloside D, CAS: 12672-45-6, stock 13.4g, assay 98.8%, MWt: 1117.32, Formula: C56H92O22, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: Cauloside D is a triterpene glycoside isolated from Caulophyllum robustum Max. Cauloside D exerts anti-inflammatory effects through the inhibition of expression of iNOS and proinflammatory cytokines[1].

Name: Cyclo(RGDyK), CAS: 217099-14-4, stock 11.6g, assay 98.4%, MWt: 619.67, Formula: C27H41N9O8, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Cytoskeleton, Target: Integrin, Biological_Activity: Cyclo(RGDyK) is a potent and selective αVβ3 integrin inhibitor with an IC50 of 20 nM.
IC50 & Target: IC50: 20 nM (αVβ3 Integrin), 3000 nM (αIIbβ3 Integrin), 4000 nM (αVβ5 Integrin)[1]
In Vitro: Cyclo(RGDyK) (c(RGDyK(SAA)) shows high affinity and selectivity for αVβ3 over αVβ5 (IC50=4000 nM) and αIIbβ3 (IC50=3000 nM)[1].

Name: DiosMetin 7-O-β-D-Glucuronide, CAS: 35110-20-4, stock 13.1g, assay 98.4%, MWt: 476.39, Formula: C22H20O12, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: DiosMetin 7-O-β-D-Glucuronide is an antioxidant constituent in the fruits of Luffa cylindrical[1].

Name: Gypenoside XIII, CAS: 80325-22-0, stock 9.5g, assay 98.4%, MWt: 754.99, Formula: C41H70O12, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: Gypenoside XIII is belonging to the gypenosides. Gypenosides, extracted from Gynostemma pentaphyllum, have various pharmacological properties and protect against cardiovascular diseases, especially atherosclerosis[1].

Name: Genistein 8-c-glucoside G8CG, CAS: 66026-80-0, stock 17.7g, assay 98.5%, MWt: 432.38, Formula: C21H20O10, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Apoptosis;Metabolic Enzyme/Protease, Target: Apoptosis;Mitochondrial Metabolism, Biological_Activity: Genistein 8-c-glucoside (G8CG) is a natural glucoside isolated from flowers of Lupinus luteus L. Genistein 8-c-glucoside induces mitochondrial membrane depolarization and induces apoptosis[1].

Name: 6-Methoxytricin, CAS: 76015-42-4, stock 10.7g, assay 98.7%, MWt: 360.31, Formula: C18H16O8, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Metabolic Enzyme/Protease, Target: Aldose Reductase, Biological_Activity: 6-Methoxytricin (Compound 6) is an flavonoid isolated from Artemisia iwayomogi. 6-Methoxytricin (Compound 6) is an inhibitor on aldose reductase (AR) and advanced glycation endproduct (AGE) formation activities with IC50 values of 30.29 μM and 134.88 μM, respectively. 6-Methoxytricin (Compound 6) has potential as an anti-diabetic complications agent[1].
IC50 & Target: IC50: 30.29 μM (AR); 134.88 μM (AGE) (6-Methoxytricin)[1]

Name: Bixin, CAS: 6983-79-5, stock 7.5g, assay 98.9%, MWt: 394.50, Formula: C25H30O4, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Metabolic Enzyme/Protease;NF-κB;Immunology/Inflammation, Target: Reactive Oxygen Species;Reactive Oxygen Species;Reactive Oxygen Species, Biological_Activity: Bixin (BX), isolated from the seeds of Bixa orellana, is a carotenoid, possessing anti-inflammatory, anti-tumor and anti-oxidant activities. Bixin treatment ameliorated cardiac dysfunction through inhibiting fibrosis, inflammation and reactive oxygen species (ROS) generation[1].
IC50 & Target: ROS generation[1]

Name: Rebaudioside J, CAS: 1313049-59-0, stock 28.6g, assay 98.9%, MWt: 1113.15, Formula: C50H80O27, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: Rebaudioside J is a constituent of Stevia rebaudiana[1].

Name: Rebaudioside F, CAS: 438045-89-7, stock 35.9g, assay 98.4%, MWt: 936.99, Formula: C43H68O22, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: Rebaudioside F is a steviol glycoside isolated from Stevia rebaudiana leaves[1].

Name: Rebaudioside E, CAS: 63279-14-1, stock 34.2g, assay 98.7%, MWt: 967.01, Formula: C44H70O23, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: Rebaudioside E is a steviol glycoside isolated from Stevia rebaudiana leaves[1].

Name: Rebaudioside I, CAS: 1220616-34-1, stock 10.9g, assay 98.9%, MWt: 1129.15, Formula: C50H80O28, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: Rebaudioside I is a natural non-claoric sweetener isolated from S. rebaudiana Morita[1].

Name: Hamaudol, CAS: 735-46-6, stock 16.7g, assay 98.2%, MWt: 276.28, Formula: C15H16O5, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Immunology/Inflammation, Target: COX, Biological_Activity: Hamaudol is a chromone isolated from Saposhnikovia divaricata. Hamaudol shows significant inhibitory activity on cyclooxygenase (COX)-1 and COX-2 activities with IC50 values of 0.30, 0.57 mM, respectively, and has potent analgesia and anti-inflammary effects[1][2].
In Vivo: Hamaudol (Compound 7) increases the potency to exhibit a potent analgesia at doses of 1, 5 and 10 mg/kg in mice, although it do not show clear dose dependency[1].

Name: 3'-O-Acetylhamaudol, CAS: 30358-88-4, stock 8.9g, assay 98.8%, MWt: 318.32, Formula: C17H18O6, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: 3'-O-Acetylhamaudol, isolated from Angelica japonica roots, exhibits anti-tumor activity through dual actions, anti-angiogenesis and intestinal intraepithelial lymphocyte activation[1].

Name: Ergolide, CAS: 54999-07-4, stock 38.4g, assay 98.1%, MWt: 306.35, Formula: C17H22O5, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: NF-κB, Target: NF-κB, Biological_Activity: Ergolide is a sesquiterpene lactone isolated from the dried flowers of Inula Britannica. Ergolide inhibits inducible nitric oxide synthase and cyclo-oxygenase-2 expression in RAW 264.7 macrophages through the inactivation of NF-κB[1].

Name: 2-Hydroxy atorvastatin (calcium salt), CAS: 265989-46-6, stock 4.9g, assay 98.9%, MWt: 594.69, Formula: C33H35FN2O6.1/2Ca, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Metabolic Enzyme/Protease, Target: Drug Metabolite, Biological_Activity: 2-Hydroxy atorvastatin calcium salt is a hydroxy metabolite of Atorvastatin calcium salt. Atorvastatin is a potent HMG-CoA reductase inhibitor with an IC50 value of 8 nM.

Name: Violanthin, CAS: 40581-17-7, stock 9.5g, assay 98.3%, MWt: 578.52, Formula: C27H30O14, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Neuronal Signaling, Target: AChE, Biological_Activity: Violanthin is isolated from the aerial parts of Piper bavinum, has potent antioxidant and antibacterial activities. Violanthin inhibits acetylcholinesterase (AChE) with an IC50 value of 79.80 μM[1].
IC50 & Target: IC50: 79.80 μM (AChE)[1]

Name: Isoviolanthin, CAS: 40788-84-9, stock 20.4g, assay 98.9%, MWt: 578.52, Formula: C27H30O14, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: Isoviolanthin is a flavonoid glycoside extracted from the leaves of Dendrobium officinale. Isoviolanthin reduces the migratory and invasive capacities of TGF-β1-treated HCC cells but exhibits no cytotoxic effects on normal live cells, and has potential as a therapeutic agent for the treatment of advanced-stage metastatic HCC[1].

Name: 3-O-Acetylbufotalin, CAS: 4029-69-0, stock 30.9g, assay 98.5%, MWt: 486.60, Formula: C28H38O7, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: 3-O-Acetylbufotalin is a derivate of bufadienolide, with anti-cancer activity[1].
In Vitro: 3-O-Acetylbufotalin (2b) inhibits the growth of six human cancer cell lines, with a mean IC50 of 159 nM[1].

Name: Crocetine dimethyl ester Dimethylcrocetin, CAS: 5892-54-6, stock 6.9g, assay 98.6%, MWt: 356.46, Formula: C22H28O4, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: Crocetine dimethyl ester (Dimethylcrocetin) is found in the stigmas of saffron (Crocus sativus L.), and has antioxidant activity[1].

Name: Demethylwedelolactone (Sulfate) Demethylwedelolactone 3-sulfate, CAS: 1318240-80-0, stock 5.4g, assay 98.7%, MWt: 380.28, Formula: C15H8O10S, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: Demethylwedelolactone Sulfate (Demethylwedelolactone 3-sulfate) is a coumestan isolated from Eclipta prostrata L.[1].

Name: Geoside Gein;Eugenyl vicianoside, CAS: 585-90-0, stock 27.8g, assay 98.7%, MWt: 458.46, Formula: C21H30O11, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: Geoside (Gein) is a natural compound isolated from stevia rebaudiana.

Name: Trierucin, CAS: 2752-99-0, stock 32.3g, assay 98.3%, MWt: 1053.75, Formula: C69H128O6, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: Trierucin is a trierucic acid triglyceride from the seed oil[1].

Name: 3,5-Diiodothyropropionic acid, CAS: 1158-10-7, stock 5.7g, assay 98.8%, MWt: 510.06, Formula: C15H12I2O4, Solubility: DMSO : 50 mg/mL (98.03 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Others, Target: Thyroid Hormone Receptor, Biological_Activity: 3,5-Diiodothyropropionic acid is a thyroid hormone analog, induces α-myosin heavy chain mRNA expression, binds to thyroid hormone receptor (TR), with Ka of 2.40 and 4.06 M-1 for TRα1 and TRβ1, respectively[1].

Name: Crocetin β-Crocetin, CAS: 25368-09-6, stock 32.6g, assay 98.4%, MWt: 342.43, Formula: C21H26O4, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: Crocetin (β-Crocetin), isolated from Crocus sativus, possesses anti-inflammatory, neuroprotective and antioxidant activity[1][2].

Name: Acetylarenobufagin, CAS: 184673-79-8, stock 2.6g, assay 98.5%, MWt: 458.54, Formula: C26H34O7, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Metabolic Enzyme/Protease, Target: HIF/HIF Prolyl-Hydroxylase, Biological_Activity: Acetylarenobufagin is a steroidal hypoxia inducible factor-1 (HIF-I) modulator[1].
IC50 & Target: HIF-I[1]

Name: Dahurinol, CAS: 38908-87-1, stock 0.1g, assay 98.9%, MWt: 502.73, Formula: C31H50O5, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: Dahurinol is a natural compound isolated from Cimicifuga acerina[1].

Name: Continentalic acid, CAS: 19889-23-7, stock 20.9g, assay 98.1%, MWt: 302.45, Formula: C20H30O2, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Anti-infection, Target: Bacterial, Biological_Activity: Continentalic acid from Aralia continentalis has minimum inhibitory concentrations (MICs) of approximately 8-16 µg/mL against S. aureus, including the Methicillin susceptible Staphylococcus aureus (MSSA) and Methicillin-resistant Staphylococcus aureus (MRSA) standard strains[1].

Name: Pseudolaric Acid C2, CAS: 82508-35-8, stock 27.2g, assay 98.2%, MWt: 418.44, Formula: C22H26O8, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: Pseudolaric Acid C2, a diterpenoid isolated from Pseudolarix kaempferi, is identified as the specific metabolite of Pseudolaric acid B in plasma, urine, bile and feces after both oral and intravenous administration to rats[1][2].

Name: 3α-Hydroxymogrol, CAS: 1343402-73-2, stock 9.2g, assay 98.6%, MWt: 476.73, Formula: C30H52O4, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Epigenetics;PI3K/Akt/mTOR, Target: AMPK;AMPK, Biological_Activity: 3α-Hydroxymogrol is a triterpenoid isolated from Siraitia grosvenorii Swingle, acts as a potent AMPK activator, and enhances AMPK phosphorylation[1].

Name: Mogroside II-A, CAS: 1613527-65-3, stock 35.8g, assay 98.4%, MWt: 801.01, Formula: C42H72O14, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: Mogroside II-A is a natural product isolated from Siraitia grosvenorii[1].

Name: Siraitic Acid B, CAS: 183374-16-5, stock 11.6g, assay 98.5%, MWt: 470.64, Formula: C29H42O5, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: Siraitic Acid B is a cucurbitane triterpenoid isolated from the root of S. grosvenori [1].

Name: Siraitic Acid A, CAS: 183374-15-4, stock 12.5g, assay 98.6%, MWt: 472.66, Formula: C29H44O5, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: Siraitic Acid A is a cucurbitane triterpenoid isolated from the root of S. grosvenori [1].

Name: Bis-NH2-PEG2 PROTAC Linker 19, CAS: 929-59-9, stock 3.7g, assay 98.3%, MWt: 148.20, Formula: C6H16N2O2, Solubility: DMSO : 250 mg/mL (1686.91 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: PROTAC, Target: PROTAC Linker, Biological_Activity: Bis-NH2-PEG2 (PROTAC Linker 19) is a PROTAC linker, which refers to the PEG composition. Bis-NH2-PEG2 can be used in the synthesis of a series of PROTACs. PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins[1].

Name: Nutlin carboxylic acid MDM2 ligand 1;E3 ligase Ligand 16, CAS: 2249750-27-2, stock 21.1g, assay 98.5%, MWt: 639.53, Formula: C32H32Cl2N4O6, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: PROTAC, Target: Ligand for E3 Ligase, Biological_Activity: Nutlin carboxylic acid (MDM2 ligand 1) is the Nutlin 3-based MDM2 ligand. Nutlin carboxylic acid (MDM2 ligand 1) can be connected to the ligand for protein by a linker to form PROTACs[1].

Name: 11-Oxomogroside IIIE, CAS: 2096516-68-4, stock 16.7g, assay 98.8%, MWt: 961.14, Formula: C48H80O19, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: 11-Oxomogroside IIIE is a cucurbitane triterpene glycoside isolated from Lo Han Kuo (Siraitia grosvenori)[1].

Name: (Arg)9 (TFA) Nona-L-arginine (TFA);Peptide R9 (TFA), CAS: 2283335-13-5, stock 23.7g, assay 98.7%, MWt: 1537.71, Formula: C56H111N36F3O12, Solubility: H2O, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: (Arg)9 TFA (Nona-L-arginine TFA), a cell-penetrating peptide, exhibits neuroprotective activity with an IC50 of 0.78 μM in the glutamic acid model.
IC50 & Target: IC50: 0.78 μM (neuroprotection)[1].
In Vitro: Poly-arginine (e.g. (Arg)9) and arginine-rich peptides (e.g. TAT, penetratin), which belong to a class of peptides with cell-penetrating properties are neuroprotective. (Arg)9 provides significant neuroprotection in a dose–response manner following glutamic acid exposure (IC50=0.78 μM). Following kainic acid exposure, (Arg)9 is neuroprotective, but less effective than in the glutamic acid model (IC50=0.81 μM). (Arg)9 also shows neuroprotection following in vitro ischemia (IC50=6 μM)[1].
In Vivo: (Arg)9) (D-isoform) is neuroprotective in rat stroke models. (Arg)9) is highly neuroprotective, with efficacy increasing with increasing arginine content, has the capacity to reduce glutamic acid-induced neuronal calcium influx and requires heparan sulfate preotoglycan-mediated endocytosis to induce a neuroprotective effect[2]. (Arg)9) (D-isoform) administered intravenously at a dose of 1000 nmol/kg 30 min after permanent middle cerebral artery occlusion (MCAO) reduces infarct volume[3].

Name: 11-Oxomogroside III, CAS: 952481-53-7, stock 17.8g, assay 98.2%, MWt: 961.14, Formula: C48H80O19, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: 11-Oxomogroside III is a cucurbitane triterpene glycoside isolated from in Siraitia grosvenorii fruits[1].

Name: Acetyllovastatin, CAS: 81189-92-6, stock 4.8g, assay 98.1%, MWt: 446.58, Formula: C26H38O6, Solubility: DMSO : ≥ 250 mg/mL (559.81 mM), Clinical_Informat: No Development Reported, Pathway: Anti-infection, Target: Fungal, Biological_Activity: Acetyllovastatin, a acetate of Lovastatin, presentes a moderate inhibitory effect against the enzyme acetylcholinesterase with an IC50 of 79 μg/mL. Lovastatin has been found to display antifungal activity, and suppresses proliferation of a number of transformed cell lines[1].
IC50 & Target: IC50: 79 μg/mL (The enzyme acetylcholinesterase)[1]

Name: N-Benzyloleamide, CAS: 883715-21-7, stock 33.9g, assay 98.4%, MWt: 401.63, Formula: C26H43NO2, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Neuronal Signaling;Metabolic Enzyme/Protease;Autophagy, Target: FAAH;FAAH;Autophagy, Biological_Activity: N-Benzyloleamide is a maccamide isolated from Lepidium meyenii (Maca). N-Benzyloleamide irreversibly inhibits fatty acid amide hydrolase (FAAH). N-benzyloleamide influences the energy metabolism and reveals antioxidant and antifatigue activities[1][2].

Name: Zingibroside R1, CAS: 80930-74-1, stock 18.4g, assay 98.8%, MWt: 794.97, Formula: C42H66O14, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Anti-infection, Target: HIV, Biological_Activity: Zingibroside R1 is dammaranae-type triterpenoid saponin, isolated from rhizomes, taproots, and lateral roots of Panax japonicas C. A. Meyer, shows excellent anti-tumor effects as well as anti-angiogenic activity[1].
Zingibroside R1 possesses some anti-HIV-1 activity.
Zingibroside R1 has inhibitory effects on the 2-deoxy-D-glucose (2-DG) uptake by EAT cells (IC50=91.3 μM)[2].
IC50 & Target: IC50: 91.3 μM (2-DG uptake)[1]

Name: (Rac)-VU 6008667, CAS: 2092917-63-8, stock 9.9g, assay 98.6%, MWt: 438.85, Formula: C24H17ClF2N2O2, Solubility: H2O : < 0.1 mg/mL (insoluble); DMSO : 125 mg/mL (284.84 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Neuronal Signaling;GPCR/G Protein, Target: mAChR;mAChR, Biological_Activity: (Rac)-VU 6008667 is a selective negative allosteric modulator of muscarinic acetylcholine receptor subtype 5 (M5 NAM) (IC50=1.8 μM, pIC50= 5.75), has high CNS penetration[1].
IC50 & Target: IC50: 1.8 μM (M5)[1]

Name: (R)-VU 6008667, CAS: 2097818-14-7, stock 4.2g, assay 98.1%, MWt: 438.85, Formula: C24H17ClF2N2O2, Solubility: DMSO : 100 mg/mL (227.87 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: (R)-VU 6008667, the less active (R)-enantiomer to VU 6008667, is devoid of M5 NAM activity (IC50>10 μM)[1].

Name: Eprodisate, CAS: 21668-77-9, stock 3.8g, assay 98.2%, MWt: 204.22, Formula: C3H8O6S2, Solubility: DMSO : ≥ 125 mg/mL (612.09 mM), Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: Eprodisate is a new compound designed to interfere with interactions between amyloidogenic proteins and glycosaminoglycans and thereby inhibit polymerization of amyloid fibrils and deposition of the fibrils in tissues[1].
Eprodisate slow the progression of AA amyloidosis-related renal disease and has possible applicability to other types of amyloidosis[2].

Name: N-Acetyl-D-mannosamine N-Acetylmannosamine; ManNAc, CAS: 3615-17-6, stock 34g, assay 98.8%, MWt: 221.21, Formula: C8H15NO6, Solubility: H2O : 125 mg/mL (565.07 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Anti-infection, Target: Bacterial, Biological_Activity: N-Acetyl-D-mannosamine (ManNAc) is an essential precursor of N-acetylneuraminic acid (NeuAc), the specific monomer of bacterial capsular polysialic acid (PA)[1].
N-Acetyl-D-mannosamine (ManNAc) can be metabolized by GNE and GlcNAc 2-epimerase (Renin binding protein, RnBP), into ManNAc-6-phosphate and GlcNAc, respectively.
N-Acetyl-d-mannosamine (ManNAc) and its derivatives activates hypocretin (HCRT) gene expression in the orexin neurons, providing a potential model for the testing of a therapy for neural disorders[2].

Name: Coenzyme A, CAS: 85-61-0, stock 33.6g, assay 98.9%, MWt: 767.53, Formula: C21H36N7O16P3S, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: Coenzyme A is is an obligatory cofactor in all living cells synthesised from pantothenate (Vitamin B5), adenosine triphosphate (ATP) and cysteine. Covalent binding of Coenzyme A to Peroxiredoxin 5 (Prdx5) results in complete inhibition of its peroxidase activity, which is reversed by reduction with DTT.Coenzyme A and its thioester derivatives are key players in major catabolic and anabolic pathways and the regulation of gene expression. Many human pathologies, including cancer, diabetes and neurodegeneration, have been associated with abnormal biosynthesis and homeostasis of CoA and its derivatives[1].

Name: Dimethyl biphenyl-4,4'-dicarboxylate, CAS: 792-74-5, stock 24.7g, assay 98.1%, MWt: 270.28, Formula: C16H14O4, Solubility: DMF : 2 mg/mL (7.40 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: Dimethyl biphenyl-4,4'-dicarboxylate (Biphenyl dimethyl dicarboxylate) is a hepatoprotectant obtained from Schizandra fructus and may induce a signal transduction similar to that associated with IFN[1].

Name: RV01, CAS: 1016897-10-1, stock 3g, assay 98.3%, MWt: 263.29, Formula: C17H13NO2, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Metabolic Enzyme/Protease, Target: Aldehyde Dehydrogenase (ALDH), Biological_Activity: RV01 is an analogue of resveratrol, inhibits DNA damage, reduces acetaldehyde dehydrogenase 2 (ALDH2) mRNA expression induced by ethanol, and exhibits hydroxyl radical scavenging activity[1]. RV01 decreases iNOS expression, with anti-neuroinflammatory activity[2].

Name: BI-2852, CAS: 2375482-51-0, stock 30.1g, assay 99%, MWt: 516.59, Formula: C31H28N6O2, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: GPCR/G Protein, Target: Ras, Biological_Activity: BI-2852 is a KRAS inhibitor for the switch I/II pocket (SI/II-pocket) by structure-based drug design with nanomolar affinity. BI-2852 is mechanistically distinct from covalent KRASG12C inhibitor (binds to switch II pocket) because it binds to a different pocket present in both the active and inactive forms of KRAS. BI-2852 blocks GEF, GAP, and effector interactions with KRAS, leading to inhibition of downstream signaling and an antiproliferative effect in KRAS mutant cells[1].
IC50 & Target: IC50: 450 nM (KRASG12D); KD: 750 nM (KRASG12D)[1]
In Vitro: BI-2852 (Compound 1) (10 nM-10 µM; 2 hours) shows a dose-dependent pERK modulation and antiproliferative effect at EC50s of 5.8 µM and 6.7 µM in soft agar and low serum conditions in NCI-H358 cells[1].

Name: (R,R)-Secoisolariciresinol diglucoside (R,R)-SDG; (R,R)-LGM2605, CAS: 158932-33-3, stock 21.4g, assay 98.8%, MWt: 686.70, Formula: C32H46O16, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: (R,R)-Secoisolariciresinol diglucoside ((R,R)-SDG) is the minor isomer of Secoisolariciresinol diglucoside in flaxseed. (R,R)-Secoisolariciresinol diglucoside ((R,R)-SDG) possesses antioxidant and free radical scavenging activities and DNA-radioprotective properties. (R,R)-Secoisolariciresinol diglucoside ((R,R)-SDG) inhibits myeloperoxidase (MPO) activity by suppressing both the peroxidase and chlorination cyclesin inflammatory cells[1][2][3].

Name: Saracatinib AZD0530, CAS: 379231-04-6, stock 36.7g, assay 98.6%, MWt: 542.03, Formula: C27H32ClN5O5, Solubility: DMSO : ≥ 32 mg/mL (59.04 mM), Clinical_Informat: Phase 3, Pathway: Protein Tyrosine Kinase/RTK;Autophagy, Target: Src;Autophagy, Biological_Activity: Saracatinib (AZD0530) is a potent Src family inhibitor with IC50s of 2.7 to 11 nM for c-Src, Lck, c-YES, Lyn, Fyn, Fgr, and Blk and shows high selectivity over other tyrosine kinases.
IC50 & Target: IC50: 2.7 nM (Src), 30 nM (v-Abl), 66 nM (EGFR), 200 nM (c-Kit)[1]
In Vitro: Saracatinib (AZD0530), an orally available Src inhibitor, demonstrates potent antimigratory and anti-invasive effects in vitro, and inhibits metastasis in a murine model of bladder cancer. Antiproliferative activity of Saracatinib varies between cell lines (IC50 0.2-10 μM). Saracatinib potently inhibits the proliferation of Src3T3 mouse fibroblasts and demonstrates variable antiproliferative activity in a range of human cancer cell lines containing endogenous Src. Sub micromolar growth inhibition of five of the human cancer cell lines tested with Saracatinib (tumor types: colon, prostate, lung, and leukemia) is observed with IC50 values of 0.2-0.7 μM. In 3-day MTS cell proliferation assays, Saracatinib inhibits proliferation of the Bcr-Abl-driven human leukemia cell line K562 with an IC50 of 0.22 μM. In the microdroplet migration assay, Saracatinib reduces the migration of human lung cancer A549 cells in a concentration-dependent manner (IC50 0.14 μM)[1].
In Vivo: Saracatinib (AZD0530) treatment potently inhibits the proliferation of subcutaneously transplanted Src3T3 fibroblasts in mice and rats in a dose-dependent manner. In both models, significant inhibition of tumor growth is seen at doses ≥6 mg/kg/day (60% inhibition in mice and 98% inhibition in rats versus animals treated with vehicle) and, at the maximum doses investigated, complete tumor growth inhibition is observed (100% inhibition at 25 mg/kg/day in mice and 10 mg/kg/day in rats)[1].

Name: BI-4916, CAS: 2244451-48-5, stock 26.5g, assay 98.2%, MWt: 527.42, Formula: C23H24Cl2N2O6S, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: BI-4916 is a prodrug of BI-4924. BI-4924 is a NADH/NAD+-competitive PHGDH inhibitor[1].

Name: SBI-797812, CAS: 2237268-08-3, stock 8.4g, assay 98.3%, MWt: 402.47, Formula: C19H22N4O4S, Solubility: DMSO : 250 mg/mL (621.16 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Metabolic Enzyme/Protease, Target: Nampt, Biological_Activity: SBI-797812 is structurally similar to active-site directed NAMPT inhibitors and blocks binding of these inhibitors to NAMPT with EC50 of 0.37 μM. SBI-797812 shifts the NAMPT reaction equilibrium towards NMN formation, increases NAMPT affinity for ATP, stabilizes phosphorylated NAMPT at His247, promotes consumption of the pyrophosphate by-product, and blunts feedback inhibition by NAD+. Treatment of cultured cells with SBI-797812 increases intracellular NMN and NAD+. Dosing of mice with SBI-797812 elevates liver NAD+[1].
IC50 & Target: NAMPT[1]

Name: (S,S)-Valifenalate (S,S)-IR5885;(S,S)-Valiphenal, CAS: 283159-94-4, stock 21.3g, assay 98.7%, MWt: 398.88, Formula: C19H27ClN2O5, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Anti-infection, Target: Fungal, Biological_Activity: (S,S)-Valifenalate ((S,S)-IR5885) is an acylamino acid fungicide and is used to control a wide range of fungi belonging to the class of Oomycetes. (S,S)-Valifenalate ((S,S)-IR5885) interferes with the cell-wall synthesis thus affecting the growth stages of the pathogens controlled, both outside (on the spores) or inside the plant (on the mycelium)[1].

Name: PT2977 MK-6482, CAS: 1672668-24-4, stock 17.4g, assay 98.4%, MWt: 383.34, Formula: C17H12F3NO4S, Solubility: DMSO : 50 mg/mL (130.43 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Metabolic Enzyme/Protease, Target: HIF/HIF Prolyl-Hydroxylase, Biological_Activity: PT2977 (MK-6482) is an orally active and selective HIF-2α inhibitor with an IC50 of 9 nM. PT2977, as a second-generation HIF-2α inhibitor, increases potency and improves pharmacokinetic profile. PT2977 is a potential treatment for clear cell renal cell carcinoma (ccRCC)[1].
IC50 & Target: IC50: 9 nM (HIF-2α)[1]
In Vitro: PT2977 potently and dose-dependently reduces mRNA levels of human cyclin D1, a target gene regulated by HIF-2α, and leads to rapid and dose-dependent reduction in EPO expression[1].

Name: Talsaclidine, CAS: 147025-53-4, stock 37.9g, assay 98.6%, MWt: 165.23, Formula: C10H15NO, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Neuronal Signaling;GPCR/G Protein, Target: mAChR;mAChR, Biological_Activity: Talsaclidine is a muscarinic agonist with preferential neuron-stimulating properties. Talsaclidine is a full agonist at the M1 subtype, and as a partial agonist at the M2 and M3 subtypes[1][2][3][4].

Name: (S)-Propafenone (S)-SA-79, CAS: 107381-32-8, stock 18.2g, assay 98%, MWt: 341.44, Formula: C21H27NO3, Solubility: DMSO : 33.33 mg/mL (97.62 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: (S)-Propafenone ((S)-SA-79) is the S-enantiomer of Propafenone. (S)-Propafenone ((S)-SA-79) exerts beta-blocking action and the sodium channel-dependent antiarrhythmic class 1 activity[1].

Name: P7C3-OMe, CAS: 313268-18-7, stock 1.4g, assay 98.5%, MWt: 504.21, Formula: C22H20Br2N2O2, Solubility: DMSO : ≥ 100 mg/mL (198.33 mM), Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: P7C3-OMe is a pro-neurogenic compound, has therapeutic benefits in neuropsychiatric and/or neurodegenerative disease. The R-enantiomer of P7C3-OMe is far more active than the S-enantiomer[1].

Name: Cimigenol, CAS: 3779-59-7, stock 15.4g, assay 98.7%, MWt: 488.70, Formula: C30H48O5, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: Cimigenol is an active compound isolated from Cimicifuga, with potent anti-tumor activity[1].

Name: 11-Deoxymogroside IIIE, CAS: 1793003-47-0, stock 2.8g, assay 98.5%, MWt: 947.15, Formula: C48H82O18, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: 11-Deoxymogroside IIIE is a natural product isolated from Siraitia grosvenorii.

Name: 5-MethoxyPinocembroside, CAS: 1450878-89-3, stock 1.4g, assay 98.9%, MWt: 432.42, Formula: C22H24O9, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: 5-MethoxyPinocembroside is a flavonoid isolated from Penthorumchinense Pursh.

Name: 8-Keto-berberine, CAS: 81397-08-2, stock 0.3g, assay 98.4%, MWt: 351.35, Formula: C20H17NO5, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: 8-Keto-berberine (compound 29) is a non-naturally occurring 11, 12-oxygenated protoberberine derived from naturally occurring 9, 10-oxygenated protoberberine[1].

Name: 2-O-β-D-Glucopyranosyl-L-ascorbic acid AA-2βG, CAS: 562043-82-7, stock 12.4g, assay 98.6%, MWt: 338.26, Formula: C12H18O11, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: 2-O-β-D-Glucopyranosyl-L-ascorbic acid (AA-2βG), isolated from Lycium Fruit, is a stable vitamin C analog with anti-tumor activity[1].

Name: Kaempferol-3-O-(6'''-trans-p-coumaroyl-2''-glucosyl)rhamnoside, CAS: 111957-48-3, stock 3.8g, assay 98.4%, MWt: 740.66, Formula: C36H36O17, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: Kaempferol-3-O-(6'''-trans-p-coumaroyl-2''-glucosyl)rhamnoside is a natural antioxidant from herbal medicines[1].
In Vitro: Kaempferol-3-O-(6'''-trans-p-coumaroyl-2''-glucosyl)rhamnoside (3-O-{2-O-[6-O-(p-Hydroxyl-E-coumaroyl)-glucosyl]-(1-2)rhamnosyl kaempferol) is a natural from herbal medicines, with antioxidant activity[1].

Name: (S)-Ceralasertib (S)-AZD6738, CAS: 1352226-87-9, stock 3.3g, assay 98.4%, MWt: 412.51, Formula: C20H24N6O2S, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Cell Cycle/DNA Damage;PI3K/Akt/mTOR, Target: ATM/ATR;ATM/ATR, Biological_Activity: (S)-Ceralasertib ((S)-AZD6738) is extracted from patent WO2011154737A1, Compound II, exhibits an IC50 of 2.578 nM[1].
(S)-Ceralasertib is a potent and selective sulfoximine morpholinopyrimidine ATR inhibitor with excellent preclinical physicochemical and pharmacokinetic (PK) characteristics.
(S)-Ceralasertib is developed improving aqueous solubility and eliminates CYP3A4 time-dependent inhibition[2].

Name: BPR1M97, CAS: 2059904-66-2, stock 20.2g, assay 98.9%, MWt: 349.25, Formula: C18H18Cl2N2O, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: GPCR/G Protein;Neuronal Signaling, Target: Opioid Receptor;Opioid Receptor, Biological_Activity: BPR1M97 is a dual-acting mu opioid receptor (MOP) and nociceptin-orphanin FQ peptide (NOP) receptor agonist with Ki values of 1.8 and 4.2 nM, respectively. BPR1M97 shows high potency and blood-brain barrier penetration, and produces potent antinociceptive effects[1].
IC50 & Target: Ki: 1.8 nM (MOP), 4.2 nM (NOP)[1]
In Vivo: BPR1M97 (1.8 mg/kg; s.c.; once) demonstrates antinociception in a murine model of cancer pain[1].

Name: FITC-Dextran, CAS: 60842-46-8, stock 19.3g, assay 98.5%, MWt: 1000, Formula: N/A, Solubility: H2O : 50 mg/mL (Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: FITC-Dextran is a marker consisting of coupling fluorescein-isothiocyanate to dextran. FITC-Dextrans are polysaccharides comprised of varying lengths of branched glucose molecules and can be used to determine solute, ion and protein permeability of the blood-brain barrier (BBB) based on the size of the dextran used[1][2][3].

Name: Phytohemagglutinin PHA-M, CAS: 9008-97-3, stock 7.4g, assay 98.8%, MWt: 1000, Formula: N/A, Solubility: DMSO : < 1 mg/mL (insoluble or slightly soluble); H2O : 50 mg/mL (Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Apoptosis, Target: Apoptosis, Biological_Activity: Phytohemagglutinin (PHA-M) is a lectin, obtained from the red kidney bean that binds to the membranes of T-cells, stimulates metabolic activity, cell division, and involves inflammatory pathways. Phytohemagglutinin (PHA-M) induces apoptosis via increasing proapoptotic protein Bax and activating caspases-3[1][2][3].
IC50 & Target: Apoptosis[1]

Name: Uridine 5′-diphosphoglucose (disodium salt) UDP-D-Glucose (disodium salt), CAS: 28053-08-9, stock 16.4g, assay 99%, MWt: 610.27, Formula: C15H22N2Na2O17P2, Solubility: H2O : 125 mg/mL (204.83 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: GPCR/G Protein;Metabolic Enzyme/Protease, Target: P2Y Receptor;Endogenous Metabolite, Biological_Activity: Uridine 5′-diphosphoglucose disodium salt (UDP-D-Glucose disodium salt) is the precursor of glucose-containing oligosaccharides, polysaccharides, glycoproteins, and glycolipids in animal tissues and in some microorganisms. Uridine-5′-diphosphoglucose is an agonist of the P2Y14 receptor, a neuroimmune system GPCR[1].

Name: Mal-PEG2-VCP-Eribulin, CAS: 2130869-18-8, stock 13g, assay 98.9%, MWt: 1374.57, Formula: C70H99N7O21, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Antibody-drug Conjugate/ADC Related, Target: Drug-Linker Conjugates for ADC, Biological_Activity: Mal-PEG2-VCP-Eribulin consists the ADCs linker (Mal-PEG2-VCP) and Eribulin[1]. Eribulin is a mechanistically unique microtubule inhibitor for cancer[2]. Mal-PEG2-VCP-Eribulin is an Eribulin-based drug for antibody conjugates[1].

Name: Phosal 50 PG, CAS: 774594-96-6, stock 5.1g, assay 98.5%, MWt: 1000, Formula: N/A, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: Phosal 50 PG is a standardized phosphatidylcholine concentrate, used in some lipid-based formulations to improve the absorption, effectiveness, and therapeutic index of the active ingredients[1].

Name: Tazemetostat (hydrobromide) EPZ-6438 (hydrobromide); E-7438 (hydrobromide), CAS: 1467052-75-0, stock 1.5g, assay 98.3%, MWt: 653.65, Formula: C34H45BrN4O4, Solubility: DMSO : 100 mg/mL (152.99 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Epigenetics, Target: Histone Methyltransferase, Biological_Activity: Tazemetostat hydrobromide (EPZ-6438 hydrobromide) is a potent, selective and orally available EZH2 inhibitor. Tazemetostat hydrobromide inhibits the activity of human polycomb repressive complex 2 (PRC2)-containing wild-type EZH2 with a Ki value of 2.5 nM. Tazemetostat hydrobromide inhibits EZH2 with IC50s of 11 and 16 nM in peptide assay and nucleosome assay, respectively. Tazemetostat hydrobromide inhibits Rat EZH2 with an IC50 of 4 nM. Tazemetostat hydrobromide also inhibits EZH1 with an IC50 of 392 nM.
IC50 & Target: Ki: 2.5 nM (EZH2)[1]
In Vitro: Tazemetostat (EPZ-6438) inhibits multi wild-type and mutant lymphoma cell lines proliferation with IC50s of 0.49 nM-7.6 μM[1].
In Vivo: Tazemetostat (EPZ-6438; 250 or 500 mg/kg twice daily for 21-28 days) practically eliminates the fast-growing G401 tumors[1].

Name: Phosphatidylcholines,soya Soybean phosphatidylcholine, CAS: 97281-47-5, stock 39.5g, assay 98.8%, MWt: 1000, Formula: N/A, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Others, Target: Others, Biological_Activity: Phosphatidylcholines,soya is a phosphatidylcholine from soybean used in the preparation of liposomes. Phosphatidylcholines,soya can be used as a vehicle in animal drug administration[1][2][3].
In Vitro: Fibroblasts show sensitivity toward the soybean phosphatidylcholine liposomes with an IC50 of 150 μM[3].

Name: Isosilybin A, CAS: 142796-21-2, stock 37.9g, assay 98.1%, MWt: 482.44, Formula: C25H22O10, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Apoptosis, Target: Apoptosis, Biological_Activity: Isosilybin A, a flavonolignan isolated from silymarin, has anti-prostate cancer (PCA) activity. Isosilybin A inhibits proliferation and induces G1 phase arrest and apoptosis in cancer cells, which activates apoptotic machinery in PCA cells via targeting Akt-NF-κB-androgen receptor (AR) axis[1][2].

Name: Isosilybin B, CAS: 142796-22-3, stock 36.1g, assay 98.5%, MWt: 482.44, Formula: C25H22O10, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Apoptosis;Others, Target: Apoptosis;Androgen Receptor, Biological_Activity: Isosilybin B, a flavonolignan isolated from silymarin, has anti-prostate cancer (PCA) activity via inhibiting proliferation and inducing G1 phase arrest and apoptosis. Isosilybin B causes androgen receptor (AR) degradation[1][2].

Name: Silybin B, CAS: 142797-34-0, stock 23g, assay 99%, MWt: 482.44, Formula: C25H22O10, Solubility: 10 mM in DMSO, Clinical_Informat: No Development Reported, Pathway: Neuronal Signaling, Target: Amyloid-β, Biological_Activity: Silybin B, a flavonolignan separated from Silybum marianum, has anti-tumor activity. Silybin B is the most potent antifibrillogenic and anti-oligomeric component of silymarin and proposes it as a promising anti Alzheimer’s disease drug candidate[1][2].

Name: Urolithin B, CAS: 1139-83-9, stock 4.3g, assay 98.9%, MWt: 212.20, Formula: C13H8O3, Solubility: DMSO : 250 mg/mL (1178.13 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: MAPK/ERK Pathway;Stem Cell/Wnt;MAPK/ERK Pathway;PI3K/Akt/mTOR;Epigenetics;PI3K/Akt/mTOR;NF-κB, Target: JNK;ERK;ERK;Akt;AMPK;AMPK;NF-κB, Biological_Activity: Urolithin B is one of the gut microbial metabolites of ellagitannins, and has anti-inflammatory and antioxidant effects. Urolithin B inhibits NF-κB activity by reducing the phosphorylation and degradation of IκBα, and suppresses the phosphorylation of JNK, ERK, and Akt, and enhances the phosphorylation of AMPK. Urolithin B is also a regulator of skeletal muscle mass[1][2].

Name: VP3.15 (dihydrobromide), CAS: 1281681-33-1, stock 32.9g, assay 99%, MWt: 528.30, Formula: C20H24Br2N4OS, Solubility: DMSO : 62.5 mg/mL (118.30 mM; Need ultrasonic), Clinical_Informat: No Development Reported, Pathway: Metabolic Enzyme/Protease;Stem Cell/Wnt;PI3K/Akt/mTOR, Target: Phosphodiesterase (PDE);GSK-3;GSK-3, Biological_Activity: VP3.15 dihydrobromide is a potent, orally bioavailable and CNS-penetrant dual phosphodiesterase (PDE)7- glycogen synthase kinase (GSK)3 inhibitor, with IC50s of 1.59 μM and 0.88 μM for PDE7 and GSK-3, respectively. VP3.15 dihydrobromide has neuroprotective and neuroreparative activities, thus as potential combined anti-inflammatory and pro-remyelinating therapies for multiple sclerosis (MS)[1].
IC50 & Target: IC50: 1.59 μM (PDE7), 0.88 μM (GSK-3)[1]

EOS Med Chem, Medicinal Chemical is Big

搜索此博客

2020年3月13日星期五

EOS Med Chem Building block stock list 2354

举报滥用情况

2016 China CPHI meet